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Abstract
Background: Severe traumatic injury continues to present challenges to healthcare systems around the world, and
post-traumatic bleeding remains a leading cause of potentially preventable death among injured patients. Now in
its fifth edition, this document aims to provide guidance on the management of major bleeding and coagulopathy
following traumatic injury and encourages adaptation of the guiding principles described here to individual
institutional circumstances and resources.
Methods: The pan-European, multidisciplinary Task Force for Advanced Bleeding Care in Trauma was founded in
2004, and the current author group included representatives of six relevant European professional societies. The
group applied a structured, evidence-based consensus approach to address scientific queries that served as the
basis for each recommendation and supporting rationale. Expert opinion and current clinical practice were also
considered, particularly in areas in which randomised clinical trials have not or cannot be performed. Existing
recommendations were re-examined and revised based on scientific evidence that has emerged since the previous
edition and observed shifts in clinical practice. New recommendations were formulated to reflect current clinical
concerns and areas in which new research data have been generated.
Results: Advances in our understanding of the pathophysiology of post-traumatic coagulopathy have supported
improved management strategies, including evidence that early, individualised goal-directed treatment improves
the outcome of severely injured patients. The overall organisation of the current guideline has been designed to
reflect the clinical decision-making process along the patient pathway in an approximate temporal sequence.
Recommendations are grouped behind the rationale for key decision points, which are patient- or problem-oriented
rather than related to specific treatment modalities. While these recommendations provide guidance for the diagnosis
and treatment of major bleeding and coagulopathy, emerging evidence supports the author group’s belief that the
greatest outcome improvement can be achieved through education and the establishment of and adherence to local
clinical management algorithms.
Conclusions: A multidisciplinary approach and adherence to evidence-based guidance are key to improving patient
outcomes. If incorporated into local practice, these clinical practice guidelines have the potential to ensure a uniform
standard of care across Europe and beyond and better outcomes for the severely bleeding trauma patient.
Keywords: Coagulopathy, Emergency medicine, Haemostasis, Practice guideline, Trauma
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Key messages
 Traumatically injured patients should be transported
quickly and treated by a specialised trauma centre
whenever possible.
 Measures to monitor and support coagulation
should be initiated as early as possible and used to
guide a goal-directed treatment strategy.
 A damage-control approach to surgical intervention
should guide patient management.
 Coagulation support and thromboprophylactic
strategies should consider trauma patients who
have been pre-treated with anticoagulants or
platelet inhibitors.
 Local adherence to a multidisciplinary, evidence-
based treatment protocol should serve as the basis of
patient management and undergo regular quality
assessment.
Background
Severe trauma is a major global public health issue, con-
tributing to about 1 in 10 mortalities and resulting in
the annual worldwide death of more than 5.8 million
people [1, 2]. According to the World Health Organization
(WHO), road traffic accidents, suicides and homicides are
the three leading causes of injury and violence-related
deaths [3]. In recent years, sudden mass casualties due to
bombing and assaults have become an new phenomenon
in Europe and other regions, resulting in hundreds of se-
verely injured and bleeding patients within a very short
period of time, thereby posing huge challenges for local
healthcare systems [4–6].
Uncontrolled post-traumatic bleeding is still the lead-
ing cause of potentially preventable death among injured
patients [7–9] and one third of all bleeding trauma pa-
tients show signs of coagulopathy at hospital admission
[10–17]. These patients develop multiple organ failure
and experience death more frequently than patients with
similar injury patterns in the absence of coagulopathy
[11, 13, 14, 18, 19]. The early acute coagulopathy associ-
ated with traumatic injury has recently been recognised
as a multifactorial primary condition that results from
a combination of bleeding-induced shock, tissue in-
jury-related thrombomodulin upregulation, thrombin-
thrombomodulin-complex generation and the activa-
tion of anticoagulant and fibrinolytic pathways (Fig. 1)
[8, 10, 13–15, 20–26]. The severity of the coagulation
disorder is influenced by environmental and therapeutic
factors that result in acidaemia, hypothermia, dilution,
hypoperfusion and consumption of coagulation factors
[10, 14, 24, 27–32]. Moreover, the coagulopathy is modi-
fied by trauma-related factors such as brain injury [33]
and individual patient-related factors that include age,
genetic background, co-morbidities, inflammation and
medication administered prior to becoming injured, espe-
cially oral anticoagulants, and pre-hospital fluid adminis-
tration [28, 34, 35].
This European clinical practice guideline, originally pub-
lished in 2007 [36] and updated in 2010 [37], 2013 [38] and
2016 [39], represents the fifth edition of the guideline and
is part of the European “STOP the Bleeding Campaign”, an
international initiative launched in 2013 to reduce mor-
bidity and mortality associated with bleeding following
traumatic injury [40]. In the last 3 years, a multitude of
studies were published that enhance understanding of the
pathophysiology of trauma-induced coagulopathy, fill
important knowledge gaps about the mechanism and effi-
cacy of trauma treatment strategies and provide evidence
that individualised goal-directed trauma treatment im-
proves the outcome of severely injured patients. This new
information has been integrated in the current version of
the guideline.
Although this set of recommendations outlines corri-
dors for diagnosis and treatment, the author group
believes that the greatest outcome improvement can be
achieved through education and the establishment of
local clinical management guidelines or algorithms. We
believe that adherence to local management guidelines
or algorithms should be assessed on a regular basis and
will lead to greater adherence. If incorporated into local
practice, these clinical practice guidelines have the po-
tential to ensure a uniform standard of care across
Europe and beyond and better outcomes for the severely
bleeding trauma patient, as has indeed be found in three
recent studies [41–43].
Methods
The recommendations made in this guideline are graded
according to the Grading of Recommendations Assess-
ment, Development and Evaluation (GRADE) system [44],
summarised in Table 1. According to the GRADE scheme,
the number associated with each recommendation reflects
the strength of the recommendation by the author group,
with “we recommend” (Grade 1) being stronger and “we
suggest” (Grade 2) being weaker, while the associated letter
(A, B or C) reflects the quality of the scientific evidence.
Comprehensive, structured, computer-based literature
searches were performed using the indexed online database
MEDLINE/PubMed, supplemented by screening of refer-
ence lists within relevant publications. The aim of each
search strategy was to identify randomised controlled trials
(RCTs), non-RCTs and systematic reviews that addressed
specific scientific queries. In the absence of high-quality sci-
entific support, case reports, observational studies and case
control studies were also considered and the literature sup-
port for each recommendation graded accordingly.
Boolean operators, medical subject headings (MeSH)
and key terms were applied to structure each literature
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Fig. 1 Schematic drawing of the factors, including those that are preexisting as well as those related to both trauma and resuscitation measures,
that contribute to traumatic coagulopathy. Adapted from [20, 24, 30–32, 38]
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search. Searches were limited to a uniform human pa-
tient population defined by the search terms and the
time period since 01 February 2015. The structured lit-
erature search strategies applied to each section of the
guideline are listed in Additional file 1. Abstracts identi-
fied by each search strategy were screened by a subset of
authors and if considered relevant, full publications eval-
uated. Evaluation of literature chosen for citation in the
guideline was performed according to the 2011 Oxford
Centre for Evidence-Based Medicine (OCEBM) working
group levels of evidence (Table 2) [45]. Each literature
citation included in this version of the guideline and the
corresponding grading according to the OCEBM levels
of evidence (Table 2) are listed in Additional file 2.
Selection of the scientific queries addressed, screening
and evaluation of the literature, formulation of the rec-
ommendations and the supporting rationales was per-
formed by members of the Task Force for Advanced
Bleeding Care in Trauma, which was founded in 2004.
The Task Force comprises a multidisciplinary team of
pan-European experts representing the fields of emer-
gency medicine, surgery, anaesthesiology, haematology
and intensive care medicine. Among the authors are
representatives of the European Society for Trauma and
Emergency Surgery (ESTES), the European Society of
Anaesthesiology (ESA), the European Shock Society (ESS),
the European Society for Emergency Medicine (EuSEM),
the Network for the Advancement of Patient Blood
Management, Haemostasis and Thrombosis (NATA) and
the European Society of Intensive Care Medicine (ESICM).
The guideline update process involved several remote
(telephone and/or internet-based) meetings, extensive
electronic communication and one face-to-face consensus
conference. In December 2017, the authors participated in
a web conference during which the queries to be ad-
dressed in the updated guideline were defined. Screening
and evaluation of abstracts and full publications identified
by the structured searches and formulation of draft
Table 1 Grading of recommendations after [44]. RCT, randomised controlled trial. Table reprinted with permission
Grade of recommendation Clarity of risk/benefit Quality of supporting
evidence
Implications
1A
Strong recommendation,
high-quality evidence
Benefits clearly outweigh risk
and burdens, or vice versa
RCTs without important
limitations or overwhelming
evidence from observational
studies
Strong recommendation, can
apply to most patients in
most circumstances without
reservation
1B
Strong recommendation,
moderate-quality evidence
Benefits clearly outweigh risk
and burdens, or vice versa
RCTs with important
limitations (inconsistent
results, methodological flaws,
indirect or imprecise) or
exceptionally strong evidence
from observational studies
Strong recommendation, can
apply to most patients in
most circumstances without
reservation
1C
Strong recommendation,
low-quality or very
low-quality evidence
Benefits clearly outweigh risk
and burdens, or vice versa
Observational studies or case
series
Strong recommendation but
may change when higher
quality evidence becomes
available
2A
Weak recommendation,
high-quality evidence
Benefits closely balanced
with risks and burden
RCTs without important
limitations or overwhelming
evidence from observational
studies
Weak recommendation, best
action may differ depending
on circumstances or patients’
or societal values
2B
Weak recommendation,
moderate-quality evidence
Benefits closely balanced
with risks and burden
RCTs with important
limitations (inconsistent
results, methodological flaws,
indirect or imprecise) or
exceptionally strong evidence
from observational studies
Weak recommendation, best
action may differ depending
on circumstances or patients’
or societal values
2C
Weak recommendation,
low-quality or very
low-quality evidence
Uncertainty in the estimates
of benefits, risks, and burden;
benefits, risk and burden may
be closely balanced
Observational studies or case
series
Very weak recommendation;
other alternatives may be
equally reasonable
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recommendations and rationales was performed by work-
ing subgroups. Each chapter was reviewed by an
assigned working subgroup and then the entire author
group. The wording of each recommendation was fina-
lised during a face-to-face consensus conference that
took place in April 2018. Following revisions and ap-
proval by the author group, the manuscript was ap-
proved by the endorsing societies between August and
November 2018. An update of this manuscript is antici-
pated in due time.
Results
I. Initial resuscitation and prevention of further bleeding
Minimal elapsed time
Recommendation 1 We recommend that severely in-
jured patients be transported directly to an appropriate
trauma facility. (Grade 1B)
We recommend that the time elapsed between injury
and bleeding control be minimised. (Grade 1A)
Rationale
Because relatively few hospitals provide all of the ser-
vices required to treat patients with multiple injuries,
many healthcare systems have developed trauma net-
works or processes. The underlying aim of trauma care
organisation is to move patients to multi-specialist care
as early as possible, yet still provide immediate critical
interventions. These aims can come into conflict, and
there are a number of different means with which to re-
solve these issues, resulting in large variations in trauma
care systems both between and within countries and a
consequent significant heterogeneity in the literature.
The evidence is weak, but there is a general consensus
that the organisation of a group of hospitals into a
“trauma system” leads to about a 15% reduction in
Table 2 Oxford Centre for Evidence-based Medicine (OCEBM) levels of evidence (2011) [45]
Question Step 1 (level 1*) Step 2 (level 2*) Step 3 (level 3*) Step 4 (level 4*) Step 5 (level 5)
How common is the
problem?
Local and current
random sample surveys
(or censuses)
Systematic review of
surveys that allow
matching to local
circumstances**
Local non-random
sample**
Case-series** N/A
Is this diagnostic or
monitoring test
accurate? (diagnosis)
Systematic review of
cross-sectional studies
with consistently
applied reference
standard and blinding
Individual cross-
sectional studies with
consistently applied
reference standard and
blinding
Non-consecutive
studies or studies
without consistently
applied reference
standards**
Case-control studies or
poor or non-
independent reference
standard**
Mechanism-based
reasoning
What will happen if we
do not add a therapy?
(prognosis)
Systematic review of
inception cohort studies
Inception cohort studies Cohort study or control
arm of randomised
trial*
Case-series or case-
control studies or poor-
quality prognostic
cohort study**
N/A
Does this intervention
help? (treatment
benefits)
Systematic review of
randomised trials or
n-of-1 trials
Randomised trial or
observational study
with dramatic effect
Non-randomised
controlled cohort/
follow-up study**
Case-series, case-control
studies or historically
controlled studies**
Mechanism-based
reasoning
What are the common
harms? (treatment
harms)
Systematic review of
randomised trials,
systematic review of
nested case-control
studies, n-of-1 trial with
the patient you are
raising the question
about, or observational
study with dramatic
effect
Individual randomised
trial or (exceptionally)
observational study
with dramatic effect
Non-randomised
controlled cohort/
follow-up study (post-
marketing surveillance)
provided there are
sufficient numbers to
rule out a common
harm. (For long-term
harms the duration of
follow-up must be
sufficient.)**
Case-series, case-control
or historically controlled
studies**
Mechanism-based
reasoning
What are the rare
harms? (treatment
harms)
Systematic review of
randomised trials or
n-of-1 trial
Randomised trial or
(exceptionally)
observational study
with dramatic effect
Is this (early detection)
test worthwhile?
(screening)
Systematic review of
randomised trials
Randomised trial Non-randomised
controlled cohort/
follow-up study**
Case-series, case-control
or historically controlled
studies**
Mechanism-based
reasoning
*Level may be graded down on the basis of study quality, imprecision, indirectness [study PICO (patient, problem or population, intervention, comparison, control
or comparator, outcome) does not match questions PICO)], because of inconsistency between studies, or because the absolute effect size is very small; level may
be graded up if there is a large or very large effect size
**As always, a systematic review is generally better than an individual study
N/A not applicable
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trauma death, with about a 50% reduction in “prevent-
able death” [46]. Inter-hospital transfer of patients does
not seem to change overall mortality [47], and the evi-
dence neither supports nor refutes direct transport from
the accident scene to a major trauma centre [48]. How-
ever, there is some evidence that a lower threshold for
trauma centre care should be used in patients aged >
65 years [49]. No definitive conclusion can be drawn
about the relationship between a hospital’s trauma patient
volume and outcomes [50, 51]. Despite a lack of evidence,
there is a consensus that “systemised” trauma care that
matches each patient to the most appropriate treatment
facility in a timely manner is advantageous, whereby the
definition of “appropriate” will depend on the patient pro-
file, the nature of the injuries and the hospital facilities
available [52].
Trauma patients in need of emergency surgery for
ongoing haemorrhage have increased survival if the
elapsed time between the traumatic injury and admis-
sion to the operating theatre is minimised. More than
50% of all trauma patients with a fatal outcome die
within 24 h of injury [7]. Despite a lack of evidence from
prospective RCTs, well-designed retrospective studies
provide evidence for early surgical intervention in
patients with traumatic haemorrhagic shock [53, 54]. In
addition, studies that analyse trauma systems indirectly
emphasise the importance of minimising the time be-
tween admission and surgical bleeding control in patients
with traumatic haemorrhagic shock [55]. Minimisation of
time to surgery is an accepted principle of trauma care
and is unlikely to ever be tested in a clinical trial due to
lack of equipoise.
Local bleeding management
Recommendation 2 We recommend local compression
to limit life-threatening bleeding. (Grade 1A)
We recommend adjunct tourniquet use to stop
life-threatening bleeding from open extremity injuries in
the pre-surgical setting. (Grade 1B)
We recommend the adjunct use of a pelvic binder to limit
life-threatening bleeding in the presence of a suspected pel-
vic fracture in the pre-surgical setting. (Grade 1B)
Rationale
Most life-threatening bleeding from extremities observed
in the civilian setting can be controlled by local compres-
sion, by either manual compression or pressure bandages
applied to the wounds. Extra local compression to the
source of bleeding can also be achieved in certain pene-
trating injuries by Foley catheter insertion directly into the
wound [56]. Foley catheter balloon tamponade was ini-
tially described in bleeding penetrating injuries of the neck
[57, 58]. In addition, the use of topical haemostatic agents
in combination with direct pressure enhances bleeding
control in the pre-hospital setting [59] (see also R21).
When uncontrolled arterial bleeding occurs as a result
of mangled extremity injuries, including penetrating or
blast injuries or traumatic amputations, a tourniquet is a
simple and efficient method with which to acutely con-
trol haemorrhage [60–64]. Tourniquet application has
become the standard of care for the control of severe ex-
ternal haemorrhage following military combat injuries,
and several publications report the effectiveness of tour-
niquets in this specific setting in adults [60–63, 65] and
children [66]. A study of volunteers showed that any
tourniquet device presently on the market works effi-
ciently [64]. The study also showed that “pressure point
control” was ineffective because collateral circulation
was observed within seconds. Tourniquet-induced pain
was not often reported by patients. No evidence or opin-
ion supports the use of tourniquets in the context of
closed injuries.
Tourniquets should be left in place until surgical con-
trol of bleeding is achieved [61, 63]; however, this time
span should be restricted as much as possible. Improper
or prolonged placement of a tourniquet can lead to
complications such as nerve paralysis and limb ischae-
mia [67]; however, these effects are rare [65]. Some
publications suggest a maximum application time of 2 h
[67]. Reports from military settings describe cases in
which tourniquets have remained in place for up to 6 h
with survival of the extremity [61]. Much recent discus-
sion has centred on the translation of this evidence to
civilian practice, as little published evidence exists. Bleed-
ing from most civilian wounds can be controlled using
local pressure; however, uncontrolled external bleeding
from either blunt [59] or penetrating [68] limb injury
should be controlled with a tourniquet.
Patients with severe high-energy and complex pelvic
trauma, haemodynamic instability and massive blood loss
belong to the most severe and highly lethal group of trauma
patients, and their management is time-sensitive and chal-
lenging [69]. Global mortality in polytraumatised patients
presenting with pelvic ring fractures remains high (33%)
despite improvements in management and treatment algo-
rithms [70]. The pelvis can create a multifocal haemor-
rhage, including significant retroperitoneal haematoma,
which may not be easily compressible or possible to man-
age using traditional surgical methods [71]. Treatment of
pelvic ring fractures requires re-approximation of bony
structures to address mechanical instability, damage-con-
trol resuscitation (DCR) to restore haemostasis, assessment
for associated injuries and triage of investigations. In
addition, multimodal haemorrhage control [external fix-
ation and compression (damage-control orthopaedics),
retroperitoneal packing (damage-control surgery), urgent
radiologic angioembolisation or resuscitative endovascular
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balloon occlusion of the aorta (REBOA)] by multidisciplin-
ary trauma specialists (general surgeons, orthopaedic sur-
geons, endovascular surgeons/interventional radiologists) is
required [69, 72–75].
Correctly placed pelvic binders lead to anatomical
closure of the pelvic ring, with a favourable haemo-
dynamic effect. These devices are increasingly being used
in the pre-hospital setting if a pelvic fracture is suspected
[76, 77]. Unstable pelvic ring fractures may be clinically
and radiologically overlooked during initial assessment,
especially in unconscious patients, and the time point for
opening and/or removal remains controversial. In-hospital
external fixation stabilises anterior pelvic ring lesions and
can be combined with posterior stabilisation using percu-
taneous sacro-iliac screws in the presence of associated
lesions to the posterior ring. The external fixator is
especially useful in the acute phase, acquiring an accept-
able reduction and an adequate stability in the partially
unstable lesions and also reduces pelvic volume and
bleeding [78]. In a small quasi-randomised study, pelvic
packing achieved more rapid control of severe pelvic
trauma than angioembolisation [79]. The median time
from admission to angiography was 102 min (range
76−214), and longer than 77 min (range 43–125) from
admission to pelvic packing (p < 0.01). The procedure time
for angioembolisation was 84min (range 62–105), while
the surgical time was 60min (range 41–92; p < 0.001). Nine
patients had to undergo pelvic packing for persistent bleed-
ing after embolisation. If haemodynamic instability persists,
a laparotomy for haemostasis according to damage-control
principles to all potentially involved systems (digestive, vas-
cular, urinary and bone) should be performed [80].
Ventilation
Recommendation 3 We recommend the avoidance of
hypoxaemia. (Grade 1A)
We recommend normoventilation of trauma patients.
(Grade 1B)
We suggest hyperventilation in the presence of signs
of imminent cerebral herniation. (Grade 2C)
Rationale
Tracheal intubation of severely injured patients is a delicate
procedure that involves risks and requires skill and proper
training of the operator. The fundamental objective of in-
tubation is to ensure adequate ventilation and oxygenation
and to guarantee the patency of the airway. There are
well-defined situations in which intubation is mandatory,
for example, in the presence of airway obstruction, altered
consciousness [Glasgow Coma Scale (GCS) ≤ 8], haemor-
rhagic shock, hypoventilation or hypoxaemia [81]; however,
other aspects should also be considered. For example, the
introduction of positive pressure can induce potentially
life-threatening hypotension in hypovolaemic patients [82],
and some authors have reported increased mortality asso-
ciated with pre-hospital intubation [83].
Several factors influence the success of intubation and
therefore patient prognosis. Rapid sequence induction
appears to be the best method [84]; however, several as-
pects remain to be clarified, such as who is best suited to
make the decision to intubate, which drugs and which res-
cue device to use and the ideal infrastructure of emer-
gency services. Most of the available data come from
retrospective studies, which are open to bias; therefore,
controversy remains about the appropriate use of tracheal
intubation in patients following traumatic injury [85].
The negative effects of hypoxaemia are well known,
particularly in patients with traumatic brain injury (TBI)
[86, 87]; therefore, high oxygen concentrations are gen-
erally targeted during the initial management of these
patients to ensure oxygen delivery to ischaemic areas.
Some studies, however, have suggested that prolonged
hyperoxia is associated with increased mortality [88, 89].
A recent meta-analysis based on high-quality evidence
[90] showed that prolonged liberal oxygen therapy in
acutely ill adults increased mortality without improving
other patient-important outcomes. Extreme hyperoxia
(PaO2 > 487 mmHg [> 65 kPa]) should therefore be
avoided in patients with TBI [91]. Another recent study
showed that the mortality increase was related to the
duration and extent of hyperoxia [92]. On the other
hand, mechanical ventilation using settings that targeted
an oxygen saturation of 88–92% compared with > 95%
did not negatively influence survival in critical care pa-
tients [93]. The negative effects of hyperoxia are likely
related to altered microcirculation associated with high
PaO2 [94] and increased production of oxygen-free radi-
cals [95] and patients with severe brain injury may be at
particular risk [96]. Therefore, although hyperoxia may
increase the oxygen content and delivery in an extremely
anaemic trauma patient and be associated with a benefit
in this specific situation, hyperoxia should be returned
to normoxia as soon as the haemoglobin (Hb) level
allows [91].
While adequate ventilation can affect the outcome of
severe trauma patients, there is a tendency for rescue
personnel to hyperventilate patients during initial resus-
citation [97, 98]. Hyperventilated trauma patients appear
to have increased mortality when compared with non-
hyperventilated patients [88]. Target PaCO2 should be
5.0–5.5 kPa (35–40mmHg).
The effect of hyperventilation on bleeding and out-
come in patients with severe trauma without TBI is not
known. There are several potential mechanisms by
which the adverse effects of hyperventilation and hypo-
capnia could be mediated, including increased vaso-
constriction with decreased cerebral blood flow and
impaired tissue perfusion. Cerebral tissue lactic acidosis
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has been shown to occur almost immediately after in-
duction of hypocapnia in children and adults with TBI
and haemorrhagic shock [99]. In addition, even a modest
level of hypocapnia [< 27mmHg (3.6 kPa)] may result in
neuronal depolarisation with glutamate release and ex-
acerbation of the primary injury via apoptosis [100]. In
the setting of absolute or relative hypovolaemia, an ex-
cessive rate of positive pressure ventilation may further
compromise venous return and produce hypotension
and even cardiovascular collapse [101, 102].
The only situation in which hyperventilation-induced
hypocapnia may play a potential role is imminent cere-
bral herniation. The decrease in cerebral blood flow pro-
duced by acute hypocapnia during hyperventilation
causes a decrease in intracranial pressure that can be
used for short periods of time and in selected cases such
as imminent brain herniation. The presence of signs
such as unilateral or bilateral pupillary dilation or de-
cerebrate posturing are indicators for an extreme risk of
imminent death or irreversible brain damage. Hyperven-
tilation may be used under these circumstances to try to
gain time until other measures are effective [103, 104].
There are no clinical studies that evaluate this practice;
however, there is a clear physiological rationale. Given
the extreme risk of death if no measures are undertaken,
the risk–benefit balance seems favourable; however, it is
important to normalise PaCO2 as soon as feasible.
Ventilation with low tidal volume (around 6mL/kg) is
now recommended in all patients treated with mechan-
ical ventilation, even during surgery [105]. Randomised
studies demonstrate that short-term ventilation (< 5 h)
with high tidal volume (12 mL/kg) without positive end-
expiratory pressure (PEEP) may promote pulmonary
inflammation and alveolar coagulation in patients with
normal lung function [106]. The early use of protective
ventilation with low tidal volume and moderate PEEP is
recommended, particularly in bleeding trauma patients,
who are all at risk of acute respiratory distress syndrome
(ARDS).
II. Diagnosis and monitoring of bleeding
Initial assessment
Recommendation 4 We recommend that the physician
clinically assess the extent of traumatic haemorrhage
using a combination of patient physiology, anatomical
injury pattern, mechanism of injury and the patient re-
sponse to initial resuscitation. (Grade 1C)
We suggest that the shock index (SI) be used to assess
the degree of hypovolaemic shock. (Grade 2C)
Rationale
Trauma physicians must quickly and accurately assess
and predict when a massive transfusion protocol, includ-
ing corresponding logistics, should be activated [107]
and terminated [108]. While blood loss may sometimes
be obvious, neither visual estimation nor physiological
parameters are satisfactory guides to estimate the degree
of bleeding [109]. Knowledge about the mechanism of
injury provides useful information to identify patients at
risk of significant haemorrhage at an early stage. For ex-
ample, the American College of Surgeons defined a
threshold of 6 m (20 ft) as a “critical falling height” asso-
ciated with major injuries, including haemorrhage [110].
Further critical mechanisms include high-energy deceler-
ation impact as well as low-velocity versus high-velocity
gunshot injuries. The mechanism of injury combined with
injury severity and the patient’s physiological presentation
should further guide the decision to initiate early surgical
bleeding control as outlined in the Advanced Trauma Life
Support (ATLS) survey [111–114]. Table 3 summarises es-
timated blood loss based on initial presentation according
to the ATLS classification system of hypovolaemic shock.
This classification has been shown to be useful as a rough
estimation of sustained blood loss in patients with
haemorrhagic shock [115]. However, several groups have
highlighted discrepancies associated with the weight
assigned to each parameter when assessing blood loss that
makes it challenging to classify patients using this system.
Mutschler and co-workers have analysed the adequacy of
this classification and found that > 90% of all trauma pa-
tients could not be categorised according to the ATLS
classification of hypovolaemic shock [116]. The same
group analysed the validity of the ATLS classification and
concluded that this system may underestimate mental
disability in the presence of hypovolaemic shock, while
overestimating the degree of tachycardia associated with
hypotension [117]. A retrospective analysis of the validity
of the ATLS classification showed that increasing blood
loss produces an increase in heart rate and a decrease in
blood pressure, but to a lesser degree than suggested by
the ATLS classification. In addition, there are no signifi-
cant changes in respiratory rate or in level of conscious-
ness with bleeding [118]. Other parameters used for this
classification, such as pulse pressure and urinary output,
may not be adequately assessed during the initial phase of
care. The individual response to fluid challenge as sug-
gested by the ATLS survey should be viewed critically in
the context of low-volume resuscitation and “permissive
hypotension”, which is currently advocated in bleeding
trauma patients.
Isolated vital signs, such as heart rate or systolic blood
pressure, have been shown to be unreliable in the assess-
ment of hypovolaemic shock. Heart rate alone has not
been shown to predict the need for massive transfusion, in
particular not in the geriatric trauma population [119]. In
contrast, the SI, defined as the ratio of heart rate to
systolic blood pressure, has been advocated to better
risk-stratify patients for critical bleeding, increased
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transfusion requirements and early mortality [120, 121].
Paladino and co-workers found that this index may be
useful to draw attention to abnormal values, but may be
too insensitive to exclude disease and should not lower
the suspicion of major injury [122]. Mutschler and
co-workers have suggested a novel and clinically reliable
classification of hypovolaemic shock based on four classes
of worsening base deficit. The objective of this study was
to correlate this classification with corresponding SI strata
for the rapid assessment of trauma patients in the absence
of laboratory parameters. Twenty-one thousand eight
hundred fifty-three adult trauma patients were retrieved
from the TraumaRegister DGU® database and divided into
four strata of worsening SI at emergency department ar-
rival (group I, SI < 0.6; group II, SI ≥ 0.6 to < 1.0; group III,
SI ≥ 1.0 to < 1.4; and group IV, SI ≥ 1.4), and demograph-
ics, injury characteristics, transfusion requirements, fluid
resuscitation and outcomes were assessed [123]. Worsen-
ing of SI was associated with increasing injury severity
scores (ISS) from 19.3 (± 12.0) in group I to 37.3 (± 16.8)
in group IV, while mortality increased from 10.9 to 39.8%.
Increments in SI paralleled increasing fluid resuscitation,
vasopressor use and decreasing Hb, platelet counts and
Quick values. The number of blood units transfused in-
creased from 1.0 (± 4.8) in group I to 21.4 (±2 6.2) in
group IV patients. Of patients, 31% in group III and 57%
in group IV required ≥ 10 red blood cell (RBC) units prior
to intensive care unit (ICU) admission. Another retro-
spective database analysis of 10,234 patients has con-
firmed the role of SI either upon arrival or at departure
from the emergency department as a detrimental sign of
poor outcome in adult trauma patients [124].
A number of scoring systems that predict the risk of
ongoing bleeding, transfusion requirements and coagu-
lopathy have been introduced, but all of these lack
prospective validation [108, 125–131]. Each scoring sys-
tem has its unique advantages and disadvantages, and
specific aspects of each scoring system may affect wide-
spread applicability and statistical performance.
Immediate intervention
Recommendation 5 We recommend that patients with
an obvious bleeding source and those presenting with
haemorrhagic shock in extremis and a suspected source
of bleeding undergo an immediate bleeding control pro-
cedure. (Grade 1C)
Rationale
The patient who presents in extremis is a patient who
has already lost a large amount of blood and is in a se-
vere shock. If bleeding continues, death in shock is an
imminent risk. The source of bleeding may be immedi-
ately obvious, and penetrating injuries are more likely to
require surgical bleeding control. In a retrospective
study of 106 abdominal vascular injuries, all 41 patients
arriving in shock following gunshot wounds were candi-
dates for rapid transfer to the operating theatre for sur-
gical bleeding control [132]. A similar observation in a
study of 271 patients undergoing immediate laparotomy
for gunshot wounds indicates that these wounds com-
bined with signs of severe hypovolaemic shock spe-
cifically require early surgical bleeding control. This
observation is true to a lesser extent for abdominal stab
wounds [133]. Data on injuries caused by penetrating
metal fragments from explosives or gunshot wounds
during the Vietnam War confirm the need for early sur-
gical control when patients present in shock [134]. Fol-
lowing blunt trauma, the mechanism of injury can to a
certain extent determine whether the patient in haemor-
rhagic shock will be a candidate for surgical bleeding
Table 3 American College of Surgeons Advanced Trauma Life Support (ATLS) classification of blood loss based on initial patient
presentation. Signs and symptoms of haemorrhage by class. Table reprinted with permission from the American College of
Surgeons [111]
Parameter Class I Class II (mild) Class III (moderate) Class IV (severe)
Approximate blood loss < 15% 15–30% 31–40% > 40%
Heart rate ↔ ↔ / ↑ ↑ ↑ / ↑↑
Blood pressure ↔ ↔ ↔ / ↓ ↓
Pulse pressure ↔ ↓ ↓ ↓
Respiratory rate ↔ ↔ ↔ / ↑ ↑
Urine output ↔ ↔ ↓ ↓↓
Glasgow Coma Scale score ↔ ↔ ↓ ↓
Base deficit* 0 to − 2 mEq/L – 2 to −6 mEq/L – 6 to −10 mEq/L – 10mEq/L or less
Need for blood products Monitor Possible Yes Massive transfusion protocol
*Base excess is the quantity of base (HCO3
−, in mEq/L) that is above or below the normal range in the body. A negative number is called a base deficit and
indicates metabolic acidosis
Original data from Mutschler et al. [117]
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control. Only a few studies address the relationship be-
tween the mechanism of injury and the risk of bleeding,
however, and none of these publications describes a ran-
domised prospective trial with high-level evidence [135].
We have found no objective data describing the relation-
ship between the risk of bleeding and the mechanism of
injury resulting in skeletal fractures in general or of
long-bone fractures in particular.
Traffic accidents are the leading cause of pelvic injury.
Motor vehicle crashes cause approximately 60% of pelvic
fractures followed by falls from great height (23%). Most
of the remainder result from motorbike collisions and
vehicle-pedestrian accidents [136, 137]. There is a
correlation between “unstable” pelvic fractures and intra-
abdominal injuries [136, 138]. An association between
major pelvic fractures and severe head injuries, concomi-
tant thoracic, abdominal, urological and skeletal injuries is
also well described [136]. High-energy injuries produce
greater damage to both the pelvis and organs. Patients
with high-energy injuries require more transfusion units,
and more than 75% have associated head, thorax, abdom-
inal or genitourinary injuries [139]. It is well documented
that “unstable” pelvic fractures are associated with massive
haemorrhage [138, 140], and haemorrhage is the leading
cause of death in patients with major pelvic fractures. Ver-
tical shear pelvic ring fractures with caudal displacement
of the hemi-pelvis may disrupt the pelvic floor and pelvic
vasculature far more than standard vertical shear injuries.
Inferior displacement of the hemi-pelvis using X-ray im-
aging should therefore alert the surgeon to the possible
presence of severe arterial injuries [141].
In blunt chest trauma haemothoraces, > 500mL should
trigger chest tube insertion. Thoracotomy is indicated for
ongoing bleeding and chest tube output > 1500mL within
24 h or > 200mL for three consecutive hours. Acute
damage-control thoracotomy should be performed for re-
fractive haemorrhagic shock due to persistent chest bleeding
enhanced by initial chest tube output > 1500mL [142, 143].
Further investigation
Recommendation 6 We recommend that patients with-
out a need for immediate bleeding control and an un-
identified source of bleeding undergo immediate further
investigation. (Grade 1C)
Rationale
Haemodynamically stable patients, or patients who can
be stabilised during initial resuscitation, with an uniden-
tified bleeding source, but not in need of immediate
bleeding control, should undergo further investigation of
the chest, abdominal cavity and pelvic ring, which can
be major sources of acute blood loss following traumatic
injury. Besides clinical examination, imaging studies,
including ultrasonography and computed tomography
(CT) [144], as well as laboratory tests, including blood
gas analysis and coagulation profiles, together with func-
tional assays, are recommended diagnostic modalities
during the primary survey [111, 145, 146].
As CT scanners are increasingly being advocated and
integrated into modern resuscitation units and emer-
gency departments, this technique may replace conven-
tional radiographic imaging and ultrasound as diagnostic
measures during the primary survey [147]. The diagnos-
tic accuracy, safety and effectiveness of these immediate
measures are dependent on sophisticated pre-hospital
treatment by trained and experienced emergency per-
sonnel and short transportation times [148, 149]. Prox-
imity of the CT scanner to the resuscitation room in the
emergency department has been shown to have a signifi-
cant positive effect on the probability of survival for the
severely injured patient [150]. Distances of more than
50m had a significant negative effect on outcome and
should be considered when new emergency departments
are planned and constructed. If a CT scanner is not
available in the emergency department, CT scanning im-
plies transportation of the patient to the CT room;
therefore, the clinician must evaluate the implications
and potential risks and benefits of the procedure. Trans-
fer times to and from all forms of diagnostic imaging
need to be considered in the context of haemodynamic
stability. During transport, all vital signs should be
closely monitored and resuscitation measures continued.
If performed quickly within a well-structured environ-
ment and by a well-organised trauma team, CT seems to
be safe, feasible and justified, even in severely injured
haemodynamically unstable patients [151]. Among
haemodynamically unstable haemoperitoneum patients,
17.2% had no documented intraperitoneal injury and
over half of the patients were treated without emergent
surgical intervention [152].
Imaging
Recommendation 7 We recommend the use of focused
assessment with sonography in trauma (FAST) ultra-
sound for the detection of free fluid in patients with
torso trauma. (Grade 1C)
We recommend early imaging using contrast-enhanced
whole-body CT (WBCT) for the detection and identifica-
tion of type of injury and potential source of bleeding.
(Grade 1B)
Rationale
Focused assessment with sonography in trauma (FAST)
The FAST examination has developed into a key instru-
ment in the acute evaluation of trauma patients with sus-
pected abdominal and thoraco-abdominal injuries [153].
FAST techniques are being used with reduced examin-
ation times and a focused assessment of specific clinical
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issues using only a few standardised cross-sectional planes
[154]. As a rapid and non-invasive diagnostic approach to
the detection of haemorrhages in the peritoneal, pleural
and pericardial cavities in the emergency department,
FAST represents a cornerstone of the primary ATLS sur-
vey [153, 155–157]. Volume status can be assessed
non-invasively using ultrasound of the inferior vena cava.
Several studies have indicated the specificity and accuracy,
but low sensitivity, of initial FAST for detecting and
excluding free intraperitoneal fluid as well as intra-abdom-
inal injuries [158–164] in both penetrating [165] and blunt
abdominal trauma [166, 167]. Liu and colleagues [168]
found a high sensitivity, specificity and accuracy of initial
ultrasound examination for the detection of haemoperito-
neum. In a retrospective registry study, free fluid or organ
injury was detected in 72.4% of patients using FAST versus
84.3% using CT, yielding a sensitivity of 92% for initial
FAST [169]. In another retrospective study that included
1540 hypotensive patients (1227 blunt, 313 penetrating
trauma), ultrasound examination had a sensitivity and
specificity close to 100% for free intra-abdominal fluid
[170]. The double-line sign, which has been described as a
wedge-shaped hypoechoic area in the Morison pouch,
bounded on both sides by echogenic lines during FAST,
may represent a false-positive finding for free intraperito-
neal fluid with an overall prevalence of 27% [171].
A recent retrospective review examined the role of
FAST as a screening tool for identifying intra-abdominal
injuries [172]. A total of 1671 blunt-trauma patients were
assessed over 1.5 years, and intra-abdominal injuries were
confirmed in 146 patients using CT and/or laparotomy.
Intraoperative findings included injuries to the liver,
spleen, kidneys and bowels. Among 114 haemodynamic-
ally stable patients, FAST was positive in 25 patients, with
a sensitivity of 22%. FAST was positive in 9 of 32 haemo-
dynamically unstable patients, with a sensitivity of 28%.
Free peritoneal fluid and splenic injury were associated
with a positive FAST on univariate analysis and were inde-
pendent predictors of a positive FAST on multiple logistic
regression. An updated Cochrane review from 2015, in-
cluding RCTs, assessed the effect of diagnostic algorithms
using ultrasonography, including FAST examinations, in
the emergency department relative to early, late and over-
all mortality of patients with suspected blunt abdominal
trauma [173]. Four studies were identified, but the trials
were of overall poor to moderate methodological quality.
Mortality data were pooled from three trials involving
1254 patients; the risk ratio (RR) in favour of the FAST
arm was 1.00 [95% confidence interval (CI) 0.50–2.00].
FAST-based pathways reduced the number of CT
scans [random-effects model risk difference (RD) − 0.52,
95% CI − 0.83 to − 0.21], but the meaning of this result
remained unclear. It is unlikely that FAST will ever be in-
vestigated by means of a confirmatory, large-scale RCT;
therefore, this review may provide the best available evi-
dence for clinical practice guidelines and management
recommendations. From the few published head-to-head
studies, it appears that negative ultrasound scans are likely
to reduce the incidence of multidetector CT (MDCT)
scans, which, given the low sensitivity of FAST (or
reliability of negative results), may adversely affect the
diagnostic yield of the trauma survey. At best, ultrasound
has no negative impact on mortality or morbidity.
In haemodynamically stable patients, a negative FAST
without a CT scan may result in missed intra-abdominal
injuries and should direct further diagnostic investigations.
A number of patients who present with free intra-abdom-
inal fluid according to ultrasound can safely undergo fur-
ther investigation using multislice CT (MSCT). Under
normal circumstances, adult patients need to be haemo-
dynamically stable when MSCT is performed outside of
the emergency department [170]. Haemodynamically
stable patients with a high-risk mechanism of injury, such
as high-energy trauma, or even low-energy injuries in eld-
erly individuals, should be scanned after ultrasound for
additional injuries using MSCT. As CT scanners are
integrated into resuscitation units, WBCT diagnosis may
replace ultrasound as a diagnostic method. In haemo-
dynamically unstable blunt-trauma patients with clear
physical findings on examination, the decision to perform
exploratory laparotomy should not be discouraged by a
negative FAST [169, 172].
Follow-up sonography as part of secondary or tertiary
surveys in patients without abdominal parenchymal
organ lesions or free intra-abdominal fluid on initial
WBCT is not routinely required, but should be per-
formed if indicated on a clinical or laboratory basis due
to its rapid and non-invasive character [174]. New
ultrasound techniques using second-generation contrast
agents [contrast-enhanced ultrasound (CEUS)] have
been developed, allowing all of the vascular phase to be
performed in real time, increasing ultrasound capability
to detect parenchymal injuries, enhancing some qualita-
tive findings, such as lesion extension, margins and its
relationship with capsule and vessels [175]. These tech-
niques are currently under investigation.
Computed tomography (CT) The advantages of MSCT,
including WBCT, among severely injured patients in
time savings, diagnostic accuracy and potentially also
survival have been documented [151, 176–184]. The in-
tegration of modern MSCT scanners in the emergency
department area prompts immediate assessment of any
trauma victim likely to survive the assessment following
admission [177, 184], thereby allowing timely diagnosis,
differentiation between various types of major vascular
injury, identification of associated findings, specific local-
isation of the source of bleeding and planning for
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bleeding control [80, 185, 186]. A 1-year review of early
management of pelvic fracture patients documented a
significant delay in the recognition of (major) pelvic frac-
tures, including those associated with hip dislocations
and (potential) pelvic bleeding with selective pelvic
X-ray versus CT scanning [187]. More than one third of
patients with thoracic stab wounds presented with nega-
tive chest X-ray, but pathologies using CT [188].
MDCT is currently considered the “gold standard” in
the assessment of intra-abdominal blunt-traumatic injury
[189]. Mesenteric active bleeding, adjacent interloop-free
fluid and bowel wall perfusion defects have been associ-
ated with surgically significant bowel injuries and an
overall accuracy, sensitivity, specificity, positive predictive
value (PPV) and negative predictive value (NPV) for
64-slice MDCT of 73.8%, 80.0%, 73.0%, 28.6%, and 96.4%,
respectively [190]. Advancements in modern MDCT tech-
nology and an improved understanding of optimal proto-
cols have enabled full-body scanning of adequate image
quality and in less than 30 s. In a retrospective study com-
paring 370 patients in two groups, Weninger and col-
leagues [184] showed that faster diagnosis using MSCT
led to shorter emergency department and operating room
time and shorter ICU stays [184]. Huber-Wagner et al.
also showed the benefit of WBCT integration into early
trauma care as CT diagnosis significantly increased the
probability of survival in patients with polytrauma [147,
150]. WBCT as a standard diagnostic tool during the earli-
est resuscitation phase provides the added benefit of iden-
tifying head and chest injuries and other bleeding sources
in multiply injured patients. Nonselective throracic CT
was superior to selective CT in detecting thoracic injuries
in blunt trauma [191], and thoracic CT showed a NPV
value of 99% in triaging haemodynamically normal pa-
tients with penetrating chest trauma [192]. A comparison
between emergency physicians and on-call radiologists on
the accuracy of CT interpretations showed that emer-
gency physicians were successful in identifying fatal injur-
ies on trauma scans following a short-term interpretation
training [193].
A series of systematic reviews has assessed the bene-
fits of WBCT in the early management of severely in-
jured patients and all showed a survival benefit with
the use of WBCT in trauma patients [194–197]. In con-
trast, the only prospective RCT conducted to date in
this area compared immediate WBCT scanning versus
conventional imaging and selective CT scanning in pa-
tients with severe trauma [A Multicenter, Randomised
Study of Early Assessment by CT Scanning in Severely
Injured Trauma Patients (REACT-2)] in four centres in
the Netherlands and one in Switzerland and found no
survival benefit with WBCT [198]. A total of 1403
trauma patients aged ≥ 18 years with compromised vital
parameters, clinical suspicion of life-threatening
injuries or severe injury were randomly assigned (1:1)
to immediate WBCT scanning or to a standard
work-up with conventional imaging supplemented with
selective CT scanning. The primary analysis included
541 patients in the immediate WBCT scanning group
and 542 in the standard work-up group. In-hospital
mortality did not differ between groups (WBCT 86
[16%] of 541 vs standard work-up 85 [16%] of 542; p =
0.92). In-hospital mortality also did not differ in sub-
group analyses among patients with polytrauma
(WBCT 81 [22%] of 362 vs standard work-up 82 [25%]
of 331; p = 0.46) and TBI (68 [38%] of 178 vs 66 [44%]
of 151; p = 0.31).
The WBCT protocol usually includes a non-contrast
scan of the brain and neck followed by a contrast-enhanced
scan of the chest, abdomen and pelvis. Several authors have
emphasised the benefit of contrast medium-enhanced CT
scanning. MSCT is the “gold standard” for the identification
of retroperitoneal haemorrhage (RPH). After injection of
intravenous (i.v.) contrast media, CT identified RPH in all
cases (100%) and may detect the source of bleeding (40%)
by extravasation of contrast media [199]. Dual-phase
contrast-enhanced CT (CECT) without CT angiography
showed a high sensitivity (93.9%) and PPV (88.6%) com-
pared with digital subtraction angiography for the detection
of active haemorrhage in patients with blunt abdomino-
pelvic trauma [200]. Anderson et al. [201, 202] found high
accuracy in the evaluation of splenic injuries resulting
from trauma after administration of an i.v. contrast
medium. Delayed-phase CT may be used to detect active
bleeding in solid organs. Fang et al. [203] demonstrated
that the pooling of contrast material within the peritoneal
cavity in blunt liver injuries indicates active and massive
bleeding. Patients with this finding showed rapid dete-
rioration of haemodynamic status, and most required
emergent surgery. Intra-parenchymal pooling of contrast
material with an unruptured liver capsule often indicates a
self-limited haemorrhage, and these patients respond well
to non-operative treatment. Tan and colleagues [204]
found that patients with hollow viscus and mesenteric in-
juries following blunt abdominal trauma exhibited an ab-
normal preoperative CT scan. Wu et al. [205] confirmed
the accuracy of CT in identifying severe, life-threatening
mesenteric haemorrhage and blunt bowel injuries. Al-
though contrast extravasation (CE) in CT scans of pelvises
with blunt trauma may be common, many patients will
not require intervention such as angioembolisation [206].
The negative predicted value of 100% should be reassuring
to trauma surgeons such that if a modern CT scanner is
used, and no CE is detected using CT, then the pelvis is
unlikely to be a source of haemorrhagic shock. All of these
findings are attributable to both increased comfort with
observing CEs and the increased sensitivity of modern
CT scanners.
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The issue of radiation is still debated, but iterative as
well as split-bolus protocols can now significantly reduce
radiation exposure [207]. Imaging algorithms including
WBCT in multi-trauma patients are standardised but
may vary substantially between centres [208]. An online sur-
vey among level-1 trauma centres in Switzerland revealed
radiation doses ranging from 1268 to 3988mGy × cm per
WBCT. Including WBCT in the initial work-up of trauma
patients results in higher radiation doses, but fewer
additional CT examinations are needed, and the time to
complete trauma-related imaging is shorter [209].
Risk-stratification criteria based upon documented sus-
pected injuries during the primary survey at the site of the
accident or the emergency department may identify
high-energy trauma patients not in need of extended
radiological imaging, including WBCT [210]. To a large
extent, WBCT in high-energy trauma patients does not
affect patient care if the patient is mentally alert, not in-
toxicated or showing signs of more than minor injuries
when clinically evaluated. The risk of missing important
traumatic findings in these patients is very low. Observa-
tion of the patient with re-examination instead of imaging
may be considered in this group, often young patients, for
whom radiation dose is an issue [210]. Davies and
co-workers have developed a scoring system with a sensi-
tivity of 97% (95% CI 88–99%) and a specificity of 56%
(95% CI 49–64%) for significant injury to stratify the use
of trauma radiographs, focused on CT and WBCT, and
which may add an objective component to decision-mak-
ing to reduce unnecessary scans [211]. Regression model-
ling identified clinical signs in more than one body region,
reduced GCS, haemodynamic abnormality, respiratory ab-
normality and mechanism of injury as independent pre-
dictors of polytrauma.
Haemoglobin
Recommendation 8 We recommend that a low initial
Hb be considered an indicator for severe bleeding asso-
ciated with coagulopathy. (Grade 1B)
We recommend the use of repeated Hb measurements
as a laboratory marker for bleeding, as an initial Hb value
in the normal range may mask bleeding. (Grade 1B)
Rationale
Hb or haematocrit (Hct) assays are part of the basic
diagnostic work-up for trauma patients. Recently, non-
invasive Hb monitoring has also been tested and showed
high precision compared with laboratory measurements
[212, 213]. Currently, the use of Hb rather than Hct is
widespread, and the latter is a calculated parameter de-
rived from the Hb. However, most studies on which
these recommendations are based analysed Hct rather
than Hb. Because both parameters are used interchange-
ably in clinical practice, in these guidelines, we refer to
both parameters according to the parameter described
by the literature.
The diagnostic value of the Hb or Hct for detecting
trauma patients with severe injury and occult bleeding
sources has been a topic of debate [214–216]. A major
limitation of the diagnostic value is the confounding in-
fluence of resuscitation measures on the Hb/Hct due to
administration of i.v. fluids and erythrocyte concentrates
[217–219]. In addition, initial Hb or Hct measurements
may not accurately reflect blood loss, because patients
bleed whole blood and compensatory mechanisms that
move fluids from interstitial spaces require time. The
suggestion that initial Hb/Hct for the detection of severe
bleeding is associated with low sensitivity has been chal-
lenged. In a retrospective study of 196 trauma patients,
Ryan et al. [220] found that Hct at admission closely cor-
relates with haemorrhagic shock. Knottenbelt et al. eval-
uated 1000 trauma patients and found lower initial Hb
level in moderately and severely shocked patients [221].
Other authors also recommended that the initial Hct
play a greater role in the assessment of blood loss in
trauma patients. In a retrospective analysis of 1492 con-
secutive trauma patients, Thorson et al. found that the
initial Hct is associated more closely with the need for
transfusion than other parameters such as heart rate,
blood pressure or acidaemia, suggesting that fluid shifts
are rapid following traumatic injury and imply a more
important role for Hct in the initial assessment of
trauma victims [222]. An initial low Hb level is one of
the predictive criteria for massive transfusion using the
trauma-associated severe haemorrhage (TASH) [126]
and Vandromme [223] scores.
Thorson et al. [224] analysed changes in Hct in two suc-
cessive determinations and concluded that the change in
Hct is a reliable parameter with which to detect blood loss.
Two prospective observational diagnostic studies also
showed the sensitivity of serial Hct measurements for the
detection of patients with severe injury [214, 216]. Holstein
and co-workers showed that a Hb level below 80 g/L in pa-
tients with pelvic trauma was associated with non-survival
[225]. Decreasing serial Hct measurements may reflect con-
tinued bleeding. However, a patient with significant bleed-
ing may maintain the serial Hct in the context of ongoing
resuscitation and physiological compensatory mechanisms.
Acute anaemia may play an adverse role in the clotting
process, because a low Hct may reduce platelet marginalisa-
tion, with a potentially negative impact on platelet activa-
tion. Moreover, Schlimp et al. [226] demonstrated strong
correlation between fibrinogen levels and Hb.
Serum lactate and base deficit
Recommendation 9 We recommend serum lactate and/
or base deficit measurements as a sensitive test to estimate
and monitor the extent of bleeding and shock. (Grade 1B)
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Rationale
Serum lactate has been used as a diagnostic parameter
and prognostic marker of haemorrhagic shock since the
1960s [227]. The amount of lactate produced by anaer-
obic glycolysis is an indirect marker of oxygen debt, tis-
sue hypoperfusion and the severity of haemorrhagic
shock [228–231]. Similarly, base deficit values derived
from arterial blood gas analysis provide an indirect esti-
mation of global tissue acidosis due to impaired perfu-
sion [230, 231]. Vincent and colleagues [232] showed
the value of serial lactate measurements for predicting
survival in a prospective study in patients with circula-
tory shock. This study showed that changes in lactate
concentration provide an early and objective evaluation
of patient response to therapy and suggested that re-
peated lactate determinations represent a reliable prog-
nostic index for patients with circulatory shock [232].
Abramson and colleagues [233] performed a prospective
observational study in patients with multiple traumatic
injuries to evaluate the correlation between the time
course of blood lactate levels and survival. All patients
in whom lactate levels returned to the normal range
(≤ 2 mmol/L) within 24 h survived. Survival decreased to
77.8% if normalisation occurred within 48 h and to 13.6%
in those patients in whom lactate levels were elevated
above 2mmol/L for more than 48 h [233]. These findings
were confirmed in a study by Manikis et al., who showed
that initial lactate levels were higher in non-survivors after
major trauma and that prolongation of time to normalisa-
tion of lactate levels of more than 24 h was associated with
the development of post-traumatic organ failure [234].
The determination of lactate and/or base deficit may be
particularly important in penetrating trauma. Following
this type of injury, triage vital signs, such as blood pres-
sure, heart rate and respiratory rate, do not reflect the se-
verity of injury and are not related to lactate or base
deficit levels [235]. A systemic review on the value of
blood lactate kinetics in critically ill patients has been pub-
lished recently [236].
The reliability of lactate determination may be lower
when traumatic injury is associated with alcohol con-
sumption. Ethanol metabolism induces the conversion
of pyruvate to lactate via lactate dehydrogenase, causing
an increase in the level of lactate in the blood. In
alcohol-associated trauma, therefore, base deficit may be
a better predictor of prognosis than lactate [237], al-
though some authors suggest that ethanol-induced acid-
osis may also affect base deficit, masking the prognosis
of trauma patients [238]. Therefore, in the case of trau-
matic injury associated with alcohol consumption, the
results of the lactate measurements should be inter-
preted with caution.
Similar to the predictive value of lactate levels, the
initial base deficit, obtained either from arterial or
peripheral venous blood [239] has been established as a
potent independent predictor of mortality in patients
with traumatic haemorrhagic shock [237]. Davis and col-
leagues stratified the extent of base deficit into three cat-
egories: mild (− 3 to − 5 mEq/L), moderate (− 6 to − 9
mEq/L) and severe (<− 10 mEq/L) and established a sig-
nificant correlation between the admission base deficit,
transfusion requirements within the first 24 h and the
risk of post-traumatic organ failure or death [240]. The
same group of authors showed that the base deficit is a
better prognostic marker of death than the pH in arterial
blood gas analyses [241]. Mutschler et al. [123] analysed a
cohort of 16,305 severely injured patients derived from the
German Trauma Registry database and concluded that the
determination of base deficit upon emergency department
admission predicts transfusion requirements and mortality
better than ATLS classification [123]. Furthermore, the
base deficit was shown to represent a highly sensitive
marker for the extent of post-traumatic shock and mortal-
ity, both in adult and paediatric patients [242, 243].
Although both the base deficit and serum lactate
levels are well correlated with shock and resuscitation,
these two parameters do not strictly correlate with each
other in severely injured patients [244], and lactate
levels more specifically reflect the degree of tissue hy-
poperfusion [230, 231, 244].
Coagulation monitoring
Recommendation 10 We recommend that routine prac-
tice include the early and repeated monitoring of haemo-
stasis, using either a combined traditional laboratory
determination [prothrombin time (PT), platelet counts
and Clauss fibrinogen level] and/or point-of-care (POC)
PT/international normalised ratio (INR) and/or a visco-
elastic method (VEM). (Grade 1C)
We recommend laboratory screening of patients
treated or suspected of being treated with anticoagulant
agents. (Grade 1C)
Rationale
Standard coagulation monitoring comprises early and re-
peated determination of PT, platelet counts and Clauss
fibrinogen level. The PT measures the activity of the
extrinsic coagulation pathway (factors II, VII, and X),
resulting in a prolonged PT value when any of these
factors is low. There is frequently confusion in the
literature over the terms PT and INR, because they are
often used interchangeably, despite being based on dif-
ferent comparative values. Strictly speaking, PT is the ra-
tio of the patient’s PT compared with a PT performed
using pooled plasma from healthy individuals. Conven-
tionally, PT testing has been used for all patients except
those treated with a vitamin K antagonist (VKA). The
INR, on the other hand, represents a PT in which the
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activating tissue factor used in the assay is assigned a
value such that the effect of the VKA is consistent
across laboratories.
Because the definition of traumatic coagulopathy is
equivalent to a prolongation of the PT [11], PT values
on admission have been shown to correlate with the de-
gree of shock and to be predictive of clinical outcome in
the presence of traumatic haemorrhage. Peltan et al., for
example, found that acute traumatic coagulopathy af-
fected 50% of patients with traumatic bleeding, defined
as a PT:INR ratio > 1.2 and 21% of subjects if traumatic
coagulopathy was defined as an INR > 1.5 [245]. The lat-
ter was significantly associated with all-cause death,
haemorrhagic shock-associated death, venous thrombo-
embolism (VTE) and multiple organ failure. As a result,
PT/INR is used to assess the severity of traumatic coag-
ulopathy and the need for transfusion.
Recently, POC monitors (portable coagulometers) that
assess the INR have improved in quality and ease of use.
They are widely applied by professionals in anticoagulant
clinics and at home by patients to monitor the effect of
VKAs. Use may be more common in the emergency de-
partment to identify patients with significant coagulopa-
thy compared with laboratory-based methods [246, 247].
It is, however, important to note that variation between
these devices and a laboratory-based PT may be 15%
[246, 248]. David et al. suggest that a near-patient INR
value of 1.5 could be used to guide fresh frozen plasma
(FFP) or prothrombin complex concentrate (PCC) admin-
istration [247]. Goodman et al. demonstrated that POC
INR testing was more rapid and cheaper than a modified
thrombelastography [TEG®; rapid TEG® (r-TEG®)] and cor-
related not only with r-TEG® values, but also with blood
product transfusion [249].
It is often misunderstood that the conventional coagu-
lation screens [PT and activated partial thromboplastin
time (APTT)] only provide information on levels of co-
agulation factor [250]. These values, therefore, will typic-
ally appear normal during early blood loss, despite the
potential for an underlying activation of coagulation and
thrombus formation [251–254]. The turnaround time
for results of VEM [TEG®, rotational thromboelastome-
try (ROTEM®)], as for POC PT/INR, has been shown to
be significantly shorter than conventional laboratory
testing, with a time saving of 30–60 min [251, 255, 256].
VEM may also be useful in the detection of coagulation
abnormalities associated with the use of direct thrombin
inhibitors such as dabigatran, argatroban, bivalirudin or
hirudin, although these tests cannot discriminate be-
tween the effects of inhibitors and the impact of trau-
matic coagulopathy [257].
VEM provides a rapid assessment of haemostasis to
support clinical decision-making. This in turn has gener-
ated a growing confidence in these methods and
increased use in children, adolescent and adult patients
[29, 256, 258]. To date, however, only one open
randomised controlled study has been completed, which
involved 111 injured patients from an academic level-1
trauma centre meeting criteria for massive transfusion
protocol activation [259]. Patients were randomised to re-
ceive either a massive transfusion protocol goal-directed
using TEG® or by conventional coagulation assays (CCA).
Survival at 28 days in the TEG® group was significantly
higher than the CCA group, with 20 deaths in the CCA
group (36.4%) compared with 11 in the TEG® group
(19.6%) (p = 0.049). Most bleeding deaths occurred within
the first 6 h following patient arrival at the clinic (21.8%
CCA group vs 7.1% TEG® group) (p = 0.032). CCA
patients required a similar number of RBC units as the
TEG® patients but more plasma units [CCA, 2.0 (0–4);
TEG®, 0.0 (0–3)] (p = 0.022), and more platelet units
[CCA, 0.0 (0–1); TEG®, 0.0 (0–0)] (p = 0.041) in the first 2
h of resuscitation. Despite these very promising results, it
should be noted that this study was open, unblinded, and
that randomisation into either of the two treatment mo-
dalities was based on alternating weeks, which potentially
introduces a bias into the care of the patients.
r-TEG® is a new variant of VEM in which coagulation
is initiated by the addition of kaolin and tissue factor,
which appears to reduce the measurement time com-
pared with conventional TEG® in adults [260, 261] and
children [262, 263]. One of several validation studies
included 808 adult trauma patients in a prospective
international multicentre cohort study from four major
trauma centres. The authors demonstrated that a
ROTEM® clot amplitude of 5 mm was a valid marker for
acute traumatic coagulopathy and a predictor of massive
transfusion [22]. Meyer et al. evaluated fibrinogen levels
in trauma patients determined using two whole-blood
VEM, TEG® functional fibrinogen (FF) and ROTEM®
FIBTEM (FIBTEM, fibrin-based extrinsically activated
test) and compared these with the plasma-based Clauss
method. Both methods correlated with the Clauss fi-
brinogen level, without variation in the strength of these
correlations [264].
Recent discussion has focused on the specific useful-
ness of VEM in the detection of early fibrinolysis. On
the one hand, Moore et al. found that VEM only demon-
strates hyperfibrinolytic traces in a minority of those
with traumatic bleeding [265]. On the other hand, Brohi
et al. have shown that VEM is a poor detector of fibrino-
lytic activation, which they suggest may be due to the
production of soluble S100A10 from the endothelium,
thereby blocking detection of tissue plasminogen activa-
tor by VEM [266]. The widespread use of tranexamic
acid (TXA) in trauma patients may be expected to coun-
teract acute fibrinolysis in these patients. At this time,
therefore, it is not possible to support the use of VEM as
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a superior option over conventional coagulation tests.
Results from the global multicentre Implementing Treat-
ment Algorithms for the Correction of Trauma Induced
Coagulopathy (iTACTIC) study are expected to reveal how
the use of VEM might impact clinical outcomes [267].
Despite the widespread use of VEM, their usefulness is
still being evaluated. In a recent systematic Cochrane re-
view, Hunt et al. [268] found no evidence for the accur-
acy of TEG®, and very little evidence to support the
accuracy of ROTEM®, therefore were unable to offer any
advice about the use of these methods [268]. In another
systematic review, Da Luz et al. [269] concluded that
only limited evidence from observational studies was
available to support the use of VEM in the diagnosis of
early traumatic coagulopathy. While these tests may be
used to predict blood product transfusion, mortality and
other important patient outcomes may be unaffected
[269]. A number of other limitations associated with the
use of VEM have been described elsewhere. TEG® may
lead to unnecessary transfusion with platelets, whereas
the application of ROTEM® may result in goal-directed
fibrinogen substitution. Although use is rapidly increas-
ing, controversy remains at present regarding the utility
of VEM for the detection of posttraumatic coagulopathy.
Agreement between the results of VEM and standard
coagulation tests also remains a matter of debate. Some
studies find acceptable agreement between results [261,
263, 270], while a number of other studies show signifi-
cant discrepancies, even among different VEM (TEG®
and ROTEM®) [29, 248, 271, 272]. In one instance,
Agren et al. suggest that TEG® functional analyses may
have overestimated fibrinogen levels (by more than one
gram per litre) [272]. Elsewhere, Hagemo et al. found
that the correlation was highly variable at different
stages of the clotting process and between centres [273],
highlighting the need for clarification and standardisa-
tion of these techniques. One additional potential limita-
tion of VEM may be the lack of sensitivity in detecting
and monitoring platelet dysfunction due to antiplatelet
drugs. If platelet dysfunction is expected, POC platelet
function tests, for example whole-blood impedance
aggregometry, should be used in addition to VEM. More
research is required to understand these variations, and
in the meantime, physicians should use their own judge-
ment when developing local policies.
Eventually, new POC devices to measure fibrinogen
concentration could represent a new means with which
to assess traumatic coagulopathy. Several monitors are
in development [274] and may compete with VEM in
the near future.
The increasing use of pre-injury anticoagulants and, in
particular, the so-called direct (non-vitamin K-dependent)
oral anticoagulants (DOACs) pose an increasing challenge
in the setting of trauma haemorrhage, as these agents can
substantially complicate the extent and dynamics of bleed-
ing [275]. Retrospectively, preexisting coagulation disorders,
either congenital or acquired, e.g. due to anticoagulant in-
take, were associated with an elevated mortality in trauma
patients with and without head injury (43% versus 17%
[276–279]). While VKAs and antiplatelet agents (APA)
can be assessed using INR measurements and platelet
function assays, to date there is no universally available
and validated (rapid) test system for any of the DOACs
that is associated with meaningful sensitivity and specifi-
city [275]. The standard PT (preferably the INR) is pro-
longed in VKA-treated patients. If time and amount of the
most recent dose of dabigatran are unknown, normal
values for thrombin time, ecarin clotting time and diluted
thrombin time suggest the absence of dabigatran in clinic-
ally relevant concentrations [275]. A normal standard
anti-Xa test may also exclude intake (or efficacy) of an
anti-Xa agent (rivaroxaban, apixaban, edoxaban, betrixa-
ban). If these tests are prolonged, a diluted thrombin time
(Hemoclot® for dabigatran) or a specific anti-Xa test (for
anti-Xa agents) should be performed [280]. Chromogenic
anti-factor-Xa-activity tests can be used to estimate the
plasma concentrations of factor Xa-inhibitors (apixaban,
edoxaban, rivaroxaban), but require calibration with
substance-specific reagents [275, 281, 282].
Platelet function monitoring
Recommendation 11 We suggest the use of POC plate-
let function devices as an adjunct to standard laboratory
and/or POC coagulation monitoring in patients with
suspected platelet dysfunction. (Grade 2C)
Rationale
Traumatic injury has been associated with platelet
dysfunction [283–285]. Unfortunately, neither CCAs nor
standard VEM reliably reflect platelet function status
[286, 287]. Light transmission aggregometry (LTA), con-
sidered the gold standard for the assessment of platelet
function, is inadequate in the acute setting [288]. Several
POC platelet function devices are available, such as the
platelet function analyser (PFA-100®), whole-blood mul-
tiple electrode impedance aggregometry (MEA), platelet
reactivity assay (e.g. VerifyNow®), vasodilator-stimulated
phosphoprotein (VASP) or VEM devices with channels
for measuring platelet function. Different POC tests cap-
ture different aspects of platelet function and are there-
fore not interchangeable in the assessment of platelet
reactivity. However, these devices may be of value in de-
tecting pharmacologically induced platelet inhibition in
trauma patients for whom prior intake of antiplatelet
agents (APA) is unknown, for example in unconscious
or confused patients, and in patients with uncertain
treatment compliance.
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The VerifyNow® platelet reactivity test for aspirin
(VN®-ASA) successfully identified TBI patients who re-
ported using aspirin therapy [289, 290]. The MEA device
allowed rapid assessment of APA activity in patients ad-
mitted for intracranial haemorrhage (ICH) requiring ur-
gent neurosurgical intervention [291] and in TBI [283,
292–294]. The thrombelastography platelet mapping
(TEG®-PM®) assay also identified APA use in trauma pa-
tients [286, 295]; however, PFA-100 showed low sensitiv-
ity and PPVs (48.6% and 63.4%, respectively) for
detecting pharmacologically induced platelet dysfunction
in trauma patients on APA [296]. In one study comparing
MEA, VerifyNow® and TEG®-PM® in adult trauma pa-
tients, specific tests for the arachidonic acid (AA) pathway
in all three devices accurately identified any APA use
(either aspirin or clopidogrel) [286]. AA tests to iden-
tify platelet dysfunction performed with TEG®-PM®
and VerifyNow® devices correlated well with MEA [area
under the curve (AUC) 0.78, 0.89, respectively]. However,
MEA and VerifyNow® had superior AUCs compared with
the TEG®-PM® percent inhibition AUC (both 0.90 vs 0.77).
The adenosine diphosphate (ADP)-specific assays on these
three devices did not correlate with APA use; however, the
number of patients pre-treated with clopidogrel was small
[286]. Trauma patients with normal platelet activity despite
a positive history of APA intake (“non-responders”) or pa-
tients with high on-treatment platelet reactivity (HTPR) can
also be identified using VerifyNow® [289, 290, 293, 297, 298].
In these patients, empiric administration of haemo-
static substances would unnecessarily increase the risk
of thrombotic events.
VerifyNow® [286, 289, 290, 293, 297, 298], MEA
[283, 284, 286, 292, 294, 299–301] and TEG®-PM®
[286, 287, 295, 302–305] can also be used to detect
platelet dysfunction in trauma patients in the absence of
APA intake. A coagulopathy POC panel consisting of
r-TEG® and VN®-ASA successfully identified a subset of
TBI patients with an occult coagulopathy that would other-
wise have been missed [290]. Platelet dysfunction, as indi-
cated by MEA, exhibits a temporal profile whereby MEA
values are low initially and subsequently increase during
the days following TBI [286, 289, 290, 292, 293, 297], simi-
lar to the changes observed perioperatively in elective hip
arthroplasty [306]. Interestingly, both the ADP pathway
and the thrombin receptor pathway measured using a
thrombin receptor activating peptide (TRAP) test are sig-
nificantly affected in trauma patients [301].
Distinguishing pharmacologic from trauma-induced
platelet receptor hypofunction is not easy, as both
conditions are associated with assay values below the
reference interval. Moreover, diagnostic cut-offs for
pathologic platelet dysfunction after traumatic injury
have not been established. For example, ADP inhibition
measured by TEG®-PM® was 42.5% in one study [287]
and as high as 86% in another [285], compared with only
4% in healthy volunteers [287]. Over 75% of the TBI pa-
tients had impairment of the ADP pathway in one study
[265] and the severity of brain injury appeared to correl-
ate with ADP inhibition on TEG®-PM® (severe TBI
93.1%, mild TBI 56.5%, control 15.5%; p < 0.01) [302].
When TEG®-PM® and MEA were compared in severely in-
jured trauma patients, results correlated poorly with the
ADP pathway and moderately with the AA pathway [299].
The utility of POC platelet function assays to predict
outcome or stratify trauma patients at a higher risk of
bleeding who may benefit subsequently from transfusion
is uncertain. By using a composite outcome, one study
found no difference in bleeding complications in trauma
patients on clopidogrel who presented with high or low
platelet inhibition measured using VerifyNow® [298].
Similarly, progression of ICH and the need for neurosur-
gical intervention was independent of platelet activity
assessed using VerifyNow® [307]. MEA values were also
not predictive of haemorrhagic progression [292] or out-
come [289, 292, 294] in some studies in trauma patients;
however, 87% of patients received haemostatic therapy
following detection of impaired platelet function, and
this strategy could have influenced the results in one
study [294]. In contrast, the MEA TRAP [283] and the
AA receptor aspirin inhibition (ASPI) test [299] were in-
dependent predictors of mortality. In another study that
included a mixed trauma population, which was not ad-
justed for confounders, ADP and TRAP values were also
different between survivors and non-survivors [284].
Others have found ADP, but not the AA test, to be a
predictor of mortality [303].
TEG®-PM® was found to be a superior indicator of
haemorrhagic shock in trauma patients compared
with MEA [299]. TEG®-PM® AA-induced platelet ac-
tivity reduction identified TBI patients with a high
risk of bleeding complications [304] and TEG®-PM®
ADP-induced platelet activity reduction [285] or in-
hibition in both pathways [299] was predictive of
blood product transfusion in severe trauma. Another
study demonstrated that the MEA and VerifyNow®
AA tests were not predictive of ICH, whereas the
TEG®-PM® AA percent inhibition may be associated
with ICH progression, with 71% specificity at 32% in-
hibition [286]. Studies reporting ADP receptor inhibition
measured using TEG®-PM® also showed an association be-
tween this parameter and mortality [287] and significant
correlations between the severity of TBI, the degree of
ADP inhibition and increased risk of mortality [302–304].
In one study, platelet ADP inhibition exceeding 60% inde-
pendently predicted in-hospital mortality amongst pa-
tients with TBI, while controlling for age, gender, the
presence of hypotension, pre-injury APA, GCS and ISS
[295]. In contrast, others found no correlation between
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TEG®-PM® values and ISS, length of hospital stay or mor-
tality in trauma patients with or without TBI [305].
The role of POC platelet function devices in guiding
haemostatic therapy is not established. One study showed
no impact of platelet transfusion on platelet activity in pa-
tients with traumatic ICH with pre-injury aspirin treat-
ment assessed using the VerifyNow® assay. There was also
no difference in ICH progression or neurosurgical inter-
vention in functional and non-functional platelet groups
after platelet transfusion [307]. Further studies using the
VerifyNow® assay showed that a single platelet apheresis
unit was not sufficient to reverse platelet inhibition in al-
most half of patients [297] and a trend toward increased
mortality in patients whose platelet function failed to nor-
malise with transfusion [289]. A dose–response relation-
ship between the quantity of platelets transfused and
reversal of VN®-ASA inhibition was observed [289].
In contrast, haemostatic measures significantly in-
creased AA-induced platelet activity measured using
MEA by 100 ± 66% [291]. Others showed that platelet
transfusion improved aspirin-induced platelet dysfunc-
tion but did not recover traumatic platelet dysfunction
measured using MEA [308]. TEG®-PM® was also not
supported as a solitary tool to guide platelet transfusions
in trauma patients [287, 305]. It seems that although
platelet transfusion may improve platelet function via
AA receptor-mediated pathways, it has little, if any, im-
pact on ADP receptor-mediated pathways [305]. More-
over, TBI patients who received platelet transfusion had
significant reductions in the degree of platelet inhibition
detected using the AA TEG®-PM® assay, but no change
in outcomes [309].
The lack of congruency among the studies sum-
marised above indicates that there is a pressing need for
future prospective studies that investigate the potential
benefit of platelet function monitoring in trauma pa-
tients. Although these devices are capable of measuring
platelet receptor inhibition to detect pre-treatment with
APA, their role in identifying trauma-induced platelet
dysfunction and in guiding haemostatic therapy remains
unclear and their use can only be recommended as an
adjunct to standard laboratory monitoring.
III. Tissue oxygenation, volume, fluids and temperature
Tissue oxygenation
Recommendation 12 We recommend permissive
hypotension with a target systolic blood pressure of
80–90 mmHg (mean arterial pressure 50–60mmHg)
until major bleeding has been stopped in the initial phase
following trauma without brain injury. (Grade 1C)
In patients with severe TBI (GCS ≤ 8), we recommend
that a mean arterial pressure ≥ 80mmHg be maintained.
(Grade 1C)
Restricted volume replacement
Recommendation 13 We recommend use of a re-
stricted volume replacement strategy to achieve target
blood pressure until bleeding can be controlled.
(Grade 1B).
Vasopressors and inotropic agents
Recommendation 14 In the presence of life-threatening
hypotension, we recommend administration of vasopres-
sors in addition to fluids to maintain target arterial pres-
sure. (Grade 1C)
We recommend infusion of an inotropic agent in the
presence of myocardial dysfunction. (Grade 1C)
Rationale
At present, the initial treatment of trauma-induced
hypotension uses the concept of DCR, with restricted vol-
ume replacement and permissive hypotension. Although
the general effectiveness of such a restricted volume re-
placement, resulting in permissive hypotension, remains
to be confirmed in RCTs, two studies published in the
1990s demonstrated increased survival when a low and
delayed fluid volume resuscitation concept was used in
penetrating [310] or penetrating and blunt [311] trauma.
A further small pilot RCT published in 2015 demon-
strated a 24-h survival benefit for hypotensive patients
with blunt trauma initially treated with a restrictive
volume administration when compared with standard
volume replacement [312]. However, in contrast to these
studies, no significant differences in survival were found
in two non-randomised controlled trials examining pa-
tients with either penetrating and blunt trauma [313] or
blunt trauma alone [314].
Moreover, future RCTs must also confirm whether the
present more or less arbitrary recommendation for sys-
tolic and mean arterial blood pressures for permissive
hypotension are safe for all trauma patients or whether
target blood pressures should be different in specific
subgroups, e.g. in blunt or penetrating trauma patients.
Existing data already show that the concept of permis-
sive hypotension should be carefully considered in the
elderly patient [315] and may be contraindicated if the
patient suffers from chronic arterial hypertension [316].
Nevertheless, the concept of DCR is supported by
several retrospective studies demonstrating that ag-
gressive resuscitation techniques, often initiated in the
pre-hospital setting, may be detrimental for trauma pa-
tients [14, 34, 317–325]. It has been shown that aggres-
sive volume administration increased the incidence of
secondary abdominal compartment syndrome (ACS)
[324], damage-control laparotomy [322], coagulopathy [14],
multiple organ failure [323], nosocomial infections [323],
the number of blood as well as mass transfusions [319, 323]
and prolonged the length of ICU and hospital stays [323].
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At the same time, increased volume administration de-
creased the likelihood of survivial [34, 320, 321, 323].
The timing and volume of i.v. fluid administration in
bleeding trauma patients was assessed in a meta-analysis
by Kwan et al. [326]. Three trials, including a total of
1957 patients, were identified that addressed the timing
of administration, and three other studies investigated
volume load, but included only 171 patients. In contrast
to the retrospective analysis described above, the
meta-analysis failed to demonstrate an advantage associ-
ated with delayed compared to early fluid administra-
tion, nor of smaller compared to larger volume fluid
administration in this small group of prospective studies
that included only a very limited number of patients. A
further meta-analysis that assessed seven retrospective
observational studies that included a total of 13,687 pa-
tients and three prospective studies that included 798
patients estimated a small benefit in favour of a re-
stricted volume replacement strategy [327]. However,
the authors cautioned that the available studies were
subject to a high risk of selection bias and clinical
heterogeneity.
It should be noted that DCR strategies using restrictive
volume replacement affecting hypotensive blood pres-
sure are contraindicated in patients with TBI and spinal
injuries. This is because an adequate perfusion pressure
is crucial to ensure tissue oxygenation of the injured
central nervous system [328]. However, it remains un-
clear how to attain the best balance between volume re-
suscitation and vasopressor administration in order to
achieve an adequate perfusion pressure. [315, 316]
In conclusion, a DCR strategy using a concept of re-
stricted fluid replacement that aims to achieve a lower
than normal systolic blood pressure of 80–90mmHg in
patients without TBI and/or spinal injury is supported
by the literature. However, strong evidence from suffi-
ciently robust RCTs is lacking.
Vasopressors may also be required transiently, even
when fluid expansion is in progress and hypovolaemia
has not yet been corrected, to sustain life and maintain
tissue perfusion in the presence of life-threatening
hypotension. Norepinephrine is commonly used to re-
store arterial pressure in septic and haemorrhagic shock
and is now considered by many to be the agent of choice
for this purpose during septic shock [329]. Although
norepinephrine has some β-adrenergic effects, it acts
predominantly as a vasoconstrictor. Arterial α-adrenergic
stimulation increases arterial resistance and may increase
cardiac afterload, while norepinephrine exerts both arterial
and venous α-adrenergic stimulation [330]. Indeed, in
addition to its arterial vasoconstrictor effect, norepineph-
rine induces venoconstriction at the level of the splanch-
nic circulation in particular, which increases the pressure
in capacitance vessels and actively shifts splanchnic blood
volume to the systemic circulation [331]. This venous ad-
renergic stimulation may to some extent recruit blood
from the venous unstressed volume, thereby filling the
blood vessels without generating intravascular pressure.
Moreover, stimulation of β2-adrenergic receptors de-
creases venous resistance and increases venous return
[331]. Animal studies of uncontrolled haemorrhage have
suggested that norepinephrine infusion reduces the
amount of fluid resuscitation required to achieve a given
arterial pressure target associated with lower blood loss
and improved survival [332, 333].
Despite a general paucity of research into the use of vaso-
pressors in hypotensive trauma patients, a double-blind
randomised trial has assessed the safety and efficacy of add-
ing vasopressin to resuscitative fluid. Patients were adminis-
tered fluid alone or fluid plus vasopressin (bolus 4 IU) and
i.v. infusion of 200mL/h (vasopressin 2.4 IU/h) for 5 h. The
fluid plus vasopressin group needed a significantly lower
total resuscitation fluid volume over 5 days than the control
group (p = 0.04). The rates of adverse events, organ dys-
function and 30-day mortality were similar [334].
An interim analysis performed during an ongoing mul-
ticentre prospective cohort study has suggested that the
early use of vasopressors for haemodynamic support
after haemorrhagic shock may be deleterious in com-
parison to aggressive volume resuscitation and should be
used cautiously [335]. However, the study was limited in
that it was a secondary analysis of a prospective cohort
study and not designed to answer the specific hypothesis
tested. Moreover, the group receiving vasopressors had a
higher rate of thoracotomy. A second study retrospect-
ively analysed the records from 225 patients who re-
ceived different vasopressor therapies during emergency
trauma surgery [336]. Whereas the use of epinephrine
was independently associated with increased mortality,
there was no difference in the mortality rate compared
with other vasopressors. The most recent paper on vaso-
pressor use in massively transfused trauma patients
retrospectively analysed 120 trauma patients and de-
scribed, not surprisingly, an association between the use
of vasopressor and mortality [337]. However, on hospital
arrival, the patients receiving a vasopressor had a much
lower GCS and a higher lactate level and showed a trend
toward the transfusion of more blood products.
In conclusion, the effects of vasopressors have not yet
been rigorously investigated in humans during haemor-
rhagic shock and prospective studies to define the effect
of vasopressors on patients during haemorrhagic shock
are warranted. Current evidence suggests that vasopres-
sors may be useful if used transiently to sustain arterial
pressure and maintain tissue perfusion in the face of
life-threatening hypotension. However, if used, it is
essential to respect the recommended objectives for sys-
tolic arterial pressure (80–90 mmHg) in patients without
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TBI. Because vasopressors may increase cardiac after-
load if the infusion rate is excessive or left ventricular
function is already impaired, an assessment of cardiac
function during the initial ultrasound examination is
essential. Cardiac dysfunction could be altered in the
trauma patient following cardiac contusion, pericardial
effusion or secondary to brain injury with intracranial
hypertension [338]. The presence of myocardial dysfunc-
tion requires treatment with an inotropic agent such as do-
butamine or epinephrine. In the absence of an evaluation of
cardiac function or cardiac output monitoring, as is often
the case in the early phase of haemorrhagic shock manage-
ment, cardiac dysfunction must be suspected if there is a
poor response to fluid expansion and norepinephrine.
Type of fluid
Recommendation 15 We recommend that fluid therapy
using isotonic crystalloid solutions be initiated in the
hypotensive bleeding trauma patient. (Grade 1A)
We recommend the use of balanced electrolyte solu-
tions and the avoidance of saline solutions. (Grade 1B)
We recommend that hypotonic solutions such as
Ringer’s lactate be avoided in patients with severe head
trauma. (Grade 1B)
We recommend that the use of colloids be restricted
due to the adverse effects on haemostasis. (Grade 1C)
Rationale
It is widely accepted that during the initial phase of
haemorrhagic trauma shock, a restrictive volume strat-
egy be supported with crystalloid solutions. The main
reason for this is that all colloid solutions can alter
haemostasis. However, if the bleeding is excessive and if
crystalloids in combination with vasopressors are not
able to maintain basic tissue perfusion, colloid infusions
represent a further, however controversial, option to re-
store perfusion. If a colloid solution is administered, it is
still unclear which colloid solution should be used in the
initial treatment of the bleeding trauma patient.
In most trauma studies, 0.9% sodium chloride was
used as the crystalloid solution. However, at least seven
studies in both non-critically and critically ill patients
suggest that the use of this crystalloid solution as the
main i.v. fluid source results in harm to patients, e.g. re-
duced renal blood flow velocity and renal cortical tissue
perfusion, hyperchloraemic acidosis, increased incidence
of kidney injury or even reduced survival [339–347]. In
contrast to 0.9% sodium chloride, balanced electrolyte
solutions comprise physiological or near-physiological
concentrations of chloride and may therefore be advan-
tageous. Similarly, in a retrospective analysis of ICU pa-
tients receiving more than 60 mL/kg 0.9% sodium
solution over a 24 h period, each 100 mEq increase in
chloride load was associated with a 5.5% increase in the
risk of death, even after controlling for total fluid vol-
ume, age, and severity (p = 0.0015) over a 1-year period
[344]. The two most recent RCTs comparing balanced
crystalloids vs 0.9% sodium chloride, one including
13,347 non-critically ill adults [342] and the other in-
cluding 15,802 critically ill patients [343], found vari-
ation in the negative side-effects of 0.9% sodium
chloride, depending on the health status, and thereby on
the physiological ability of each patient to compensate.
In one of the studies, non-critically ill patients receiving
balanced crystalloid solutions compared with saline were
shown to have a lower incidence of major kidney-related
adverse events within 30 days, without an influence on
the length of hospital stay [342]. In the other study, crit-
ically ill patients receiving balanced crystalloid solutions
compared with saline were shown to have a lower rate
of composite outcome death from any cause, new renal
replacement therapy or persistent renal dysfunction
[343]. In a small prospective randomised trial involving
46 trauma patients, a balanced electrolyte solution im-
proved acid-base status and resulted in less hyperchlor-
aemia at 24 h post-injury compared with 0.9% sodium
chloride [346]. Moreover, a secondary analysis demon-
strated that the use of balanced electrolyte solutions re-
sulted in a net cost benefit in comparison to the use of
0.9% saline chloride [345]. On the other hand, another
recently published study could not exclude the possibil-
ity that an acetate-based balanced crystalloid solution in-
creased patient bleeding during cardiac surgery, which
warrants further investigation [348]. In conclusion, for
critically ill patients such as trauma patients, a balanced
electrolyte solution should be favoured over 0.9% so-
dium chloride, and if a 0.9% sodium chloride solution is
used, it should be limited to a maximum of 1–1.5 L.
Hypotonic crystalloid solutions, such as Ringer’s lactate,
should be avoided in patients with TBI in order to minim-
ise a fluid shift into the damaged cerebral tissue. A
secondary analysis from the Prospective, Observational,
Multicenter, Major Trauma Transfusion (PROMMTT)
study revealed that Ringer’s lactate solutions were associ-
ated with higher adjusted mortality compared with normal
saline (HR 1.78; CI 1.04–3.04; p = 0.035) [349].
A recent study has suggested that solutions with the po-
tential to restore pH may also be advantageous. It was
shown that Ringer’s acetate solution ameliorated splanch-
nic dysoxia more rapidly, as evidenced by gastric
tonometry, than Ringer’s lactate [350]. Whether there are
benefits associated with the use of certain isotonic bal-
anced crystalloids with respect to a reduced morbidity or
mortality, however, is not clear and remains to be
evaluated [339, 344, 347].
Colloid solutions have been used more effectively to
restore intravascular volume, as would be expected from
basic physiologic concept of fluid exchange across the
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vasculature. A review of RCTs indicated that colloid so-
lutions can result in lower fluid requirements than crys-
talloids in all types of patient, including trauma victims,
with a ratio of 1.5:1 [351]. A large pragmatic study pro-
spectively comparing colloids to crystalloids reported the
same 1.5:1 ratio [352].
Particularly in situations in which there is a need for
rapid volume replacement due to severe shock, colloids
have often been administered. However, it is still unclear
whether colloids really have a beneficial effect on mor-
bidity or mortality. The most recent meta-analysis com-
paring colloids or crystalloids failed to demonstrate that
any colloid reduces morbidity or mortality compared to
resuscitation with crystalloids in critically ill or elective
surgical patients [353, 354]. The authors concluded that
there is no evidence that resuscitation with colloids has
any beneficial effect on survival [355]. However, neither
the time point of fluid resuscitation nor the duration
and dosages of fluid resuscitation have been analysed or
openly discussed. Nevertheless, at the present time, good
data are lacking to demonstrate the survival benefit of
colloids compared with other types of solutions.
Conflicting meta-analyses have shown increased kid-
ney injury and increased mortality in critically ill pa-
tients treated with hydroxyethyl starch (HES) solutions
[355–357]. On the other hand, it has also been shown
that there is no difference in the incidence of death or
acute kidney failure in surgical patients receiving HES
solutions [358]. It seems doubtful that any conclusions
can be drawn from these studies, which were performed
mostly under different conditions than are present in the
acute hypovolaemic trauma patient. In addition to these
conflicting results, an in vitro study using blood from
healthy volunteers demonstrated that coagulation and
platelet function are impaired by all HES and gelatine
solutions [359]. However, gelatine-induced coagulopathy
was reversible with the administration of fibrinogen,
whereas HES-induced coagulopathy was not. So far, only
one small RCT described a benefit for a HES solution in
trauma patients. HES (130/0.4) provided a significantly
more rapid decline in blood lactate levels and less renal
injury than saline solution in penetrating trauma pa-
tients [360]. However, because only 42 blunt trauma pa-
tients were included in the study, no differences in these
parameters could be demonstrated using the different so-
lutions. At present, other colloids, including gelatine solu-
tions, cannot be recommended without restrictions [361].
A number of studies have investigated hypertonic
solutions. In 2008, a double-blinded RCT in 209
patients with blunt traumatic injuries analysed the
effect of treatment with 250 mL 7.5% hypertonic
saline and 6% dextran 70 compared to lactated
Ringer’s solution on organ failure [362]. The
intention-to-treat analysis demonstrated no significant
difference in organ failure and in ARDS-free survival.
However, there was improved ARDS-free survival in
the subset (19% of the population) requiring 10 U or
more of packed RBC [362]. A relatively small clinical
trial involving nine patients with intracranial pressure
> 20 mmHg found that hypertonic saline reduced
intracranial pressure more effectively than dextran so-
lutions with 20% mannitol when compared in equi-
molar dosing [363]. However, Cooper et al. found
almost no difference in neurological function 6
months after TBI in 229 patients who had received
pre-hospital hypertonic saline resuscitation compared to
conventional fluid [364]. Moreover, two large prospective
randomised multicentre studies reported by Bulger and
co-workers [365, 366] analysed the effect of out-of-hospital
administration of hypertonic fluids on neurological out-
come following severe TBI and survival after traumatic
hypovolaemic shock. These studies were not able to
demonstrate any advantage compared to normal 0.9%
saline among the 2184 patients included. In contrast, a
recent retrospective analysis in 34 trauma patients
demonstrated that hypertonic solutions interfere with
coagulation [367]. Two recently published meta-
analyses, one including nine trials with 3490 trauma
patients and one including 12 trials including 2932
haemorrhagic shock patients, confirmed that there is
no beneficial effect of hypertonic saline with or without
dextran in general trauma patients [368, 369].
In conclusion, at least during the initial treatment
phase and as part of the restricted volume replacement
strategy, administration of crystalloids is advocated.
The data published to date demonstrate that balanced
crystalloid solutions are preferable to 0.9% saline solu-
tion, especially if administered in larger amounts. In pa-
tients with TBI, hypotonic solutions, crystalloids as well
as colloids, should be avoided. If small-volume resusci-
tation fails to restore the target blood pressure in spite
of additional use of norepinephrine, or if extensive vol-
ume resuscitation is necessary in the intra-hospital
phase of initial trauma management, this can be
achieved either with large-volume balanced crystalloid
administration or with colloids. Large-volume balanced
crystalloid solutions are not independently associated
with multiple organ failure [370]. In contrast, a retro-
spective study showed that resuscitation with at least 1
L crystalloid per unit RBC seems to be associated with
reduced overall mortality [371]. However, at present, it
is not clear whether colloids should be used if crystal-
loids fail to restore target blood pressure. Hypertonic
saline solutions do not demonstrate any advantage to
other less expensive crystalloids. The evidence suggests
that hypertonic saline solutions are safe, but will nei-
ther improve survival nor improve neurological out-
come after TBI.
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Erythrocytes
Recommendation 16 We recommend a target Hb of 70
to 90 g/L. (Grade 1C)
Rationale
Oxygen delivery to tissues is the product of blood flow
and arterial oxygen content, which is directly related to
the Hb concentration; therefore, decreasing Hb might be
expected to increase the risk of tissue hypoxia. However,
compensatory responses to acute normovolaemic an-
aemia occur, including macro- and microcirculatory
changes in blood flow and capillary recruitment, so the
consequences of low Hb in terms of tissue oxygenation
are difficult to predict based on macrocirculatory hae-
modynamic parameters and Hb levels. This has been
demonstrated in haemorrhagic shock patients, in whom
RBC transfusion was able to improve microcirculation
and tissue oxygenation independent of macrocirculation
and Hb level [372, 373]. However, the transfusion of
RBCs containing methaemoglobin and thus not partici-
pating in oxygen delivery also improved microcirculation
[372], most likely due to increased blood viscosity [374].
Erythrocytes are oxygen sensors and modulators of
vascular tone and microcirculation. Erythrocytes play a
fundamental role in matching microvascular oxygen
supply with local tissue oxygen demand. Although a
number of theories to explain this critical function have
been proposed [transport of nitric oxide (NO) in the
form of S-nitrosothiol by erythrocyte, deoxyhaemoglobin
acting as a nitrite reductase converting nitrite to NO
and release of adenosine triphosphate (ATP) from the
erythrocyte, resulting in the production of mediators],
none has been either universally accepted or fully tested
in the intact microcirculation [375]. In addition, erythro-
cytes may contribute to haemostasis by influencing the
biochemical and functional responsiveness of activated
platelets through the rheological effect on platelet mar-
gination and by supporting thrombin generation [376].
The effects of the Hct level on blood coagulation have
not been fully elucidated [377]. An acute reduction of
the Hct level results in an increase in the bleeding time
[378], with restoration upon re-transfusion [379]. This
may relate to the presence of the enzyme elastase on the
surface of RBC membranes, which may activate coagula-
tion factor IX [380, 381]. However, an animal model
showed that a moderate reduction in Hct level does not
increase blood loss from a standard spleen injury [379],
and an isolated in vitro reduction of the Hct level did
not compromise blood coagulation as assessed using
TEG® [382].
RCTs that have evaluated Hb thresholds for transfu-
sion in critically ill patients have consistently found that
restrictive transfusion strategies (Hb thresholds between
70 and 90 g/L) are as safe as, or safer than, liberal
strategies (thresholds ≥ 90 g/L) [383–387] with the pos-
sible exception of patients with acute coronary syn-
drome. Recently, in high-risk patients undergoing
cardiac surgery, a restrictive strategy regarding red cell
transfusion was non-inferior to a liberal strategy with re-
spect to the composite outcome of death from any
cause, myocardial infarction, stroke or new-onset renal
failure with dialysis, with fewer RBCs transfused [388].
These studies excluded patients with massive bleeding
and no prospective RCT has compared restrictive and lib-
eral transfusion regimens in trauma patients. A subset of
203 trauma patients from the Transfusion Requirements
in Critical Care (TRICC) trial [384] was re-analysed [389].
A restrictive transfusion regimen (Hb transfusion trigger
< 70.0 g/L) resulted in fewer transfusions compared with
the liberal transfusion regimen (Hb transfusion trigger <
100 g/L) and appeared to be safe. However, no statistically
significant benefit in terms of multiple organ failure or
post-traumatic infections was observed. It should be
emphasised that this study was neither designed nor pow-
ered to answer these questions with precision. In addition,
it cannot be ruled out that the number of RBC units trans-
fused merely reflects the severity of injury. Nevertheless,
RBC transfusions have been shown in multiple studies to
be associated with increased mortality [390–394], lung in-
jury [391, 395, 396], increased infection rates [397, 398]
and renal failure in trauma victims [394].
Because anaemia is a possible cause of secondary
ischaemic damage, concerns have been raised about the
safety of restrictive transfusion strategies in the subpop-
ulation of patients with TBI. Most early clinical informa-
tion comes from retrospective observational studies with
important methodological limitations. These data have
yielded inconsistent results on the effects of RBC trans-
fusion on markers of cerebral perfusion and metabolism
in patients with isolated severe TBI. Two systematic re-
views published in 2012 stressed the lack of high-level
scientific evidence for a specific Hb transfusion trigger
in this setting [399, 400]. A retrospective review of data
collected prospectively in 1158 patients with a GCS ≤ 8
in the absence of haemorrhagic shock found that RBC
transfusion was associated with worse outcomes (28-day
survival, ARDS-free survival, 6-month neurological out-
come) when the initial Hb was > 100 g/L [401]. No rela-
tionship between RBC transfusion and outcomes was
found in patients with an initial Hb ≤ 100 g/L [401]. In a
RCT of 200 patients with TBI at two clinical sites, Rob-
ertson et al. compared two Hb transfusion thresholds
(70 or 100 g/L), and separately compared administration
of erythropoietin or placebo [402]. Patients were en-
rolled within 6 h of injury and 99 patients were assigned
to the 70 g/L transfusion threshold and 101 patients to the
100 g/L threshold. Neither the administration of erythro-
poietin nor maintenance of Hb concentration > 100 g/L
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resulted in improved neurological outcome at 6months,
and the 100 g/L threshold was associated with a higher in-
cidence of adverse events [402].
Alternative methods of increasing Hb have been stud-
ied. The erythropoietic response is blunted in trauma
patients [403]; therefore, the administration of erythro-
poietin appears an attractive option. In a first pros-
pective randomised trial in ICU patients (n = 1302, 48%
being trauma patients), a significant reduction in RBC
transfusion percentage from 60.4 to 50.5% (p < 0.001)
and reduction in the median number of RBC units
transfused from two to one (p < 0.001) was observed
[404]. In the subgroup of trauma patients, 28-day mortality
was also reduced [odds ratio (OR) 0.43 (0.23–0.81)] [404].
In a subsequent prospective randomised trial in ICU pa-
tients (n = 1460, 54% being trauma patients), no significant
reduction in RBC transfusions was observed [405]. Throm-
botic complications were higher in erythropoietin-treated
patients [HR 1.58 (1.09 to 2.28)]; however, this difference
was observed exclusively in patients without heparin
prophylaxis [405]. Recently, in a double-blind, placebo-
controlled trial undertaken in 29 centres within 24 h of
moderate or severe TBI, 606 patients were randomly
assigned to receive erythropoietin (40,000 units subcutane-
ously) or placebo once per week for a maximum of three
doses. Erythropoietin did not reduce the number of pa-
tients with severe neurological dysfunction (GOS-E level
1–4), the transfusion of RBC or increase the incidence of
deep venous thrombosis (DVT) of the lower limbs [406].
Mortality at 6months tended to be lower in patients
treated with erythropoietin (11%) than in control patients
with a mortality of 16% (RR 0.68; 95% CI 0·44–1·03;
p = 0.07) [406]. Interestingly, erythropoietin treatment of
critically ill trauma patients resulted in a substantial re-
duction of mortality (RR 0.63; 0.49–0.79, p = 0.0001) in a
recent meta-analysis [407].
The limited effect of erythropoietin treatment on
transfusion needs may be surprising given the blunted
response in trauma patients [403]. However, iron metab-
olism is also altered after trauma, with iron not being
fully available for haematopoiesis [403]. Neither iron me-
tabolism nor availability are fully understood following
traumatic injury and complicated by the fact that certain
proteins such as ferritin are massively upregulated after
trauma as part of the acute phase response [403]. Intra-
venous iron may therefore represent another attractive
option with which to foster haematopoiesis. Indeed,
studies that assess the effect of i.v. iron (with [408, 409]
or without [410] concomitant epoetin alpha) showed re-
duced RBC transfusions [408–410], postoperative infec-
tions [409, 410], length of hospital stay [409] and
mortality in patients with hip fractures [409]. While i.v.
iron appears to be promising, oral iron is largely inef-
fective. However, a recent multicentre, randomised,
double-blind, trial during the perioperative period of hip
fracture did not find that ferric carboxymaltose with or
without erythropoietin induced a reduction of RBC
transfusion despite obtaining significant increases in Hb
levels at discharge and 60 days after discharge [411]. In a
randomised, placebo-controlled, blinded study in anaemic
intensive care patients, early administration of low-dose
i.v. ferric carboxymaltose, compared with placebo, did not
result in a significant lowering of RBC transfusion require-
ments during hospital stay [412]. Patients who received
i.v. iron had a significantly higher Hb concentration at
hospital [412].
Temperature management
Recommendation 17 In order to optimise coagulation,
we recommend early application of measures to reduce
heat loss and warm the hypothermic patient to achieve
and maintain normothermia. (Grade 1C)
Rationale
Since coagulopathy following traumatic injury increases
mortality [39], it is recommended to target “normother-
mia”, with a core temperature between 36 and 37 °C in
order to create optimal preconditions for coagulation.
Hypothermia, a core body temperature < 35 °C, is asso-
ciated with acidosis, hypotension and coagulopathy in
severely affected patients. The effects of hypothermia in-
clude altered platelet function, impaired coagulation fac-
tor function (a 1 °C drop in temperature is associated
with a 10% drop in function), enzyme inhibition and
fibrinolysis [413–415]. Body temperatures below 34 °C
compromise blood coagulation, but this has only been
observed when coagulation tests (PT and APTT) are
performed at the low temperatures present in patients
with hypothermia, but not when assessed at 37 °C, as is
routine practice for such laboratory tests.
The profound clinical effects of hypothermia ultim-
ately lead to higher morbidity and mortality [416], and
hypothermic patients require more blood products
[417]. In a retrospective study of 604 trauma patients who
required massive transfusion, a logistic regression analysis
demonstrated that a temperature lower than 34 °C was as-
sociated with a greater independent risk of mortality of
more than 80% after controlling for differences in shock,
coagulopathy, injury severity and transfusion requirements
[OR 1.87; 95% CI 1.18–3.0; p = 0.007] [418]. A recent
study performed a secondary analysis using 10 years of
data from the Pennsylvania Trauma Outcome Study
(PTOS). It analysed 11,033 patients with severe TBI and
demonstrated that spontaneous hypothermia at hospital
admission was associated with a significant increase in the
risk of mortality [419]. Steps to prevent hypothermia and
the risk of hypothermia-induced coagulopathy include
removing wet clothing, covering the patient to avoid
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additional heat loss, increasing the ambient temperature,
forced air warming, warm fluid therapy, and, in extreme
cases, extracorporeal re-warming devices [420–422]. Re-
cently, the use of a hypothermia prevention and manage-
ment kit has been advocated [423]. This kit is a low-cost,
lightweight, low-volume commercial product that sustains
10 h of continuous dry heat with an oxygen-activated,
self-heating liner and provides thermal insulation due to
the multi-layer composite construction of the outer shell.
The kit was designed to prevent hypothermia during tac-
tical casualty evacuation; however, application in the civil-
ian sector for the active re-warming of trauma patients is
conceivable. In comparison to other methods and devices,
the hypothermia prevention and management kit achieved
and maintained significantly higher temperatures than all
other methods and controls at 120min [424].
IV. Rapid control of bleeding
Damage-control surgery
Recommendation 18 We recommend that damage-
control surgery be employed in the severely injured pa-
tient presenting with deep haemorrhagic shock, signs of
ongoing bleeding and coagulopathy. (Grade 1B)
Other factors that should trigger a damage-control ap-
proach are hypothermia, acidosis, inaccessible major ana-
tomic injury, a need for time-consuming procedures or
concomitant major injury outside the abdomen. (Grade 1C)
We recommend primary definitive surgical manage-
ment in the haemodynamically stable patient and in the
absence of any of the factors above. (Grade 1C)
Rationale
The severely injured patient arriving at the hospital with
continuing bleeding or deep haemorrhagic shock gener-
ally has a poor chance of survival without early control
of bleeding, proper resuscitation and blood transfusion.
This is particularly true for patients who present with
uncontrolled bleeding due to multiple penetrating injur-
ies or patients with major abdominal injury and unstable
pelvic fractures with bleeding from fracture sites and
retroperitoneal vessels. The final common pathway in
these patients is the exhaustion of physiological reserves,
with resulting profound acidosis, hypothermia and coag-
ulopathy, also known as the “bloody vicious cycle” or
“lethal triad”.
In 1983, Stone et al. described the techniques of abbre-
viated laparotomy, packing to control haemorrhage and
of deferred definitive surgical repair until coagulation
has been established [425]. Several articles have since de-
scribed the beneficial results of this approach, now re-
ferred to as “damage control” [426–428]. This approach
should be considered in patients with major abdominal
injury and a need for adjunctive angioembolisation,
major abdominal injury and a need to evaluate other
injuries as early as possible, major abdominal injury and
traumatic amputation of a limb. Factors that should trig-
ger a damage-control approach in the operating theatre
are temperature ≤ 34 °C, pH ≤ 7.2, an inaccessible major
venous injury, a need for time-consuming procedures in
a patient with suboptimal response to resuscitation or
inability to achieve haemostasis due to recalcitrant coag-
ulopathy [429, 430].
Damage-control surgery of the abdomen consists of
three components: the first component is an abbreviated
resuscitative laparotomy for control of bleeding, the res-
titution of blood flow where necessary and the control
of contamination. This should be achieved as rapidly as
possible without spending unnecessary time on trad-
itional organ repairs that can be deferred to a later
phase. The abdomen is packed and temporary abdom-
inal closure is performed. Packing aims to compress liver
ruptures or exert direct pressure on the sources of
bleeding and abdominal packing may permit further at-
tempts to achieve total haemostasis through angiography
and/or correction of the “lethal triad”. The removal of
packs should preferably be deferred for at least 48 h to
lower the risk of re-bleeding.
The second component of damage-control surgery is
intensive care treatment, focused on core re-warming,
correction of the acid-base imbalance and coagulopathy,
as well as optimising the ventilation and the haemo-
dynamic status. If complementary angiography and/or
further injury investigation is needed, it should be per-
formed during this phase.
The third component is the definitive surgical repair
that is performed only when target parameters have
been achieved [133, 426–428, 431–433]. Although the
concept of “damage control” intuitively makes sense, no
RCTs exist to support it. Retrospective studies support
the concept showing reduced morbidity and mortality
rates in selective populations [428].
The same “damage control” principles have been ap-
plied to orthopaedic injuries in severely injured patients.
Scalea et al. were the first to coin the term “damage con-
trol orthopaedics” [434]. Relevant fractures are primarily
stabilised with external fixators rather than primary de-
finitive osteosynthesis [434–436]. The less traumatic na-
ture and shorter duration of the surgical procedure aims
to reduce the secondary procedure-related trauma.
Definitive osteosynthesis surgery can be performed after
4–14 days when the patient has recovered sufficiently.
Retrospective clinical studies and prospective cohort studies
seem to support the concept of damage control. The only
available randomised study shows an advantage for this
strategy in “borderline” patients [436]. The damage-control
concept has also been described for thoracic and neuro-
surgery [437, 438]. In addition to damage-control surgical
approaches, damage-control anaesthesia or resuscitation
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comprises a number of important measures described in
the other recommendations within this document.
Pelvic ring closure and stabilisation
Recommendation 19 We recommend that patients
with pelvic ring disruption in haemorrhagic shock
undergo immediate pelvic ring closure and stabilisation.
(Grade 1B)
Packing, embolisation and surgery
Recommendation 20 We recommend that patients
with ongoing haemodynamic instability, despite ad-
equate pelvic ring stabilisation, receive early surgical
bleeding control and/or pre-peritoneal packing and/or
angiographic embolisation. (Grade 1B)
We suggest that the use of aortic balloon occlusion be
considered only under extreme circumstances in patients
with pelvic fracture in order to gain time until appropriate
bleeding control measures can be implemented. (Grade 2C)
Rationale
The mortality rate for patients with severe pelvic ring
disruptions and haemodynamic instability remains high
[439, 440]. There is no consensus as to the optimal
treatment paradigm for patients presenting with haem-
orrhage from severe pelvic fractures. Angioembolisation
and an external fixator are the most common ap-
proaches. REBOA is considered by some practitioners to
be an important adjunct in the treatment of patients
with severe pelvic fracture and in shock. However, this
method is still in the early stages of development and is
not currently used widely across trauma centres [441].
Pelvic ring injuries are associated with a high mortality
rate within the first 24 h, due mainly to exsanguinations.
Injured patients are managed using a multidisciplinary
damage-control strategy. Unstable patients should
undergo surgical haemostasis control immediately. Ar-
terial embolisation is an effective means of achieving this
and justifies the permanent availability of this approach
in level-1 trauma centres. Following CT assessment of
injuries, stable patients can undergo arterial embolisa-
tion if active arterial bleeding or vascular damage is
present. The selective or nonselective embolisation
methods and agents used depend on the patient’s haemo-
dynamic status and an assessment of the injury whenever
possible [442]. The early detection of these injuries and
initial efforts to reduce disruption and stabilise the pelvis
as well as containing bleeding is therefore crucial.
Severe pelvic trauma is a particularly challenging condi-
tion, requiring a multidisciplinary trauma team, including
a general surgeon, orthopaedic surgeon, endovascular sur-
geon/interventional radiologist. The pelvis can harbour a
multifocal haemorrhage that is not easily compressible or
managed using traditional surgical methods such as tying
off a blood vessel or removing an organ. Treatment often
requires a triage of multiple investigations that can lead to
the re-approximation of bony structures, including DCR,
assessment of associated injuries and multimodal haemor-
rhage control via external fixation, pre-peritoneal packing,
angioembolisation and/or REBOA, for example [71].
Markers of pelvic haemorrhage include anterior-posterior
and vertical shear deformations on standard roentgeno-
grams, CT “blush” (active arterial extravasation), bladder
compression pressure, pelvic haematoma evident using
CT and ongoing haemodynamic instability, despite ad-
equate fracture stabilisation [443–445].
If the patient is haemodynamically unstable and in
haemorrhagic shock, the urgent treatment goal is rapid
achievement of haemostasis. An initial strategy, per-
formed while DCR is ongoing and before proceeding to
arteriography, relies on the insertion of an intra-aortic
occlusion balloon and/or extra-peritoneal pelvic packing.
If haemodynamic instability persists, a laparotomy for
haemostasis should be performed without delay. In a
haemodynamically stable patient, contrast-enhanced sys-
tematic CT is required to obtain a comprehensive as-
sessment of the lesions prior to surgery [80].
The initial therapy for pelvic fractures includes control
of venous and/or cancellous bone bleeding by pelvic
closure as a first step [446]. Some institutions use pri-
marily external fixators to control haemorrhage from
pelvic fractures [443], but pelvic closure may also be
achieved using a pelvic binder, a pelvic C-clamp or im-
provised methods such as a bed sheet [446, 447]. Based
on the available literature, pelvic circumferential com-
pression devices are widely used in the initial manage-
ment of patients with suspected pelvic bleeding. There is
evidence to suggest that external compression reduces
disrupted pelvic rings. However, some complications
have been reported following the application of pelvic
circumferential compression devices. Until this can be
clarified, judicious application of pelvic circumferential
compression devices will continue to be recommended
[448]. In addition to the pelvic closure, fracture stabilisa-
tion and the tamponade effect of the haematoma, pre-,
extra- or retroperitoneal packing may reduce or control
the venous bleeding [449–451]. Pre-peritoneal packing is
used to decrease the need for pelvic embolisation and
may be performed simultaneously, or soon after, initial
pelvic fracture stabilisation. The most commonly embo-
lised vascular bed and therefore the most studied is the
pelvis [452]. Pelvic packing could potentially aid in early
intra-pelvic bleeding control and provide crucial time
for more selective haemorrhage management [449, 451].
Delayed interventions are common in damage-control
laparotomy, with abdominal interventions often spread
over multiple explorations. In such cases, mortality has
been shown to increase in patients undergoing emergent
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re-exploration, or to delay the repair of major vascular
injuries. Ideal treatment of damage-control laparotomy
patients may include addressing injuries more com-
pletely at the first laparotomy instead of deferring care
for other priorities [453].
REBOA has been used in patients with end-stage
shock following blunt and penetrating trauma, together
with embolisation of the vascular bed in the pelvis. In a
military setting with hand-held ultrasound, it has been
reported that 7 Fr femoral sheath access ER-REBOA® were
positioned and inflated in the aorta without radiography. In
all reported cases, REBOA resulted in immediate nor-
malisation of blood pressure and permitted induction of
anaesthesia, initiation of whole-blood transfusion, damage-
control laparotomy and attainment of surgical haemostasis
(range of inflation time 18–65min). No access- or
REBOA-related complications were reported, and all pa-
tients survived to achieve transport to the next echelon of
care in stable condition. It has been suggested that the use
of this device by non-surgeons and surgeons not specially
trained in vascular surgery in the non-hospital setting may
be useful as a stabilising and damage-control adjunct,
allowing time for resuscitation, laparotomy and surgical
haemostasis [454]. However, some authors, such as
Maruhashi et al. [455], advise the use of REBOA with cau-
tion on the basis that it may increase the bleeding of minor
thoracic injury in severe multiple trauma patients.
In the case of major pelvic injury, it is nevertheless
agreed that damage-control interventional radiology and
urgent resuscitative surgery should be initiated early and
simultaneously [456]. Adjunct techniques can be com-
bined with a consecutive laparotomy if deemed neces-
sary [451]. This may decrease the high mortality rate
observed in patients with major pelvic injuries who have
undergone laparotomy as the primary intervention.
However, non-therapeutic laparotomy should be avoided
[457]. Time to pelvic embolisation for haemodynamically
unstable pelvic fractures may impact survival [439, 458].
Angiography and embolisation are currently accepted as
highly effective means with which to control arterial
bleeding that cannot be controlled by fracture stabilisation
[73, 443, 447, 449, 457, 459, 460]. Radiological manage-
ment can also be usefully applied to abdominal and thor-
acic bleeding [461–465]. Martinelli et al. [466] reported the
use of intra-aortic balloon occlusion to reduce bleeding
and permit transport to an angiography theatre. In con-
trast, Morozumi et al. suggested the use of mobile digital
subtraction angiography for arterial embolisation per-
formed in the clinic by trauma surgeons [467]. A number
of authors argue that permissive hypotension could achieve
better survival by achieving pelvic stabilisation and/or angi-
ography through DCR, hypertonic solutions and controlled
hypothermia. Institutional differences in the capacity to
perform timely angiography and embolisation may explain
the different treatment algorithms suggested by many au-
thors. Reports on transcatheter angiographic embolisation
suggest a 100% higher mortality during off-hours due to
lack of radiological service [468]. Therefore, a multidiscip-
linary approach to these severe injuries is required.
Local haemostatic measures
Recommendation 21 We recommend the use of topical
haemostatic agents in combination with other surgical
measures or with packing for venous or moderate
arterial bleeding associated with parenchymal injuries.
(Grade 1B)
Rationale
A wide range of local haemostatic agents is currently
available for use as adjuncts to traditional surgical tech-
niques to obtain haemorrhagic control. These topical
agents can be particularly useful when access to the site
of bleeding is difficult. Local haemostatic agents include
collagen, gelatine or cellulose-based products, fibrin and
synthetic glues or adhesives that can be used for both ex-
ternal and internal bleeding while polysaccharide-based
and inorganic haemostatics are still mainly used and ap-
proved for external bleeding.
The use of topical haemostatic agents should consider
several factors, such as the type of surgical procedure,
cost, bleeding severity, coagulation status and each
agent’s specific characteristics. Some of these agents
should be avoided when auto-transfusion is applied, and
several other contraindications need to be considered
[469, 470]. The capacity of each agent to control bleed-
ing was initially studied in animals, but increasing ex-
perience in humans is now available [469–484].
The different types of local haemostatic agents are
briefly presented according to their basis and haemo-
static capacity.
 Collagen-based agents trigger platelet aggregation,
resulting in clot formation when in contact with a
bleeding surface. They are often combined with a
procoagulant substance such as thrombin to
enhance the haemostatic effect. A positive
haemostatic effect has been shown in several human
studies [471, 479, 480, 485].
 Gelatine-based products can be used alone or in
combination with a procoagulant substance [470].
Swelling of the gelatine in contact with blood
reduces the blood flow and, in combination with a
thrombin-based component, enhances haemostasis
[476, 477, 482]. These products have been
successfully used for local bleeding control in brain or
thyroid surgery when electrocautery may cause damage
to nerves [481] or to control bleeding from irregular
surfaces such as during post-sinus surgery [484].
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 Absorbable cellulose-based haemostatic agents
have been widely used to treat bleeding for many
years, and case reports as well as a prospective
observational human study support their
effectiveness [483]. The oxidised cellulose-based
product can be impregnated with polyethylene
glycol and other salts and achieve comparable and
more rapid haemostasis compared to the combined
products described below [475].
 Fibrin and synthetic glues or adhesives have
both haemostatic and sealant properties, and their
significant effect on haemostasis has been shown
in several randomised controlled human studies
involving vascular, bone, skin and visceral
surgery [472, 474, 478].
 Polysaccharide-based haemostatics can be divided into
two broad categories [470]: N-acetyl-glucosamine-
containing glycosaminoglycans purified from
microalgae and diatoms, and microporous
polysaccharide haemospheres produced from potato
starch. Some minerals, such as kaolin, also seem to
have haemostatic effects. The mechanism of action is
complex and depends on the purity or combination
with other substances such as cellulose or fibrin. A
number of different products in the form of pads,
patches or bandages are currently available and have
been shown to be efficient for external use and for
splanchnic bleeding. Observational studies have
shown that haemorrhage control is achieved using a
poly-N-acetyl glucosamine- or kaolin-based bandage
applied to patients with severe hepatic and abdominal
injuries, acidosis and clinical coagulopathy [480, 486].
V. Initial management of bleeding and coagulopathy
Antifibrinolytic agents
Recommendation 22 We recommend that TXA be ad-
ministered to the trauma patient who is bleeding or at
risk of significant haemorrhage as soon as possible and
within 3 h after injury at a loading dose of 1 g infused
over 10 min, followed by an i.v. infusion of 1 g over 8 h.
(Grade 1A)
We recommend that protocols for the management of
bleeding patients consider administration of the first
dose of TXA en route to the hospital. (Grade 1C)
We recommend that the administration of TXA not
await results from a viscoelastic assessment. (Grade 1B)
Rationale
Tranexamic acid (trans-4-aminomethyl cyclohexane-1-
carboxylic acid, TXA) is a synthetic lysine analogue that is
a competitive inhibitor of plasminogen. TXA is distributed
throughout all tissues, and the plasma half-life is 120min
[487]. The Clinical Randomisation of Antifibrinolytic
therapy in Significant Haemorrhage (CRASH-2) trial [488]
assessed the effects of early administration of a short
course of TXA on death, vascular occlusive events and the
administration of blood product transfusion to trauma pa-
tients who were bleeding or at risk of significant bleeding.
The trial randomised 20,211 adult trauma patients with or
at risk of significant bleeding to either TXA (loading dose
1 g over 10min followed by infusion of 1 g over 8 h) or
matching placebo within 8 h of injury. The primary out-
come was in-hospital death within 4 weeks of injury. All
analyses assessed the intention-to-treat population. All-
cause mortality was significantly reduced with TXA by
1.5%; the risk of death due to bleeding was significantly re-
duced by 0.8% and a reduction in bleeding deaths by one
third, mainly through preventing exsanguination within
the first 24 h [489, 490]. Paediatric patients were not in-
cluded in the CRASH-2 study; however, an ongoing study
is investigating the use of TXA in children [491] and a
study in children undergoing craniosynostosis surgery
[492, 493] administered an initial bolus of 15–30mg/kg
followed by 2−10mg/kg/h. One retrospective study has
suggested that TXA is of no benefit in patients with visco-
elastic hyperfibrinolysis [494] and another found TXA to
reduce multiple organ failure and mortality in severely in-
jured shocked patients [495]. This discrepancy is probably
attributable to methodological limitations.
The risk of thrombosis after the use of the lysine ana-
logues TXA and ε-aminocaproic acid had been of major
theoretical concern; however, CRASH-2 showed that the
rate of VTE was not altered, while arterial thromboses,
especially myocardial infarction, were lower with the use
of TXA. TXA use to prevent or manage haemorrhage
has been studied in approximately one million patients
without increased rates of thrombosis [496–499].
No adverse events were described with the use of
TXA in CRASH-2, although an increased rate of sei-
zures has been described in patients undergoing cardiac
surgery receiving considerably higher doses of TXA than
recommended here [500]. This may reflect the role of fi-
brinolytic molecules as neurotransmitters.
An unplanned subgroup analysis of the CRASH-2 data
[501] showed that early treatment (≤ 1 h from injury)
significantly reduced the risk of death due to bleeding by
2.5%. Treatment administered between 1 and 3 h also re-
duced the risk of death due to bleeding by 1.3%. Treat-
ment given after 3 h increased the risk of death due to
bleeding by 1.3%; therefore, we recommend that TXA be
administered within 3 h following injury. Further data
from over 20,000 patients randomised to TXA versus
placebo in post-partum haemorrhage has also shown
that benefit is most apparent within the first 3 h.
Gayet-Ageron et al. showed that the benefits of TXA
were more marked when given as soon as possible after
injury and its efficacy decreased by 10% every 15 min
from time of injury [502].
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In order to ensure that TXA is administered early,
TXA administration at the pre-hospital site of injury
needs to be planned, and we recommend that protocols
for the management of bleeding patients strongly con-
sider administration of the first dose of TXA at the site
of injury. El-Menyar et al. looked at the efficacy of
pre-hospital TXA in a meta-analysis and showed that it
reduced 24-h and 30-day mortality and thromboembolic
events. However, the authors found only two studies and
concluded that further RCTs are required [503]. This is
in keeping with a recent study demonstrating the benefit
of on-scene administration of TXA in patients with
major trauma. In this study, the normally occurring de-
terioration of the coagulation status between the site of
injury and hospital admission was clearly mitigated by
the on-scene TXA administration [504].
If TXA is restricted to massive transfusion protocols
or only used in patients clinically judged to be at “high
risk”, it is estimated that only 40% of the potential popu-
lation who would benefit from this treatment will be
treated [505]. For all potential patients to receive TXA,
TXA should therefore be administered to all patients
with trauma and significant bleeding. Thus, TXA should
be included as part of each institutional “trauma man-
agement protocol” not the “massive blood loss” or
“major haemorrhage” protocols. The benefit of on-scene
TXA administration has recently been shown to be inde-
pendent of the severity of injury [504].
Secondly, Moore et al. suggested that TXA be admin-
istered only in those patients with hyperfibrinolysis
determined using TEG®, as many patients who have trau-
matic injuries lack a hyperfibrinolytic trace, a so-called
“hypofibrinolytic shutdown” [506]. However, Raza et al.
have clearly shown that TEG® is poor at detecting fibrino-
lytic activation when compared with more sensitive assays
[507]. Furthermore, support for the unreliability of
ROTEM® in detecting hyperfibrinolysis comes from Gall
et al., who showed that S100A10, an endothelial receptor
for plasminogen, leaches off the endothelium during
trauma and interferes with detection of fibrinolysis using
ROTEM® [266]. We therefore recommend that TXA be
administered as soon as possible, without waiting for
viscoelastic results.
The cost-effectiveness of TXA in patients with traumatic
injury has been calculated in three countries [508, 509]:
Tanzania as an example of a low-income country, India as
a middle-income country and the UK as a high-income
country. The cost of TXA administration to 1000 patients
was US$17,483 in Tanzania, US$19,550 in India and
US$30,830 in the UK. The estimated incremental cost of
administering TXA per life-year gained was $48, $66 and
$64 in Tanzania, India and the UK, respectively.
ε-Aminocaproic acid is also a synthetic lysine analogue
that has a potency ten-fold weaker than that of TXA. It is
administered at a loading dose of 150mg/kg, followed by
a continuous infusion of 15mg/kg/h. The initial elimin-
ation half-life is 60–75min and must therefore be admin-
istered by continuous infusion in order to maintain
therapeutic drug levels until the bleeding risk has dimin-
ished. This agent is a potential alternative to TXA if TXA
is not available. Due to concerns about safety [510], the
use of aprotinin is not advised in bleeding trauma patients,
now that TXA has been shown to be efficacious and safe.
Coagulation support
Recommendation 23 We recommend that monitoring
and measures to support coagulation be initiated imme-
diately upon hospital admission. (Grade 1B)
Rationale
While several general pathophysiological mechanisms
have been described that result in trauma-related coagu-
lopathy, including hyperfibrinolysis [16, 29, 252, 511], it
is essential to quickly determine the type and degree of
coagulopathy in the individual patient in order to deter-
mine the most prominent cause or causes to be treated
specifically in a goal-directed manner [512]. Early thera-
peutic intervention improves coagulation [513], which can
reduce the need for transfusion of RBC, FFP and platelets
[17, 42, 43, 259, 514], the incidence of post-traumatic
multi-organ failure [42] and length of hospital stay [17], as
well as improving survival [41, 43, 259, 515, 516]. The suc-
cess of early algorithm-based and goal-directed coagula-
tion management in reducing transfusions and improving
outcomes, including mortality, has also been demon-
strated in patients undergoing cardiac surgery [517–519].
It is, therefore, expected that early algorithm-based and
goal-directed coagulation management treatment would
also improve the outcome of severely injured patients
[41–43, 259, 520, 521]. This has indeed been shown in a
prospective randomised study [522] and in two studies
assessing the introduction of such a concept in two large
Italian and one Swiss trauma centre [43, 523]. In other
studies, however, no survival benefit could be shown
[513, 524, 525]. These variations may be because studies
that failed to show an effect tended to base decisions on
traditional laboratory values such as PT, APTT and plate-
let count, and therapies that were often limited to FFP
and platelet transfusions.
Initial coagulation resuscitation
Recommendation 24 In the initial management of pa-
tients with expected massive haemorrhage, we recom-
mend one of the two following strategies:
 FFP or pathogen-inactivated FFP in a FFP:RBC ratio
of at least 1:2 as needed. (Grade 1C)
 Fibrinogen concentrate and RBC. (Grade 1C)
Spahn et al. Critical Care           (2019) 23:98 Page 28 of 74
Rationale
The current concept for the resuscitation of patients
with massive bleeding with immediate coagulation sup-
port was introduced in May 2005, based on reports from
the ongoing conflict in Iraq. The US Army’s Institute of
Surgical Research recommended the immediate adminis-
tration of coagulation components in a 1:1:1 ratio for
RBC, plasma and platelets until laboratory measure-
ments to adjust therapy were available [526]. In the fol-
lowing years, the best initial strategy to support
coagulation became a matter of debate, and two different
strategies were proposed. Based on the results of 37
studies, recent guidelines from the Eastern Association
for the Surgery of Trauma recommend the transfusion
of equal amounts of RBC, plasma and platelets during
the early, empiric phase of resuscitation [527]. However,
other authors, mainly in Europe, strongly support the
use of factor concentrate as the first line of initial coagu-
lation resuscitation in patients with significant bleeding.
A few European studies have tried to compare these two
strategies; however, there are no good data to date, and no
definitive conclusion can be reached. The Reversal of
Trauma Induced Coagulopathy Using Coagulation Factor
Concentrates or Fresh Frozen Plasma (RETIC) trial, a
small single-centre RCT comparing plasma to factor
concentrate-based resuscitation, has recently been termi-
nated early after an interim analysis revealed potential
harm to patients randomised to the plasma arm [42].
Initial resuscitation is usually defined as the period be-
tween arrival in the emergency department and availabil-
ity of results from coagulation monitoring (coagulation
screen, fibrinogen level and/or VEM and platelet count).
However, in recent years, studies have focused on the
potential advantage of supporting coagulation already in
the pre-hospital setting either by plasma transfusion
(pre-thawed [528, 529] or freeze-dried [530, 531]) or by
administration of fibrinogen [532].
Many authors agree that early and aggressive plasma
transfusion reduces mortality [533]. A prospective multi-
centre study that included a large population of patients
undergoing massive transfusion showed that high
FFP:RBC and platelet:RBC ratios are associated with a sur-
vival benefit, also when time-dependency is accounted for
[317]. However, the optimal FFP:RBC and platelet:RBC ra-
tio remained controversial. The Pragmatic, Randomized
Optimal Platelet and Plasma Ratios (PROPPR) trial, a ran-
domised clinical trial in 680 trauma patients who were
suspected to have sustained or had experienced massive
blood loss [534] reported that there was no difference in
overall survival between early administration of plasma,
platelets and red blood cells in a 1:1:1 ratio (FFP:plate-
lets:RBC) compared with 1:1:2. However, more patients in
the 1:1:1 group achieved “anatomic” haemostasis and
fewer experienced death due to exsanguination by 24 h.
The early use of platelets and a high level of FFP use in
the 1:1:1 group was not associated with a significantly in-
creased rate of complications.
FFP transfusion is not free of risk. Complications asso-
ciated with FFP treatment include transfusion-associated
circulatory overload (TACO), ABO blood group incom-
patibility, transmission of infectious diseases (including
prion diseases) and mild allergic reactions. Transfusion-re-
lated acute lung injury (TRALI) [535] is a severe adverse
effect associated with the presence of leucocyte antibodies
in transfused plasma. The risk of TRALI has been greatly
reduced by avoiding the use of plasma from women with a
history of pregnancy. Transmission of infectious diseases
can be minimised by the use of pathogen-inactivated
plasma (industrial purified plasma).
Further controversy concerns the use of plasma to cor-
rect the decreased fibrinogen levels associated with
haemorrhagic shock. Haemostasis is critically dependent
on fibrinogen as a substrate for clot formation and the
ligand for platelet aggregation. Fibrinogen is the single
coagulation factor that is affected more and earlier in
association with trauma-induced coagulopathy. Many
bleeding trauma patients with trauma-induced coagulop-
athy present with a fibrinogen depletion, below levels
currently recommended for therapeutic supplementation.
Schlimp et al. [226] demonstrated that levels of fibrinogen
lower than 1.5 g/L are detected in as many as 73% of pa-
tients with an admission Hb lower than 100 g/L and in
63% of those with a base excess (BE) lower than − 6.
Moreover, Rourke et al. [536] found low fibrinogen in 41%
of the patients who were hypotensive on admission. In this
study, hypotension, increasing shock severity and a high
degree of injury (ISS ≥ 25), were all associated with a re-
duction in fibrinogen levels.
Although plasma contains all coagulation factors, ad-
ministration of plasma to bleeding patients brings no
consistent correction of any measure of clot function
and may dilute fibrinogen levels, but cannot contribute
to a significant increase [12]. Moreover resuscitation
with a large amount of plasma is associated with dilution
of RBC and platelets [12]. Several authors, mainly in
Europe, strongly disagree with the initial transfusion of
patients based on an empirical ratio rather than guided
by concurrent laboratory data (goal-directed therapy)
[537]. Only in the absence of rapid near-patient coagula-
tion testing to facilitate goal-directed therapy may initial
treatment with blood components in a fixed ratio consti-
tute a reasonable approach. If concurrent coagulation re-
sults are available, they should be used to guide therapy.
Initial fibrinogen levels below the normal range are in-
dependently associated with higher in-hospital mortality
[538] and survival improves with fibrinogen administra-
tion [539]. Unless pre-thawed plasma is available [540],
plasma transfusion cannot be initiated at the same time
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as universal RBC transfusion and significant delays have
been reported in achieving the targeted plasma:RBC
ratio [541]. During this interval, the fibrinogen level is
likely to be lower than desired. Fibrinogen concentrate is
widely used in Europe to rapidly restore fibrinogen
levels. For very initial coagulation support, while waiting
for the results of viscoelastic or laboratory tests, it has
been proposed to administer 2 g of fibrinogen to mimic
the expected 1:1 ratio corresponding to the first four
units of RBC and potentially correct hypofibrinogenae-
mia, if already present [523]. Experimental data show
that administration of fibrinogen does not suppress en-
dogenous fibrinogen synthesis [542].
VI. Further goal-directed coagulation management
Goal-directed therapy
Recommendation 25 We recommend that resuscitation
measures be continued using a goal-directed strategy,
guided by standard laboratory coagulation values and/or
VEM. (Grade 1B)
Rationale
There is increasing interest in the use of goal-directed
strategies guided by either POC VEM [543–549] or
CCAs [522, 550] to augment DCR during the acute care
of bleeding trauma patients [551–554]. A recent survey
among surgeons and anaesthesiologists in Germany re-
vealed that 90% used CCA to guide decision-making in
the diagnosis and treatment of bleeding trauma patients,
whereas 56% reported that they also used extended
VEM such as ROTEM® or TEG® [555], and this predom-
inantly in advanced trauma centres [556]. POC VEM
may provide more rapid information about the under-
lying haemostatic deficiencies, including information on
which part of the clotting process is disrupted, as well as
on the dynamics of clot formation and lysis [557, 558],
thereby allowing optimised and targeted coagulation
therapy according to individual deficits, particularly with
respect to the early use of coagulation factor concen-
trates (CFC) [544, 547, 559].
A recent retrospective military study, involving 134 pa-
tients requiring transfusion over 6 months, compared
transfusion practices before and after incorporation of
ROTEM® measurement into DCR protocols at a US
Role-3 hospital in Afghanistan. The study showed an
improved adherence to DCR practices after the intro-
duction of ROTEM®, suggesting that DCR without visco-
elastic data may result in reduced haemostatic support
and underestimate the need for platelet and fibrinogen
administration [553]. Goal-directed administration of
fibrinogen concentrate and other coagulation factors
(e.g. PCC) in a retrospective observational civilian study
resulted in significant improvements in fibrin polymer-
isation as measured by an increase in ROTEM®-FIBTEM
maximum clot firmness (MCF) and a normalisation in
ROTEM®-EXTEM (EXTEM, extrinsically activated test)
clotting times below the upper threshold [560] and a re-
duction in transfusion needs [561].
VEM are highly specific for hyperfibrinolysis, which is
considered the much more lethal and resource-intense
phenotype of fibrinolysis compared with shutdown
[562], and these tests should be used during early
trauma resuscitation to identify injured patients with sys-
temic hyperfibrinolysis [544]. Recent clinical and experi-
mental work suggests that antifibrinolytic therapy should
be employed in acutely injured patients and optimally
guided by ROTEM® or TEG® [563]. To date, a number of
algorithms including treatment thresholds have been
proposed for both ROTEM® [544, 546, 564] and TEG®
[565, 566]; however, these are based largely upon retro-
spective data or expert opinion [33, 273, 544, 565–567].
ROTEM® and TEG® assays show similar clinical perform-
ance; however, results are not interchangeable, arguably
due to different coagulation triggers, different coagulation
activators and reagents [567]. Of further note, the initial
correlation between CCA, for example INR, and ROTEM®
parameters such as EXTEM clotting time at admission,
may decrease over time, possibly due to injury severity,
base deficit or the administration of blood products, par-
ticularly fibrinogen concentrate, during therapy [568].
The first Cochrane review on the diagnostic accuracy
of ROTEM® and TEG® for trauma-induced coagulopathy
in adult trauma patients with bleeding during the period
between 1970 and 2013 identified three studies, but
found no evidence on the accuracy of TEG® and only
very limited evidence on the accuracy of ROTEM®, sug-
gesting that these tests be reserved for research use only
[268]. An updated Cochrane review from 2016 on the
use of ROTEM® and TEG® to monitor and guide haemo-
static treatment and transfusion versus usual care in
adults and children with bleeding included 15 studies,
but was not limited to trauma patients and included
only two trials judged to be at low risk of bias [569].
Compared with transfusion guided by any method,
ROTEM® or TEG® appeared to reduce overall mortality
(7.4% vs 3.9%; RR 0.52, 95% CI 0.28–0.95; I2 = 0%, 8
studies, 717 participants); however, only eight trials pro-
vided data on mortality, and two were zero-event trials.
A statistically significant effect of ROTEM® or TEG® was
observed relative to the proportion of participants
transfused with pooled RBC (RR 0.86, 95% CI 0.79–0.94;
I2 = 0%, 10 studies, 832 participants), FFP (RR 0.57, 95%
CI 0.33–0.96; I2 = 86%, 8 studies, 761 participants) or
platelets (RR 0.73, 95% CI 0.60–0.88; I2 = 0%, 10 studies,
832 participants), as well as overall haemostatic transfu-
sion with FFP or platelets. Meta-analyses also showed
fewer participants with dialysis-dependent renal failure.
A recent meta-analysis systematically reviewed and
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assessed 15 RCTs (including 1238 patients) performed
with patients in acute need of blood transfusion due to
bleeding to evaluate the effect of viscoelastic test guid-
ance on bleeding, transfusion requirements and mortal-
ity. While only one trial included trauma patients, this
study confirmed the transfusion-saving effect associated
with ROTEM® and TEG® guidance, including reduced
bleeding volume [570]. A systematic literature update of
the 2011 Australian National Blood Authority patient
blood management guidelines for critical bleeding con-
firmed substantial evidence gaps, in particular with regard
to the effect of component therapies, including the ratio of
RBCs to component therapies [571]. Overall, viscoelastic
test-based restrictive transfusion management may prevent
unnecessary plasma and platelet transfusion, thereby redu-
cing the risk of transfusion-related adverse events and
transfusion-associated hospital costs [572, 573].
Curry and co-workers have calculated that a 4 g dose
of fibrinogen concentrate is equal to two pools of cryo-
precipitate via ex vivo ROTEM® spiking data and results
in a clinically meaningful increase in clot strength
reflected by ROTEM®-EXTEM and ROTEM®-FIBTEM
clot firmness [574]. The authors used this dose of cryo-
precipitate in their prospective, randomised multicentre
study in the UK to assess the feasibility of administering
cryoprecipitate within 90min of hospital admission in
bleeding trauma patients. Eighty-five percent (95% CI
69–100%) of patients received cryoprecipitate in addition
to standard treatment within 90 min of hospital admis-
sion. Fibrinogen concentrations were maintained under
supplementation above 1.8 g/L at all time-points during
active haemorrhage, while 28-day mortality showed a
non-significant trend towards reduced mortality with early
fibrinogen supplementation [cryoprecipitate, 2 (10%) vs
standard, 6 (28.6%)].
Early goal-directed haemostatic resuscitation of trauma-
induced coagulopathy was further explored recently in a
single-centre, pragmatic prospective RCT in the USA that
tested whether a massive transfusion protocol goal-directed
by TEG® could improve survival compared with a massive
transfusion protocol guided by CCA [259]. One hundred
and eleven patients were included in the intent-to-treat
analysis (TEG®, n = 56; CCA, n = 55). Survival in the TEG®
group was significantly higher than the CCA group (log-
rank p = 0.032, Wilcoxon p = 0.027); there were 20 deaths
in the CCA group (36.4%) compared with 11 in the TEG®
group (19.6%) (p = 0.049). Most deaths occurred within the
first 6 h after arrival (21.8% CCA group vs 7.1% TEG®
group) (p = 0.032). CCA patients required a similar number
of RBC units as the TEG® patients [CCA, 5.0 (2–11); TEG®
4.5 (2–8)] (p = 0.317), but more plasma [CCA, 2.0 (0–4);
TEG®, 0.0 (0–3)] (p = 0.022) and more platelet units
[CCA, 0.0 (0–1); TEG®, 0.0 (0–0)] (p = 0.041) during the
first 2 h of resuscitation. This was the first prospective RCT
that demonstrated that utilisation of a goal-directed, TEG®--
guided massive transfusion protocol to resuscitate severely
injured patients improves survival compared with a proto-
col guided by CCA and utilises less plasma and platelet
transfusions during the early phase of resuscitation.
The RETIC study using first-line CFC or FFP in bleed-
ing trauma patients or patients presumed to bleed was
conducted as a single-centre, parallel group, open-label,
randomised trial at a level-1 trauma centre in Austria. In
the study, trauma patients with a coagulopathy identified
by abnormal fibrin polymerisation or prolonged clotting
time using ROTEM® received either FFP (15 mL/kg of
bodyweight) or CFC (primarily fibrinogen concentrate
[50 mg/kg of bodyweight]) [42]. The study was termi-
nated early, for futility and safety reasons, with 100 pa-
tients allocated (FFP, n = 48 and CFC, n = 52) due to the
high proportion of patients in the FFP group who re-
quired rescue therapy compared with those in the CFC
group (23 [52%] in the FFP group vs 2 [4%] in the CFC
group; OR 25.34 [95% CI 5.47–240.03], p < 0.0001) and
an increased need for massive transfusion in the FFP
group (13 [30%] in the FFP group vs 6 [12%] in the CFC
group; OR 3.04 [0.95–10.87], p = 0·042). The interim
analysis for the predefined endpoint upon premature
study termination showed multiple organ failure in
29 (66%) patients in the FFP group and in 25 (50%)
patients in the CFC group (OR 1.92 [95% CI 0.78–4.86],
p = 0.15).
In another RCT, Nascimento and co-workers assessed
the effects of a transfusion strategy guided by laboratory
results versus a fixed-ratio (1:1:1) transfusion protocol in
patients with severe trauma [522]. At a single centre, 78
patients were randomly assigned to either a transfusion
protocol guided by laboratory results (n = 38) or the
fixed-ratio (1:1:1) transfusion protocol (n = 40). Plasma
wastage was higher with the fixed-ratio protocol (22%
[86/390] of FFP units vs 10% [30/289]). In the intention-
to-treat analysis, all-cause 28-day mortality was 5/35
(14.3%) in the laboratory-result-guided transfusion group
versus 13/40 (32.5%) in the group that was treated ac-
cording to the fixed-ratio 1:1:1 protocol [RR 2.27 (95%
CI 0.98–9.63)]. The introduction of a novel standard op-
erating procedure (SOP) using a Hb/CCA-oriented and
coagulation-factor-based algorithm for the early correc-
tion of trauma-induced coagulopathy in patients requir-
ing a massive transfusion was retrospectively assessed
using a pre- and post-implementation approach at a sin-
gle centre in Germany [550]. The main objective was the
effect on transfusion requirements and the standardised
mortality ratio (SMR), which is the ratio of observed
deaths to expected/predicted deaths. Eighty-seven pa-
tients were assessed. The SMR decreased from 0.95 be-
fore to 0.72 after SOP implementation, which was not
statistically significant (p = 0.16) due to the small sample
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size, but was considered clinically relevant. However, a
significant reduction in the requirement of RBC transfu-
sions (22.8 ± 8.1 units vs 17.6 ± 7.6 units) was observed
(p = 0.003) as well as a faster correction of laboratory co-
agulopathy upon ICU admission for fibrinogen and
Quick value and a clear trend to better results for INR
and PTT.
The introduction of an early coagulation support
protocol, including POC testing, which replaced the
former high plasma:RBC ratio strategy in two Italian
trauma centres was associated with a marked reduction
in blood-product consumption, reaching statistical sig-
nificance for plasma (65%) and platelets (52%), and with
a non-significant trend toward a reduction in early and
28-day mortality [523]. The overall costs for transfusion
and coagulation support, including POC tests, decreased
by €76,340 (23%) after early coagulation support protocol
implementation in 2013. Whiting and co-workers assessed
the clinical effectiveness and cost-effectiveness of viscoelas-
tic test devices to assist with the diagnosis, management
and monitoring of haemostasis disorders during and after
a variety of bleeding entities, including trauma-induced co-
agulopathy [558], based upon an extended search of six-
teen databases up to December 2013. Of note, only a few
trauma studies could be retrieved. Nevertheless, apart from
the well-known reduction in RBC, platelet and FFP trans-
fusion in the groups that used viscoelastic test devices and
the absence of differences in clinical outcomes, the use of
viscoelastic testing was associated with cost-savings and
more effective than CCAs. For the trauma population, the
cost-savings owing to viscoelastic testing devices were
more substantial, amounting to per-patient savings of £688
for ROTEM® and £721 for TEG® compared with CCA. This
finding was entirely dependent on material costs, which
are slightly higher for ROTEM®.
Fresh frozen plasma-based management
Recommendation 26 If a FFP-based coagulation resus-
citation strategy is used, we recommend that further use
of FFP be guided by standard laboratory coagulation
screening parameters (PT and/or APTT > 1.5 times nor-
mal and/or viscoelastic evidence of a coagulation factor
deficiency). (Grade 1C)
We recommend that FFP transfusion be avoided in pa-
tients without major bleeding. (Grade 1B)
We recommend that the use of FFP be avoided for the
treatment of hypofibrinogenaemia. (Grade 1C)
Rationale
Plasma (thawed FFP or pathogen-inactivated plasma) has
been used for many years and throughout the world as a
source of coagulation factors, physiological anticoagulants
and other haemostatic factors. FFP contains > 70% the
normal level of all clotting factors. Preclinical studies have
shown the protective and regenerative effects of plasma
on haemorrhage-induced glycocalyx disruption [575] and
endothelial damage. Retrospective studies [576] and the
PROPPR study have suggested that early transfusion of
plasma in a balanced ratio of 1:1 to 1:2 is associated with
lower mortality in patients with critical haemorrhage, al-
though the optimal ratio has not yet been established [534].
Plasma transfusions, however, are not free of risk and
in patients without substantial bleeding, the risk of
TACO, multiple organ dysfunction syndrome (MODS),
ARDS and infections may exceed the potential benefits
[577, 578]. Moreover, a recent retrospective study sup-
ported FFP transfusion as an independent risk factor for
increased mortality or worse outcomes across a
spectrum of surgical risk profiles including TBI [579].
Different plasma preparations show great variability. FFP
contains a variable amount of fibrinogen and is associated
with significant risk of allergic reactions and TRALI [580].
Pathogen-inactivated plasma has a more standardised con-
tent of fibrinogen and minimises the risk of TRALI and ex-
ogenous infection compared with FFP [581].
Frozen plasma products must be thawed in prepar-
ation for transfusion and this time-consuming process
may delay plasma transfusion. The use of readily trans-
fusable thawed liquid plasma has been shown to allow a
higher plasma:RBC ratio within the first hour of transfu-
sion, thus potentially increasing its efficacy in preventing
coagulopathy. However, liquid plasma is only available in
a few high-volume trauma centres [540]. With a relative
shortage of type AB plasma, to allow plasma transfusion
for resuscitation of patients whose blood type is un-
known, the use of type A plasma has been proposed
[582–584]. Preliminary data show that transfusion of in-
compatible type A plasma to patients with blood groups B
and AB as part of a massive transfusion protocol does not
appear to be associated with significant increases in mor-
bidity or mortality [585]. Freeze-dried plasma use has
been recently implemented in the military setting [530] as
well as in civilian pre-hospital care [531] and might help
to reduce the time needed to start plasma transfusion.
Although plasma transfusion may support coagulation,
Khan and Brohi observed that there was no consistent
correction of any measure of clot function nor any large
increase in the procoagulant factor level when FFP was
delivered during the acute phase of ongoing bleeding
[12, 586]. Moreover resuscitation with large amounts of
plasma is associated with dilution of RBC and platelets
[539]. Anaemia may further contribute to a reduction in
platelet marginalisation, with a potentially negative im-
pact on platelet activation.
We recommend the use of FFP if a plasma-based co-
agulation strategy is applied and there is evidence of co-
agulation factor deficiency as evidenced by a PT and/or
APTT > 1.5 times the normal control. A prolongation of
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“clotting time” or “reaction time” using VEM may also
be considered as an indication for the administration of
FFP; however, the scientific evidence for this is scarce
and a normalisation of fibrinogen level as described in
R28 will often normalise these parameters.
Coagulation factor concentrate-based management
Recommendation 27 If a CFC-based strategy is used,
we recommend treatment with factor concentrates based
on standard laboratory coagulation parameters and/or
viscoelastic evidence of a functional coagulation factor
deficiency. (Grade 1C)
Provided that fibrinogen levels are normal, we suggest
that PCC is administered to the bleeding patient based
on evidence of delayed coagulation initiation using
VEM. (Grade 2C)
We suggest that monitoring of FXIII be included in
coagulation support algorithms and that FXIII be sup-
plemented in bleeding patients with a functional FXIII
deficiency. (Grade 2C)
Rationale
Traumatic coagulopathy is characterised by an increased
fibrinolytic activity and a low fibrinogen concentration
[8, 22, 23, 29, 226, 266, 536, 587–589]. Besides early ad-
ministration of TXA (see recommendation R22) early fi-
brinogen administration is also of key importance,
ideally guided by a fibrinogen concentration < 1.5 g/L or
viscoelastic evidence of a functional fibrinogen defi-
ciency [41–43, 590, 591]. Exogenous sources of fibrino-
gen comprise FFP, cryoprecipitate and fibrinogen
concentrate [592]. Because the fibrinogen concentration
in FFP is highly variable and often relatively low, admin-
istration may further dilute the in vivo fibrinogen level,
and FFP administration is also associated with adverse
outcomes [395, 593]. Therefore, most trauma centres ad-
minister cryoprecipitate or fibrinogen concentrate to
treat low fibrinogen levels. An individualised CFC-based
strategy targets the specific needs of each individual
patient based on standard laboratory coagulation param-
eters and/or viscoelastic evidence of a functional coagu-
lation factor deficiency [41–43, 590].
Injury severity is often inversely correlated with low fi-
brinogen levels at hospital admission [23, 226, 594, 595].
Rugeri et al. described a median fibrinogen level of 0.9 g/L
[interquartile range (IQR) 0.5–1.5 g/L] in trauma patients
with coagulopathy [29]. Schöchl and co-workers found ap-
proximately 50% of patients with an admission fibrinogen
level < 1.5 g/L [587]. Rourke and colleagues reported 40%
of hypotensive trauma patients with a fibrinogen concen-
tration < 1.5 g/L [536] and Schlimp et al. reported that
54% of patients with a Hb < 120 g/L also had a fibrinogen
concentration < 1.5 g/L, increasing to approximately 75%
with an admission Hb < 100 g/L or progressively negative
BE [226]. An additional recent study describes median fi-
brinogen levels of 0.9 g/L (IQR 0.6–1.2 g/L) [588].
Fibrinogen concentrations are variable among different
FFP preparations [511], influenced by donation altitude
[596] and dependent on the type of pathogen in-
activation method applied [597–599]. Final fibrinogen
concentrations range from 1.0 to 3.0 g/L, most often
approximately 2 g/L for non-pathogen-inactivated FFP
[592] and below 2 g/L for pathogen-inactivated FFP
[597, 598]. With such a low fibrinogen concentration,
FFP administration will not rapidly increase fibrinogen
levels in the bleeding trauma patient; indeed, in reality,
fibrinogen concentration decreased significantly after the
transfusion of 4 units of FFP in trauma patients [600]. In
addition, the use of FFP has been associated with in-
creased multi-organ failure [593] and TRALI [395, 593]
in trauma patients. Finally, transfusion of FFP inevitably
results in a decrease in Hb concentration that may trig-
ger RBC transfusion, which will dilute the coagulation
potential of the blood further, thus aggravating traumatic
coagulopathy [601, 602]. Cryoprecipitate or fibrinogen
concentrate are therefore preferred by many trauma spe-
cialists for the treatment of low fibrinogen levels. The
application of individualised CFC-based strategies result
in favourable clinical outcomes, including reduced mor-
tality [41–43, 590, 601, 602]. Fibrinogen concentrate has
been adopted by the Canadian Armed Forces as part of
a remote DCR strategy in Special Operating Forces op-
erating in austere environments [603].
The usefulness of PCC has been demonstrated, with evi-
dence of reduced haematoma formation in patients with
head injury [604, 605], and is preferable to FFP for the rapid
reversal of the effects of VKAs [606–609] (for further
details, see recommendation R33). Thromboelastometry
(TEM) is useful to guide individualised goal-directed
coagulation therapy in patients with traumatic coagulopathy
[17, 560, 610, 611]. In the initial phase, a low fibrinogen con-
centration is expected [8, 22, 23, 29, 226, 266, 536, 587–589].
However, thrombin generation is preserved or even in-
creased [612, 613]. Initial treatment should therefore com-
prise fibrinogen administration, which not only increases
the MCF in FIBTEM, but also shortens the clotting time
in EXTEM [560]. Only if the EXTEM clotting time re-
mains prolonged, despite a fibrinogen level > 1.5 g/L
should PCC be administered to normalise the EXTEM
clotting time [516, 614].
It is important to avoid the overly liberal use of PCC
in trauma patients, because PCC administration results
in increased thrombin potential over days that is not
reflected by standard laboratory tests and might expose
the trauma patient to an increased risk of delayed
thrombotic complications [613]. Therefore, the risk of
thrombotic complications resulting from PCC treatment
should be weighed against the need for rapid and
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effective correction of coagulopathy [615–620]. While
the incidence of thrombotic complications mirrors that
of patients treated with FFP [621, 622], safety data on
the use of PCC in trauma patients are scarce beyond the
emergency reversal of pre-treatment with a VKA [623].
A higher incidence of thromboembolic events has been
reported in trauma patients with the use of three-factor
PCC compared to four-factor PCC [624]. According to
some expert opinion, activated PCC (aPCC) may be as-
sociated with a higher risk of thrombosis compared to
non-activated PCC [625] due to the presence of acti-
vated factor IX, because the thrombogenic trigger asso-
ciated with PCC infusion occurs at the level of factor X
activation as a part of aPCC [626]. Therefore, in patients
who have received PCC, the application of thrombopro-
phylactic measures as early as possible after bleeding has
been controlled is prudent.
Coagulation factor XIII (FXIII), formerly known as a
“fibrin stabilising factor”, is a transglutaminase circulat-
ing in tetrameric form consisting of two A and two B
subunits. The A subunit of FXIII is activated to FXIIIa
by thrombin and FXIIIa catalyses the cross-linking of fi-
brin. [627] Strong cross-linking of fibrin prevents fibrin-
olysis [628] and FXIII activity seems to be an important
independent modulator of clot firmness [592, 629].
In the neurosurgical setting, a postoperative FXIII
level < 60% was found to be an independent risk factor
for postoperative intracranial bleeding in an observational
study of 876 patients [630] and in another study with
1264 neurosurgical patients [631]. In patients undergoing
cardiac surgery, low FXIII levels were also associated with
increased postoperative blood loss [632, 633].
FXIII is present in different concentrations in cryopre-
cipitate, FFP and FXIII concentrate [592, 627]. Recom-
binant FXIII-A2 (rFXIII-A2) has been developed for the
prophylaxis and treatment of bleeding in patients with
inherited FXIII A-subunit deficiency [634]. Levy et al. re-
ported a preliminary study of rFXIII-A2 in cardiac sur-
gery. Patients scheduled for coronary artery bypass
grafting were randomly assigned to receive a single dose
of rFXIII-A2 or placebo following cardiopulmonary by-
pass after an initial dose of protamine. Treatment with
rFXIII-A2 restored levels of FXIII to preoperative levels
was well tolerated but did not reduce the need for RBC
transfusion [635]. Efficacy and safety of the prophylactic
use of rFXIII-A2 on blood transfusions were also evalu-
ated in an RCT in adult patients undergoing cardiac sur-
gery, but no reduction in transfusion requirements was
found [636].
There are no specific RCTs evaluating FXIII levels
and/or FXIII replacement therapy in trauma patients.
However, acquired low levels of FXIII have been found
in patients with major trauma and coagulopathy [637]. If
cryoprecipitate is not available, as in most European
countries, and a CFC-based strategy is used, very little if
any factor XIII is administered. Monitoring factor XIII
levels and replacement below a certain threshold there-
fore is suggested as part of coagulation support algo-
rithms. At present, however, the need for and a defined
optimal level of FXIII replacement in major trauma
patients has not been determined. The updated guide-
lines for the management of severe perioperative bleed-
ing from ESA suggests the administration of FXIII
concentrate in the presence of bleeding and a FXIII
level < 30% [638]. The use of FXIII concentrate at a
FXIII level < 60% was part of multimodal algorithms in
two recent studies in major trauma patients, resulting in
major reductions in transfusion requirements and im-
provements in clinical outcomes, including a reduction in
the duration of stay in the ICU, organ dysfunction and
hospital mortality in one study [42, 43].
Fibrinogen supplementation
Recommendation 28 We recommend treatment with
fibrinogen concentrate or cryoprecipitate if major bleed-
ing is accompanied by hypofibrinogenaemia (viscoelastic
signs of a functional fibrinogen deficit or a plasma
Clauss fibrinogen level ≤ 1.5 g/L). (Grade 1C)
We suggest an initial fibrinogen supplementation of
3–4 g. This is equivalent to 15–20 single-donor units of
cryoprecipitate or 3–4 g fibrinogen concentrate. Repeat
doses should be guided by VEM and laboratory assess-
ment of fibrinogen levels. (Grade 2C)
Rationale
Fibrinogen is the final component in the coagulation
cascade, the ligand for platelet aggregation and there-
fore key to effective coagulation and platelet function
[377, 639]. Hypofibrinogenaemia is a common compo-
nent of the coagulopathy associated with massive bleeding
[640], fibrinogen is the first coagulation factor to fall below
critical levels [641] and hypofibrinogenaemia is associated
with increased mortality [642]. There are no fibrinogen re-
serves outside the plasma, which means that a sharp fall
in fibrinogen level cannot be quickly compensated. How-
ever, plasma fibrinogen levels do increase with age and
atherosclerosis and behave as an acute phase protein.
Interestingly, in accord with this, Ohmori et al. found that,
unlike young people, those > 65 years, had higher fibrino-
gen levels following major blood loss, suggesting that fi-
brinogen level is a poor early indicator of blood loss in the
older population [643]. Schlimp et al. and others have
demonstrated that fibrinogen levels upon admission
strongly correlate with rapidly obtainable routine labora-
tory parameters such as Hb and BE [226, 589]. Fibrinogen
levels lower than 1.5 g/L were detected in as many as 73%
of trauma patients with an admission Hb lower than
100 g/L and in 63% of those with a BE lower than − 6
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[644]. Rourke et al. [536] observed low fibrinogen levels
in 41% of hypotensive patients on admission.
Coagulopathic civilian trauma patients had a median fi-
brinogen concentration of 0.9 g/L (IQR 0.5–1.5 g/L) in
conjunction with a maximum fibrinogen thromboelasto-
metric MCF of 6mm (IQR 0–9mm) using TEM, whereas
only 2.5% of healthy volunteers had a MCF of < 7mm
[29]. In trauma patients, a MCF of 7mm was associated
with a fibrinogen level of approximately 1.5–2.0 g/L [587].
During postpartum haemorrhage, fibrinogen plasma con-
centration is the only coagulation parameter independ-
ently associated with progress towards severe bleeding,
with a level < 2 g/L having a PPV of 100% [645].
Our recommendation to supplement fibrinogen in pa-
tients with traumatic bleeding when levels fall below 1.5 g/L
is supported by other international guidelines [591]. The
required fibrinogen dosage may be estimated based on the
results of thromboelastometric monitoring using a simple
formula. The administration of 0.5 g fibrinogen to an
80 kg patient may increase the A10 MCF by 1mm, the
application of which may facilitate a rapid and predictable
increase in plasma fibrinogen to a target level [602].
There are methodological issues with all of the tech-
niques applied to measure fibrinogen concentration
[646, 647]. The Clauss method is the gold standard
laboratory assay; however, in the presence of artificial
colloids such as HES this method may overestimate the
actual fibrinogen concentration [647]. Functional fi-
brinogen measurement using TEM is also influenced by
Hct [648] and FXIII levels [649].
Three questions remain unanswered with respect to
the use of supplementary fibrinogen. First, it is not clear
whether use, especially early use, of fibrinogen reduces
mortality. An early observational study suggested that
fibrinogen substitution can improve survival in combat-
related trauma [650]. In the civilian setting, the use of
TEM-guided fibrinogen replacement reduced exposure
to allogeneic blood products [17, 516, 523]. Retrospect-
ive reviews of single-centre experiences in the manage-
ment of massive blood loss in trauma patients have also
suggested a reduced mortality when compared with ex-
pected mortality [516] and increased 30-day survival [651].
Data from an open-label single-centre RCT that investi-
gated the use of factor concentrates versus FFP suggested
that early use of fibrinogen was more effective than early
use of FFP, as fewer patients required rescue therapy [42].
In contrast, a retrospective analysis of those who re-
ceived cryoprecipitate versus those who did not showed
no improved outcome, although cryoprecipitate was only
administered to patients with fibrinogen < 1.0 g/L and
this group showed no improved clinical outcome [652].
The retrospective Military Application of Tranexamic
Acid in Trauma Emergency Resuscitation (MATTERs II)
study of massive military bleeding suggested that
cryoprecipitate may independently add to the survival
benefit of TXA in the seriously injured patient who re-
quires transfusion [653]. However, cryoprecipitate is
often administered with great delay. In the PROMMTT
study [654], the median time from admission to the first
cryoprecipitate unit was 2.8 h (IQR 1.7–4.5), and in the
Activation of Coagulation and Inflammation in Trauma
(ACIT) study [586], cryoprecipitate was administered
only after the first six units of blood.
As yet, there are still no adequately powered pros-
pective clinical trials to demonstrate the risk–benefit re-
lationship associated with administration of additional
fibrinogen from other sources to manage bleeding
trauma patients [264, 655]. A small randomised, con-
trolled feasibility trial suggested that the early adminis-
tration of cryoprecipitate in trauma patients is possible
and 85% of recipients received cryoprecipitate within
90 min. The same group have organised an ongoing mul-
ticentre randomised trial known as CRYOSTAT II, which
will investigate the effect of early cryoprecipitate on clin-
ical outcome [574].
Second, the effect of fibrinogen supplement use on the
rate of post-traumatic VTE has never been systematically
addressed. Post-traumatic fibrinogen levels are expected
to rise as part of the acute phase response after major
surgery and trauma [613, 656–658], even without intra-
operative fibrinogen administration. Interestingly, intra-
operative administration of fibrinogen concentrate in
trauma patients [613] or in patients undergoing cardiac
surgery resulted in higher intra- and early postoperative
fibrinogen levels, but fibrinogen levels were identical on
postoperative days 1–7 in patients with and without in-
traoperative fibrinogen administration [658, 659].
Finally, no studies to date have adequately ad-
dressed whether cryoprecipitate and fibrinogen con-
centrates show similar efficacy and safety profiles;
therefore, there is insufficient evidence to support a
firm statement about which of the two strategies is
best, or whether a combined used of both strategies
could be beneficial [660].
The rationale for fibrinogen administration should be
read in conjunction with that for FFP (R26).
Platelets
Recommendation 29 We recommend that platelets
be administered to maintain a platelet count above
50 × 109/L. (Grade 1C)
We suggest maintenance of a platelet count above
100 × 109/L in patients with ongoing bleeding and/or
TBI. (Grade 2C)
If administered, we suggest an initial dose of four
to eight single platelet units or one aphaeresis pack.
(Grade 2C)
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Rationale
Although platelets play a pivotal role in haemostasis
after injury, the threshold and timing of platelet transfu-
sion in trauma patients is controversial. In initial acute
blood loss, the bone marrow and spleen variably release
platelets into the circulation, and therefore their de-
crease in the peripheral blood is delayed. As a result,
platelet counts are typically within the normal range
(150 × 109/L to 400 × 109/L) during early traumatic
coagulopathy [661, 662]. Upon admission, platelet
count < 150 × 109/L has been reported in only 4% of
trauma patients with an ISS of 5 and in 18% of pa-
tients with ISS > 5 [661]. Platelet counts decreased
markedly in the 2 h following hospital admission and
1 × 109/L/h over the next 22 h, suggesting an important
role for the treatment administered [662]. A platelet count
of 50 × 109/L may be anticipated when approximately two
blood volumes have been replaced by fluid or red cell
components [641].
However, platelet count on admission may be predictive
of outcome, as documented in some cohorts of massively
transfused trauma patients, in which platelet count was
inversely correlated with injury severity [661], morbidity
[663] and mortality [661]. A low or decreasing platelet
count also predicts greater mortality in trauma patients
[662] and a lower than normal platelet count predicts pro-
gression of ICH [663–665], need for neurosurgical inter-
vention [664] and mortality after TBI [663–665].
Although the platelet count may have a predictive
value for outcome, platelet transfusion to increase the
number of platelets has contradictory effects. Proactive
administration of platelets in patients with massive
bleeding due to ruptured aortic abdominal aneurysms
increased survival from 30 to 45% when the platelet
count was > 50 × 109/L as compared with < 50 × 109/L
and further increased to 69% for those with platelet
count > 100 × 109/L [666]. In contrast, platelet transfu-
sion did not restore the platelet count in trauma patients
in one study [667] and did not influence the outcome in
patients with TBI and moderate thrombocytopenia
(50–107 × 109/L) [668]. Accordingly, at this time, there is
weak scientific evidence to support a particular platelet
count threshold for platelet transfusion in the severe
bleeding trauma patient [669, 670].
The fact that the association between lower platelet
counts and higher mortality applies to platelet counts
well into the normal range [662] suggests that platelet
dysfunction may play a role [285]. Moderate or even
mildly decreased platelet aggregation has been shown to
be strongly associated with mortality [283, 284, 671].
However, platelet transfusion did not improve platelet
dysfunction in general trauma [667] or TBI patients
[308]. Repeated measurements after platelet transfusion
demonstrated that non-responders to transfusion had a
trend towards higher mortality compared with patients
with increased platelet function after transfusion [289].
Notably, platelets may attenuate fibrinolysis by providing
an additional source of plasminogen activator inhibitor-1,
which may be beneficial during the early treatment of
traumatic coagulopathy [667]. As platelet dysfunction may
be present after injury, even before substantial fluid or
blood products have been administered, and continues
during the resuscitation period, there is a potential role
for early platelet transfusion in the management of trau-
matic coagulopathy [285].
Early, up-front administration or higher doses of plate-
lets given in predefined ratios with other blood products
in trauma patients with massive bleeding who are not yet
thrombocytopenic is controversial. Although most of the
combat [672, 673] and civilian studies [651, 674–676], one
meta-analysis [677] and one systematic review [678] that
investigated the impact of platelet transfusion in severe
trauma and massive transfusion, showed an improved
survival rate among patients receiving high platelet:RBC
ratios, such evidence provided by retrospective and obser-
vational studies may be subject to serious confounding
factors, such as survivorship bias [677] or co-interventions
[679]. The timing of platelet transfusion relative to the ini-
tiation of RBC and FFP transfusion was not reported in
most of the studies, and there may be more than one
optimal ratio depending on trauma severity, degree and
dynamics of blood loss and previous fluid administration
[677]. Considering that significant dilution of platelet
count resulted when a 1:1:1 ratio of RBC, plasma and
platelets was administered [539], the actual number of
platelets transfused to each patient is unknown because
blood bank standards estimate only the minimum number
of platelets contained in apheresis and pooled platelet
units [678].
One additional reason for the lack of clarity on the
role of platelet transfusion is the difficulty in separating
the effect of a high platelet:RBC ratio from the effect of
a high plasma:RBC ratio in most observational studies.
In comparison with increased plasma:RBC ratios, the
impact exerted by platelets on survival was not as strong
[680, 681], higher than the impact of high amount of
plasma [651, 673] or even absent [682, 683]. In patients
with TBI, transfusion of a high platelet:RBC ratio and a
low plasma:RBC ratio was found to be associated with
improved survival [684]. Interestingly, patients with
penetrating injuries [681] and females [680] do not
benefit from high platelet:RBC ratios, and no difference
in mortality was observed in patients with non-massive
transfusion receiving higher platelet:RBC ratios [685].
However, large prospective cohort studies showed that
a high platelet:RBC ratio was associated with survival
benefit as early as 6 h after admission, suggesting that
survivor bias is unlikely [576, 679]. Significant protective
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association between higher platelet ratios and mortality
was concentrated during the first 6 h only, in contrast to
high plasma ratios, which were protective throughout
the first 24 h [576]. A recent observational study con-
firms that a high platelet:RBC ratio (≥ 1:1.5) within 4 h
post-injury but not later (4–24 h) is significantly associ-
ated with a lower rate of multiple organ failure and mor-
tality within 30 days post-injury, although with higher
rates of wound infection and pneumonia [686].
A large multicentre RCT (PROPPR), designed to
evaluate the benefit of blood product ratios (1:1:1 or
1:1:2 FFP:platelets:RBC) on patient outcome indicated
no survival benefit at 24 h or 30 days of empiric immedi-
ate (within minutes of arrival to a trauma centre) platelet
transfusion [534]. Of note, the intervention in this trial
differed both in the ratio of FFP and platelets, but also
the order of administration, with the 1:1:1 group receiv-
ing platelets as the first product and the 1:1:2 not receiv-
ing platelets until the second batch of blood product
was provided, after six RBC and three FFP units had
been administered. More patients in the 1:1:1 group
achieved haemostasis and fewer experienced death as a
result of exsanguination at 24 h. However, these out-
comes were not pre-specified outcomes of the trial and
had the analysis not combined exsanguination with
other causes of death, exsanguination alone would not
have emerged as a significant cause of death [687]. Un-
fortunately, this study did not independently examine
the effects of plasma and platelets on outcomes.
A systematic review of six RCTs, five in trauma pa-
tients, on the optimal dose, timing and ratio of blood
products for massive transfusion, found no evidence of a
mortality or morbidity benefit using higher ratios. The
authors concluded that there is insufficient evidence to
recommend a 1:1:1 plasma and platelet to RBC ratio
over a 1:1:2 ratio or standard care [688].
The discrepancies between observational and rando-
mised trials on the benefit of early administration of high
doses of platelets are not fully explained. Interestingly,
trauma patients receiving massive transfusion, specifically
platelet transfusions, showed a further reduction in plate-
let count, with a disproportionate decrease in function
that was donor-related [300], putting the quality of the
platelet product administered in question [689].
A theoretical shortcoming of ratio-driven resuscitation
is over-transfusion with plasma and platelets, resulting
in no benefit or in added morbidity such as multiple
organ failure [578, 675]. Recent observations suggest
that both early FFP (0–6 h) and delayed (7–24 h) platelet
transfusions are risk factors for hypoxaemia and ARDS
after 24 h, respectively [690], and non-massively trans-
fused blunt trauma patients receiving > 250 mL platelets
were more likely to develop ARDS [691]. A recent pro-
spective multicentre cohort study concluded that in
critically ill patients, transfusion of platelets, but not of
RBC and plasma, is an independent risk factor for acquir-
ing a nosocomial infection [692]. The introduction of
pathogen-reduction technologies may abrogate many of
the adverse effects associated with pathogen contamin-
ation of platelet products, but with a risk of decreased
platelet transfusion effectiveness [693, 694].
The storage of transfused platelets may also play a role
in the effectiveness of platelet transfusion. After adjust-
ment for confounders, patients receiving aphaeresis
platelets stored for 5 days had a 2.4-fold higher risk of
developing complications, including acute renal failure,
ARDS and sepsis, than patients transfused with fresher
platelets [695]. Although cold-stored platelets may have
a reduced circulating life, they have superior haemostatic
effects, compared with room-temperature platelets, and
therefore potential benefits in the treatment of critical
traumatic bleeding [696].
The therapeutic dose of platelets is one aphaeresis plate-
let product, which is approximately equivalent to four to
six units of pooled platelets, and contains approximately
3–4 × 1011 platelets [669, 670]. The platelet-rich plasma
used in the USA contains fewer platelets than the
high-output platelet concentrate manufactured by apher-
esis or pooling five buffy coats mainly used in Europe
[697]. This difference should be considered when analys-
ing the results of studies supporting higher levels of
platelet transfusion. Furthermore, the buffy coat method
has been shown to contain higher quantities of platelet-
derived micro-particles versus leuko-reduced platelets
from apheresis or platelet-rich plasma preparation. Even
with apheresis-derived platelet products, metabolites ac-
cumulating during storage may have an impact on platelet
recovery and survival, which could impact clinical out-
comes [689].
A dose of four to eight platelet units or a single-donor
aphaeresis unit is usually sufficient to provide haemosta-
sis in a thrombocytopenic bleeding patient and should
increase the platelet count by 30–50 × 109/L. However,
the usual 60–70% recovery rate in peripheral blood may
be lower under conditions associated with increased
platelet consumption [697]. Although ABO-identical, or
at least ABO-compatible platelets are recommended in
order to provide a good yield, it is acceptable to use
ABO incompatible platelets to reduce waste [669].
Calcium
Recommendation 30 We recommend that ionised
calcium levels be monitored and maintained within
the normal range during massive transfusion. (Grade
1C)
We suggest the administration of calcium chloride to
correct hypocalcaemia. (Grade 2C)
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Rationale
The normal concentration of the ionised form of cal-
cium ranges from 1.1–1.3 mmol/L and is influenced by
the pH; a 0.1 unit increase in pH decreases the ionised
calcium concentration by approximately 0.05 mmol/L
[698]. Ionised calcium plays an essential role in the for-
mation and stabilisation of fibrin polymerisation sites;
therefore, a reduction in the concentration of calcium
has an impact on all platelet-related functions [698]. In
addition, contractility of the heart and systemic vascular
resistance are low in the presence of reduced ionised cal-
cium levels. Laboratory tests may not reflect the negative
impact of hypocalcemia on the clotting process, as blood
samples are recalcified before being analysed.
Acute hypocalcaemia is a common complication of
massive transfusion [699] and low ionised calcium levels
at admission are associated with increased mortality
[700]. In patients receiving blood transfusions, hypocal-
caemia results from the citrate chelation of serum Ca2+.
Each unit of packed RBC and FFP contains approxi-
mately 3 g of citrate used as a preservative and anti-
coagulant. Normally, the liver metabolises and clears
citrate in a matter of minutes. However, in patients who
are in haemorrhagic shock and require massive transfu-
sion, liver function is often impaired due to hypoperfu-
sion. Hypocalcaemia in critically ill patients requiring
massive transfusion is detrimental, because Ca2+ plays a
crucial role in normal coagulation. Ca2+ is a cofactor in
the activation of factor II, VII, IX, and X, along with pro-
tein C and protein S of the coagulation cascade, and it
also contributes to platelet adhesion at the site of vessel
injury. Hypocalcaemia during the first 24 h can predict
mortality and the need for multiple transfusions better
than the lowest fibrinogen concentrations, acidosis and
the lowest platelet counts [701]. Measurement of ionised
calcium levels can easily be performed together with a
blood gas analysis by the majority of blood gas analysers
available on the market.
A retrospective study on patients who received massive
transfusion and who developed hypocalcaemia (Ca2+ < 1.12)
showed that severe hypocalcaemia (Ca2+ < 0.90) was asso-
ciated with a significantly higher APTT, higher blood lac-
tate levels, lower platelet count and lower blood pH
compared with moderate hypocalcaemia (Ca2+ ≥ 0.90).
Patients in the Ca2+ < 0.90 group received more blood
products (34 vs 22 units) and mortality was significantly
higher (49% vs 24%) [702].
Transfusion-induced hypocalcaemia with ionised Ca2+
levels below 0.9 mmol/L or serum total corrected cal-
cium levels of 7.5 mg/dL or less requires prompt calcium
replacement, as ionised Ca2+ levels below 0.8 mmol/L
are associated with cardiac dysrhythmias. The ionised
calcium concentration should therefore be maintained
within the normal range. However, no data are available
to demonstrate that the prevention of ionised hypocal-
caemia reduces mortality among patients with critical
bleeding who require massive transfusion.
To correct hypocalcaemia, calcium chloride is pre-
ferred to calcium gluconate, as 10% calcium chloride
contains 270 mg of elemental calcium per 10 mL,
whereas 10% calcium gluconate contains 90 mg of
elemental calcium per 10 mL [703]. Calcium chloride
may also be preferable to calcium gluconate in the
presence of abnormal liver function, because de-
creased citrate metabolism results in slower release of
ionised calcium.
Recombinant activated coagulation factor VII
Recommendation 31 We do not recommend the use of
recombinant activated coagulation factor VII (rFVIIa) as
first-line treatment. (Grade 1B)
We suggest that the off-label use of rFVIIa be consid-
ered only if major bleeding and traumatic coagulopathy
persist despite all other attempts to control bleeding and
best-practice use of conventional haemostatic measures.
(Grade 2C)
Rationale
rFVIIa acts on the endogenous coagulation system, but
depends on adequate numbers of platelets and fibrino-
gen to support effective activity [704, 705]. Following
trauma, pH and body temperature should be restored as
near to physiological levels as possible, since even small
reductions in pH and temperature result in slower coagu-
lation enzyme kinetics [413, 415, 706]. This is of particular
importance because thrombin generation is typically
normal in patients following major trauma [613].
Predictors of a poor response to rFVIIa are pH < 7.2
(p < 0.0001), platelet count < 100 × 109/L (p = 0.046)
and blood pressure ≤ 90 mmHg (p < 0.0001) [707]. Initial
research based on data from the Australian and New Zea-
land Haemostasis Registry suggests that administration of
rFVIIa in patients with blood pH < 6.9 is of no value [708].
Subsequent research showed that pH < 7.1 prior to rFVIIa
administration was independently associated with an
increased 28 day mortality [709–711].
rFVIIa should be considered only if treatment with a
combination of surgical approaches, best-practice use of
blood products, the use of antifibrinolytics and correc-
tion of severe acidosis, severe hypothermia and hypocal-
caemia fail to control bleeding. Best-practice use of
blood products includes RBC, platelets, FFP and cryo-
precipitate/fibrinogen resulting in a Hct above 24%,
platelets above 50 × 109/ L and fibrinogen above 1.5–
2.0 g/L. A recent French cohort study that included
patients with severe blunt or penetrating trauma
treated with rFVIIa for persistent massive bleeding
showed that adherence to the above criteria prior to
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the administration of rFVIIa was associated with
lower mortality and fewer transfusions [712].
Despite a large number of case studies and series
reporting that treatment with rFVIIa is beneficial in the
treatment of bleeding following trauma, there have been
only a limited number of high-quality studies supporting
these claims [713–715]. In a multicentre, randomised,
double-blind, placebo-controlled study the efficacy of
high-dose rFVIIa in patients with blunt (n = 143) or
penetrating (n = 134) trauma was reported. After receiv-
ing eight units of RBC, patients assigned to the rFVIIa
arm received 200 μg/kg initially with a second and third
rFVIIa dose of 100 μg/mg 1 and 3 h later. Patients with
blunt trauma, who survived for more than 48 h and were
assigned to receive rFVIIa, were shown to require
fewer RBC transfusions and fewer massive transfusions (>
20 units of RBC) compared with placebo. In contrast, there
were no significant effects in the penetrating trauma pa-
tients, although trends towards reduced RBC requirements
and fewer massive transfusions were observed [716]. Simi-
lar results and trends were observed in other retrospective
studies and case reports [717–719]. A further randomised
clinical trial aimed to evaluate rFVIIa as an adjunct to dir-
ect haemostasis in major trauma patients who bled four to
eight RBC units within 12 h of injury and were still bleed-
ing despite strict DCR and operative management. Patients
were treated with rFVIIa (200 μg/kg initially; 100 μg/kg
at 1 and 3 h) or placebo. The trial was terminated early
(n = 573) due to challenges in obtaining informed con-
sent and enrolling more severely injured patients,
resulting in low mortality rates that prompted a futility
analysis. Thrombotic adverse events were similar across
study cohorts [720]. A recent Cochrane meta-analysis
concluded that the efficacy of rFVIIa outside its current
licensed indications is unproven and even associated
with an increased incidence of arterial thromboses.
Therefore, rFVIIa should only be used for licensed indi-
cations or in the context of a study [721]. Similarly, an-
other meta-analysis found more arterial thromboses in
rFVIIa-treated patients [722].
Indeed, the use of rFVIIa to treat traumatic coagulo-
pathy represents an “off-label” indication and ad-
ministration may increase the risk of thromboembolic
complications [723]. A meta-analysis showed a higher
risk of arterial thromboembolic adverse events (5.6% in
patients receiving rFVIIa versus 3.0% in placebo-treated
patients) among over 2000 patients enrolled in placebo-
controlled trials outside currently approved indications
in various clinical settings [724]. This result, however,
was contradicted in a study of trauma patients, in which
rFVIIa use was not associated with an increased risk of
thromboembolic complications [725]. A higher dose of
rFVIIa (100 μg/kg) was not associated with greater inci-
dence of thromboembolic events when compared to
lower dose (30 μg/kg) in a retrospective single-centre co-
hort study that analysed 152 surgical and trauma pa-
tients. However, a higher incidence of thromboembolic
events (approximately 21%) was observed in patients
undergoing cardiothoracic surgery and suffering pene-
trating trauma [726].
In patients with isolated head injury and traumatic
ICH, the use of rFVIIa was shown to have no positive ef-
fect on patient outcomes, and even found to be harmful
[727, 728]. Current evidence does not support the use of
any haemostatic drugs, including rFVIIa, for reducing
mortality or disability in patients with TBI and related
ICH [729].
VII. Reversal of antithrombotic agents
Antithrombotic agent reversal
Recommendation 32 We recommend reversal of the
effect of antithrombotic agents in patients with ongoing
bleeding. (Grade 1C)
1. VKAs
2. Direct oral anticoagulants—FXa inhibitor
3. Direct oral anticoagulants—Thrombin inhibitor
4. Antiplatelet agents
Rationale
Reversal of the different anticoagulants is considered in
separate chapters in this guideline, as the strategy and
mechanism behind the reversal of each is different. We
wish to remind the reader that patients take antithrom-
botic medication because they have an underlying
thrombotic risk. The need for reversal thus needs to be
weighed against the prothrombotic state of the individ-
ual. For example, a patient with an old-fashioned pros-
thetic mitral valve will have a high risk of thrombosis
once anticoagulation is counteracted; therefore, full re-
versal of the anticoagulant is only justified in presence of
life-threatening bleeding.
Once the antithrombotic agent has been reversed then
the patient is at risk of thrombosis, due to the absence of
anticoagulation, to the acute phase response that occurs
following trauma and possibly to prothrombotic effects of
the reversing agent. Appropriate thromboprophylaxis
should therefore be initiated as soon as possible after
bleeding has been controlled.
Reversal of vitamin K-dependent oral anticoagulants
Recommendation 33 In the bleeding trauma patient,
we recommend the emergency reversal of vitamin
K-dependent oral anticoagulants with the early use of
both PCC and 5mg i.v. phytomenadione (vitamin K1).
(Grade 1A)
Spahn et al. Critical Care           (2019) 23:98 Page 39 of 74
Rationale
Coumarin (more accurately, 4-hydroxycoumarin) deriva-
tives are VKAs and are still widely used, despite the
growing use of DOACs. Warfarin is the most commonly
used VKA in the world, and the coumarins have a
similar effect but a shorter (acenocoumarol) or longer
(phenprocoumon) half-life [730].The most common use
for VKAs is the prevention of stroke in patients with
atrial fibrillation. Other indications include prevention of
thrombosis in those with previous venous or arterial
thromboembolism or with mechanical heart valves.
There are three therapeutic options for the reversal of
VKAs such as warfarin: vitamin K, PCC and FFP.
The biochemical reversal of VKA can be achieved
rapidly with the administration of PCC [607, 731]. All
modern guidelines on warfarin use advise the rapid res-
toration of a normal INR, although evidence that this re-
duces intracranial haematoma growth in those with ICH
or improves clinical outcome is limited to case series.
[604, 732–735], one suggesting more improvement if
PCC was administered rapidly [734].
For immediate reversal of VKAs, the missing coagula-
tion factors, FII, FIX and FX, can be replaced with PCC
[736]. However, in the past, there has been significant
variability in the FVII content of different formulations
and three-factor PCC has very little FVII. Modern PCC
formulations contain significant amounts of FVII and
can completely reverse the effect of VKAs upon infu-
sion. Unfortunately, some countries only have access to
three-factor PCC, which achieves poor correction of the
INR, and is therefore not recommended if four-factor
PCC is available. Because the half-life of administered
FVII is only about 6 h, it is important that phytomena-
dione (vitamin K1) is administered with PCC to stimu-
late physiological generation of the vitamin K-dependent
coagulation factors after this time [736].
The alternative to PCC is FFP, which contains the
missing coagulation factors diluted among all the other
constituents of plasma. However, large volumes of FFP
are required, reversal is not always achieved and there
are risks of TACO and TRALI [736]. A recent systematic
review and meta-analysis of 19 studies (18 cohort and
one RCT) that included 2878 patients demonstrated that
PCC provides more rapid and complete factor replace-
ment [OR 0.64 (95% CI 0.27–1.5) for PCC versus FFP]
[731]. In addition, thromboembolic complications were
observed in fewer PCC recipients (2.5%) than FFP recipi-
ents (6.4%). However, similar poor clinical outcomes
were seen in both groups [731].
Four-factor PCC is administered intravenously in a
dose of 25–50 U/kg, and there are algorithms avail-
able with which to calculate the most appropriate
dose based on bodyweight and INR level [736]. A
stepwise dosage is recommended, e.g. 25 U/kg if INR
is 2–4.0, 35 U/kg if INR is 4–6.0 and 50 U/kg if INR
is > 6.0 [737].
Vitamin K should also be administered intravenously.
After reversal, it is important to check INR regularly for
the next week, as a minority of patients require over a
week to clear warfarin from their blood and thus may
require additional vitamin K [738]. A rare and unpre-
dictable but important side effect of i.v. vitamin K is an
anaphylactic reaction, in some cases resulting in cardiac
arrest, with an incidence of 3 per 100,000 doses via a
non-immunoglobulin E (IgE) mechanism, possibly due
to the solubiliser in the vitamin K solution [739].
“Overcorrection” of warfarin reversal with additional
PCC and vitamin K1 can lead to harm. More than 10 mg
vitamin K1 can prevent re-warfarinisation for days and
overuse of PCC (administration of further PCC when
INR is in the normal range) may create a prothrombotic
state, which could lead to further thrombosis [736].
The use of PCC is associated with an increased risk of
both venous and arterial thrombosis during the recovery
period, which is related to preexisting risk and possibly
the use of PCC [736]. A higher incidence of thrombo-
embolic events has been reported in trauma patients
with the use of three-factor PCC compared with
four-factor PCC [624]. Therefore, in patients who have
received PCC, thromboprophylaxis is prudent as early as
possible after bleeding has been controlled.
Direct oral anticoagulants—factor Xa inhibitors
Recommendation 34 We suggest the measurement of
plasma levels of oral direct anti-factor Xa agents such as
apixaban, edoxaban or rivaroxaban in patients treated or
suspected of being treated with one of these agents.
(Grade 2C)
We suggest that measurement of anti-Xa activity be
calibrated for the specific agent. If measurement is not
possible or available, we suggest that advice from an ex-
pert haematologist be sought. (Grade 2C)
If bleeding is life-threatening, we suggest administra-
tion of TXA 15mg/kg (or 1 g) intravenously and that
the use of PCC (25–50 U/kg) be considered until specific
antidotes are available. (Grade 2C)
Direct oral anticoagulants—direct thrombin inhibitors
Recommendation 35 We suggest the measurement of
dabigatran plasma levels using diluted thrombin time in
patients treated or suspected of being treated with dabi-
gatran. (Grade 2C)
If measurement is not possible or available, we suggest
measurement of the standard thrombin time to allow a
qualitative estimation of the presence of dabigatran.
(Grade 2C)
If bleeding is life-threatening in those receiving
dabigatran, we recommend treatment with idarucizumab
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(5 g intravenously) (Grade 1B) and suggest treatment
with TXA 15mg/kg (or 1 g) intravenously. (Grade 2C)
Rationale
In recent years, DOACs have been approved for the
treatment and prevention of VTE, prevention of stroke
in atrial fibrillation and acute coronary syndrome. These
anticoagulants function primarily as direct factor Xa
inhibitors (apixaban, edoxaban, rivaroxaban) or as a
thrombin inhibitor (dabigatran) [740]. These agents ac-
count for the majority of DOAC prescriptions in many
countries, and there is limited but increasing clinical ex-
perience with trauma patients treated with one of these
drugs [741–747]. Reassuringly, most studies have shown
that patients on DOAC do not suffer from excessive
general or intra-cerebral bleeding or higher mortality. It
should be emphasised, however, that most of these
studies included elderly patients (median age 67–85 years)
suffering minimal blunt trauma, ranging from falls (with-
out a formal ISS evaluation) to median ISS values of a
maximum of 9 points. Moreover, comparison has been
made with patients on VKAs, who also exhibit a higher
mortality after trauma than non-anticoagulated patients
[741]. In a single study that described a standard trauma
population (median age 42 years), a similar mortality in
dabigatran- and VKA-treated patients (13.9%) was
observed for each group, which was higher than in
those taking aspirin or clopidogrel in the control
groups (6–8%) [741].
The DOAC plasma concentration is the most import-
ant factor that determines whether an active reversal of
medication is necessary. Increasing DOAC plasma levels
have been shown to progressively affect laboratory [748]
and viscoelastic coagulation tests [257, 749–751] and
produce increased bleeding volume in laboratory ani-
mals with standardised injuries [752]. Early assessment
of both laboratory coagulation tests and direct measure-
ments of DOAC levels, therefore, is crucial in trauma
patients receiving or suspected of having received
DOAC [753]. It is important to remain highly cognizant
that any presenting patient may be anticoagulated, since
most severely injured patients are too unwell to relay
this information to the treating emergency physician.
Measurement using three generally available laboratory
tests, PT, anti-factor Xa and thrombin time, allows for
the assessment of whether a patient is anticoagulated,
and if so, by which agent, VKA, a FXa inhibitor or a
thrombin inhibitor, respectively. Viscoelastic coagulation
tests may also be helpful, since DOAC, but not thera-
peutic levels of VKA, prolong the clotting time
(ROTEM®) and reaction (R) time (TEG®) progressively,
along with increasing DOAC plasma concentration.
However, if the patient has a trauma-induced
coagulopathy, it will not be possible to discriminate be-
tween the effects of each possible prior treatment [257,
749–751].
If anti-factor Xa activity has been detected, PCC
(25–50 U/kg) treatment may be initiated. We suggest an
initial dose of 25 U/kg, repeated if necessary, as a cautious
approach given the possible thrombotic potential of PCC
products [620]. The co-administration 15mg/kg (or 1 g)
of TXA is indicated in trauma patients (see R22). In May
2018, the US Food and Drug Administration (FDA)
approved andexanet alpha [754] as an antidote for the
urgent reversal of rivaroxaban and apixaban. However,
such approval by the European Medicines Agency (EMA)
is lacking for the time being.
Whether PCC treatment results in improved haemo-
stasis with reduced bleeding may depend on the level of
anti-factor Xa activity. No effect on bleeding was seen in
rabbits with a rivaroxaban plasma concentration of ap-
proximately 500–700 ng/mL [755]. In rats, progressive
doses of four-factor PCC, however, reduced the volume
bled. In these experiments, bleeding volume was nor-
malised in animals with a rivaroxaban plasma concentra-
tion of approximately 150 ng/mL by administering a
PCC dose of 25 U/kg. At a higher rivaroxaban plasma
concentration of approximately 280 ng/mL, normalisa-
tion of bleeding required a PCC dose of 50 U/kg.
However, at a rivaroxaban plasma concentration of ap-
proximately 480 ng/mL, even the administration of 100 U/
kg PCC was unable to reduce the elevated blood loss [752].
In the presence of life-threatening bleeding and
anti-FIIa activity due to dabigatran, treatment with idar-
ucizumab (5 g i.v.) should be initiated [756, 757]. Be-
cause the effect of idarucizumab is short-lived, repeated
doses may be necessary [758]. Once idarucizumab has
been administered, it is also important to repeat all co-
agulation tests (laboratory and viscoelastic tests) within
5–10 min, because these tests are affected by dabigatran.
Hence, only after dabigatran neutralisation are they able
to show the underlying trauma-induced coagulopathy
usually present in patients following major trauma [759].
Antiplatelet agents
Recommendation 36 We suggest treatment with plate-
let concentrates if platelet dysfunction is documented in
a patient with continued bleeding who has been treated
with APA. (Grade 2C)
We suggest administration of platelets in patients with
ICH who have been treated with APA and will undergo
surgery. (Grade 2B)
We suggest that the administration of platelets in pa-
tients with ICH who have been treated with APA and will
not undergo surgical intervention be avoided. (Grade 2B)
We suggest that the administration of desmopressin
(0.3 μg/kg) be considered in patients treated with
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platelet-inhibiting drugs or von Willebrand disease.
(Grade 2C)
Rationale
Conflicting data exist about the effects of APA on trau-
matic bleeding. Patients with ongoing antithrombotic
treatment admitted for any bleeding event to the
emergency department [760], as well as general trauma
patients without brain injury [761], did not show a
significant increase in mortality risk. In elderly patients
(≥ 65 years of age) with severe trauma and pre-injury
anticoagulants and APA, only the warfarin group had a
significantly higher risk of bleeding [762], but in other
studies pre-injury APA usage was significantly associated
with massive transfusion [763] and haemostatic treat-
ments within 24 h [764], but without an impact on sur-
vival. Prior use of APA was also a risk factor for the
development of complications in blunt chest trauma
[765]. In contrast, geriatric (60 to 80 years) traumatic fall
patients on clopidogrel, but not on other APA (aspirin
or dypiridamole) or anticoagulants, had a higher
mortality, length of hospital stay and complication rate
compared with controls [766].
Data from non-elective orthopaedic procedures are
also divergent. Aspirin was associated with increased
need for postoperative blood transfusion and higher
all-cause mortality during the first year after hip fracture
surgery [767], but did not independently affect morbidity
and mortality in patients with pelvic fractures, despite
the increase in RBC transfusion [768]. Two meta-ana-
lyses of case series with controls [769, 770], and one sys-
tematic review [771], found a similar risk of bleeding or
transfusion volume in patients with hip fracture surgery
on pre-injury clopidogrel, compared with those not tak-
ing the agent at the time of surgery performed within
48 h. The authors recommend usual protocols with early
surgery in all patients, and although there may have
been a small increase (5%) in the proportion of patients
requiring transfusion [769], mortality was not increased
[769]. Further studies documented the safety (no in-
crease in mortality or complications) of early operation
for hip fracture on patients taking clopidogrel [772, 773].
However, a higher drop in Hb is expected in those on
dual APA therapy [773, 774]. In contrast, in another
study, patients who underwent surgery for intertro-
chanteric fracture while on clopidogrel had a poorer
prognosis compared with controls: intraoperative blood
transfusion, ICU and hospital stays and 1-year mortality
were higher, despite having the same rate of postopera-
tive complications [775].
The discrepant results in the above studies may reflect
the differences in patient- and region-related factors,
perioperative continuation or short (48–72 h) interrup-
tion of the APA and the lack of a confounding factor
analysis. The possible explanations for the low risk of
bleeding in patients receiving clopidogrel found in some
studies include individual responsiveness to the agent
and interactions with other drugs, such as proton pump
inhibitors, administered perioperatively [771].
The role of pre-injury APA treatment in the genesis of
ICH in patients with blunt head trauma is also contro-
versial. A meta-analysis of cohort and case-control
studies found that APA (mainly clopidogrel) use was as-
sociated with an increased risk of ICH in patients with
head injury and the association was most relevant in pa-
tients with mild TBI [776], thus supporting the addition
of the APA-use criterion to improve the out-of-hospital
identification of older adults requiring trauma-centre
care [777]. The risk of subdural haematoma is particu-
larly marked for the combined treatment of clopidogrel
with a VKA [778]. However, due to the limited literature,
the association with traumatic ICH could not be estab-
lished in patients receiving aspirin monotherapy [776].
Interestingly, aspirin and not clopidogrel use was signifi-
cantly associated with intracranial bleeding in older pa-
tients (> 60 years) admitted after ground level fall in one
study [779]. In contrast, a prospective study performed
in head-injured older adults transported by Emergency
Medicine Services in 11 US hospitals found no differ-
ence in the incidence of ICH between those with or
without pre-injury anticoagulant or APA use [780]
and a longer period of observation for delayed ICH in
patients on APA or anticoagulant medication is not
supported [781]. Another prospective cohort study
showed a low incidence of traumatic ICH after
ground level fall and no difference in patients on
APA or anticoagulants [782].
The relationship between outcome and pre-injury
APA is conflicting in the setting of both non-trauma and
trauma-related ICH. In patients hospitalised for first-
time ICH, aspirin with or without clopidogrel users had
a 20–25% increased 30-day stroke mortality compared
with non-users [783] and increased ICH volume and
mortality was also shown in one RCT performed in pa-
tients treated with aspirin [784]. Fatal subdural haema-
toma was more strongly associated with antithrombotic
drug use than non-fatal subdural haematoma [778].
Similarly, patients with APA pre-treatment had a signifi-
cantly higher risk of death during hospital stay after haema-
toma evacuation (OR 2.5; 95% CI 1.24–4.97, p < 0.01)
compared with patients without APA pre-treatment; how-
ever, no difference was registered in patients with or with-
out APA receiving conservative therapy [785]. Prior APA
use was independently associated with haematoma volume
in a prospective study [786], but not in a further retrospect-
ive study using propensity score matching [787]. However,
a meta-analysis of seven trials in patients on different APA
showed a higher risk of prior APA use for haematoma
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growth but not for mortality [786]. Another meta-analysis
of 22 trials on patients with primary ICH showed that prior
APA treatment was associated with high mortality that
might be attributed mainly to its strong effect on early time
[788]. In contrast, only dual APA treatment (mainly aspirin
and clopidogrel), but no single agent was associated with
higher in-hospital mortality in a large database of patients
with ICH [789].
In patients with blunt head trauma, a previous
meta-analysis of case-control and cohort studies showed
only a slight and non-significant increased risk of death
in patients who were taking pre-injury APA [790]. Fur-
ther studies found both an association with worsening of
the lesion [791, 792], need for neurosurgical intervention
[791], prolonged hospital stay and increased rate of dis-
ability [793], or no influence on survival [794, 795],
neurological outcome [786, 796], need for neurosurgical
intervention [794, 797], haemorrhagic complications and
need of re-operation after decompressive craniectomy
[798], questioning the need for routine neurosurgical
consultation [797] or repeat CT [799] in cases of mild
head trauma or low-altitude falls in patients treated with
APA (mainly aspirin, clopidogrel or both).
Those that have specifically analysed the use of clo-
pidogrel prior to traumatic ICH reported an increased
risk for unfavorable long-term neurological outcomes
[800], progression of the lesion and need for neuro-
surgical intervention [801]. In contrast, aspirin expos-
ure was not associated with progression of
haemorrhage on CT, clinical deterioration or mortality
in traumatic ICH [289, 802]. In older patients on pre-
operative low-dose aspirin undergoing emergency neuro-
surgery for traumatic ICH, there was also no increased
perioperative bleeding, length of hospital stay or in-hospital
mortality, but these results should be corroborated with the
higher perioperative platelet transfusion rate in patients re-
ceiving aspirin therapy [803]. A recent meta-analysis con-
firmed a statistical association between clopidogrel and
clinical deterioration or neurosurgical intervention, but no
association between aspirin use and these outcomes in TBI
patients [804].
Lower platelet counts add additional risks. A platelet
count of < 100 × 109/L is associated with progression of
haemorrhagic injury in TBI (pooled OR 4.74 [95% CI
2.44–9.20], p < 0.001) [805] and patients with hae-
morrhagic progression contusion and a platelet count
of < 150 × 109/L exhibited a faster rate of expansion
[806]. TBI patients on pre-hospital APA with a plate-
let count of < 135 × 109/L were 12.4 times (95% CI
7.1–18.4) more likely to experience progression of ini-
tial ICH on repeated head CT scan; those with a
platelet count of 95 × 109/L or less were 31.5 times
(95% CI 19.7–96.2) more likely to require neurosurgi-
cal intervention [665].
These variable findings, coupled with the fact that
some patients are non-responders to aspirin, clopidogrel
or both agents, suggest that reliable measures of platelet
function would be useful to guide reversal therapies in
the setting of the bleeding trauma patient. Patients with
occult platelet dysfunction who would benefit from
platelet transfusion could be identified or unnecessary
platelet transfusion avoided [289]. Currently, there is no
agreement on the optimal assay for platelet function (see
R11) and controversy exists as to whether bleeding in
the setting of APA use warrants platelet transfusion.
Studies addressing the ability of platelet transfusion to
improve the laboratory metrics of platelet function have
yielded mixed results. An in vitro study performed in
healthy volunteers taking aspirin and clopidogrel showed
that an equivalent of one or two to three platelet pools
(apheresis units) could normalise platelet function in pa-
tients on aspirin and aspirin plus clopidogel, respectively
[807]. However, in further ex vivo studies, platelet sup-
plementation completely reversed the effect of aspirin
[808, 809], but had a limited effect on ADP-dependent ag-
gregation inhibited by clopidogrel [808, 810], prasugrel
[810, 811] or ticagrelor [808–810, 812], even at high doses
of platelets (up to five apheresis units) [808]. Platelet
transfusion also failed to restore platelet aggregation
inhibited by ticagrelor and had a small reversing effect in
clopidogrel-treated healthy subjects [813]. In TBI patients,
platelet transfusion improved or restored platelet function
in patients on aspirin [289, 292, 308], but only minimally
in others [307] or only partially in both aspirin or clopido-
grel [297] but not in collagen trauma-induced platelet dys-
function [308] or only in patients on aspirin but not on
clopidogrel [309]. The same contrasting effect of platelet
transfusion between aspirin and clopidogrel responders
was shown prior to emergency surgery [814]. However,
the multiple platelet function assays and different platelet
suspensions (of potentially variable quality) used in these
studies make comparisons difficult. Another explanation
for the observation that platelet transfusion shows no ob-
vious benefit is that the inhibitory effect of the APA is not
normalised due to recent ingestion of APA, which may
also inactivate transfused platelets [815]. The time-
dependent effect of platelet transfusion has been shown
for both clopidogrel [808], prasugrel [811] and ticagrelor
[812, 815] and recurring platelet transfusion may be justi-
fied. A dose response to platelet transfusion was noted in
one study, and two thirds of aspirin-treated initial
non-responders corrected with the second platelet trans-
fusion [289].
Biological plausibility coupled with assay results in-
dicating the presence of significant platelet inhibition
make it difficult not to treat these patients with
platelet transfusions when injured, although current
evidence to support this practice is conflicting.
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Successful perioperative management of patients on
aspirin and clopidogrel requiring urgent surgery by
administering two apheresis platelet units preopera-
tively was recently reported [816]. However, the
bleeding and re-intervention rate was 12.2% and 6.6%,
respectively.
A systematic review of five retrospective registry
studies on traumatic ICH [817] and a meta-analysis that
included six small studies on the impact of platelet
transfusion on survival in patients treated with pre-in-
jury APA who experienced ICH, either spontaneous or
traumatic, found no clear benefit [276]. In a further
systematic review of seven retrospective studies of
APA-associated ICH in both trauma and non-trauma
settings, the pooled in-hospital mortality for platelet
transfusion in traumatic ICH patients was 1.77 (95% CI
1.00–3.13), whereas the pooled in-hospital mortality for
platelet transfusion in primary intra-parenchymal haem-
orrhage was 0.49 (95% CI 0.24–0.98). However, due to
the methodological limitations of the reviewed studies,
no conclusions were drawn by the authors [818]. One
important potential confounding factor in these studies
is the dose of platelets, which was either not reported or
suboptimal for normalisation of platelet function. The
timing of platelet administration could be another con-
founding factor but this was not confirmed in a large
retrospective study in patients with TBI while on APA
[819]. Patients receiving early platelet transfusion within
4 h were more severe and had a higher rate of worsening
haematoma and mortality.
In a double-blind RCT in patients with ICH while on as-
pirin and undergoing craniotomy, those aspirin-sensitive
who received platelet transfusion (either one unit, two
units vs no units of frozen apheresis platelets) had less
ICH recurrence, lower postoperative haematoma volume,
lower mortality and better functional outcome at 6
months compared with those who did not [784]. In con-
trast, fresh apheresis platelet transfusion was inferior to
standard of care for patients taking aspirin or clopidogrel
in a recent multicentre, randomised, open-label phase 3
trial in 190 patients with acute stroke due to spontaneous
ICH associated with APA (platelet transfusion in cerebral
haemorrhage, PATCH) [820]. Notably, the PATCH trial
did not include patients with a GCS < 8 or those thought
to need operative intervention. The odds of death and de-
pendence at 3months were higher in the platelet transfu-
sion group (OR 2.05; 95% CI 1.18–3.56). There was also
an increase in haematoma growth at 24 h in patients
treated with platelet transfusion (2.01 mL vs 1.16 mL,
p = 0.08), which was reflected in more severe adverse
events due to haematoma expansion.
Further observational studies in ICH patients have
shown either that platelet transfusion had no negative ef-
fects [821] or was not associated with improved outcome
[822]. Platelet transfusion given before cranial decom-
pressive surgery was partially effective in patients on clopi-
dogrel [823]. In TBI patients on APA pre-treatment,
platelet transfusion did not improve the neurological out-
come [309, 794, 803], but was associated with increased
infections and complications [794].
The limited evidence that APA use prior to ICH actually
has any impact on haemorrhage expansion or outcome,
together with the lack of substantive data to suggest that
platelet transfusion improves outcome and the risks asso-
ciated with platelet transfusion, do not favour platelet
transfusion in patients with APA-associated ICH who will
not undergo a neurosurgical procedure [824].
Besides platelet transfusion, potential antiplatelet re-
versal therapies include rFVIIa, TXA and desmopressin.
In healthy volunteers, rFVIIa reversed the inhibitory ef-
fects of aspirin [825] and clopidogrel [826]. The effective
dose was lower than the dose used in haemophilia pa-
tients [826]. Interestingly, TXA was shown to partially
improve platelet function both in patients treated with
dual antiplatelet therapy as measured using MEA [827]
and in aspirin-free patients [828].
Desmopressin (1-deamino-8-D-arginine vasopressin,
DDAVP) releases endothelial von Willebrand factor and
factor VIII, enhances platelet adherence and platelet ag-
gregate growth on human artery subendothelia and is
the first choice in the treatment of bleeding in patients
with von Willebrand disease, a disorder which occurs in
roughly 1 in 100 patients [829]. It is also beneficial
perioperatively in patients with mild inherited platelet
defects [830].
Two meta-analyses [831, 832] and a Cochrane analysis
[833] showed modest but significant reduction in peri-
operative RBC transfusion needs due to treatment with
desmopressin. The more recent meta-analysis focused
on platelet dysfunction and reversal of APA in cardiac
surgery [832] and was able to demonstrate a reduction
in blood loss [− 254 (− 408 to − 100) mL], a reduction in
blood transfusion requirements [− 0.65 (− 1.16 to − 0.13)
units per patient] and a reduced risk of re-operation due
to bleeding [OR 0.39 (0.18 to 0.84)]. Identification of im-
paired platelet function with a PFA-100® [834] or MEA
[835] might be helpful in the identification of patients
who could benefit from desmopressin therapy. In con-
trast, desmopressin did not improve platelet function
measured with three different devices (MEA, ROTEM®
and Sonoclot®) in vitro [836].
Desmopressin has been shown to improve platelet
function in volunteers on aspirin [837] or clopidogrel
[838]. It had no effect on inhibition of platelet aggrega-
tion by ticagrelor, although primary haemostatic activity
was significantly increased [839]. Equivalent data for
prasugrel appear not to have been published, and there
is evidence from a recent animal study that bleeding was
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not reduced in prasugrel-treated animals due to desmo-
pressin [840].
Two small prospective studies have shown that des-
mopressin can improve platelet function in patients with
ICH who have received aspirin [841] or not [842] prior
to the event. However, desmopressin and platelet admin-
istration was not associated with either a decreased risk
of early radiographic haemorrhage progression (OR 1.40;
95% CI 0.80–2.40; p = 0.2) or mortality (OR 1.50; 95% CI
0.60–4.30; p = 0.4) in patients with traumatic ICH [843].
Interestingly, desmopressin prevents the development of
hypothermia-induced impairment of primary haemosta-
sis [837, 844] and significantly increases platelet aggrega-
tion during hypothermia and acidosis [845].
Although the evidence is scarce, desmopressin has
been recommended in ICH patients treated with APA
[824] and in trauma patients with von Willebrand dis-
ease [846]. The recommended dose in ICH is 0.4 μg/kg
[824], but the usual dose in von Willebrand disease is
0.3 μg/kg diluted in 50mL saline and infused over 30min
[829]. When administering desmopressin, an antifibrinoly-
tic (e.g. TXA) should be administered in parallel.
VIII. Thromboprophylaxis
Thromboprophylaxis
Recommendation 37 We recommend early mechanical
thromboprophylaxis with intermittent pneumatic com-
pression (IPC) while the patient is immobile and has a
bleeding risk. (Grade 1C)
We recommend combined pharmacological and IPC
thromboprophylaxis within 24 h after bleeding has been
controlled and until the patient is mobile. (Grade 1B)
We do not recommend the use of graduated compres-
sion stockings for thromboprophylaxis. (Grade 1C)
We do not recommend the routine use of inferior
vena cava filters as thromboprophylaxis. (Grade 1C)
Rationale
The risk of hospital-acquired VTE is high, exceeding
50%, following multiple trauma. Pulmonary embolism
(PE) is the third leading cause of death in those who sur-
vive beyond the third day [847]. There are few RCTs that
have investigated thromboprophylaxis in trauma pa-
tients, and the use of graduated compression stockings
has never been evaluated in this group. A meta-analysis
was unable to show any reduction in the rate of DVT
with IPC [848]; however, mechanical methods are widely
used due to the low bleeding risk.
There is inadequate research on the use of mechanical
thromboprophylaxis in critical care. Of note, there is no
evidence to show graduated compression stockings re-
duce the risk of death due to a PE in any area. The clots
in legs or stockings after stroke (CLOTS 3) study was
the first large RCT to investigate the utility of IPC alone,
without pharmacological thromboprophylaxis in 2876
stroke patients. The study showed a clear benefit, with a
reduction in DVT from 12.1 to 8.5% and an absolute
reduction of 3.6% (95% CI 1.4 to 5.8), with a
non-significant reduction in death [849], suggesting that
IPC alone was ideal for patients who are not yet ready
for combined pharmacological and IPC thromboprophy-
laxis after admission. While the population in this study
was different from those in critical care, both popula-
tions have similar risk factors (immobility and acute
phase response). The recent Cochrane review [850] on
the use of combined IPC and pharmacological thrombo-
prophylaxis compared to either alone concluded that
there is moderate evidence to suggest a significantly bet-
ter reduction in VTE with combination therapy.
A systematic review and meta-analysis [851] showed
that any type of heparin thromboprophylaxis decreases
DVT and PE in critically ill medical and surgical pa-
tients, and low molecular weight heparin (LMWH) com-
pared with twice daily unfractionated heparin (UFH)
decreases both the overall rate and symptomatic rate of
PE. Major bleeding and mortality rates did not appear to
be significantly influenced by heparin thromboprophy-
laxis in the ICU setting. Another study of 289 patients
who developed VTE during or after a critical care stay
showed that thromboprophylaxis failure was more likely
in association with an elevated body mass index, a per-
sonal or family history of VTE and those administered
vasopressors [852].
LMWH has an efficacy similar to UFH but is associated
with a lower rate of heparin-induced thrombocytopenia.
In addition, less frequent injections are required due to its
longer half-life and more reliable pharmacokinetics; there-
fore, LMWH is also preferred due to ease of administra-
tion. The severity of trauma has been associated with the
risk of heparin-induced thrombocytopenia; therefore, the
greater the risk, the greater the importance of monitoring
platelet counts in trauma patients [853]. In those with a
bleeding risk, mechanical methods alone are preferable
until the bleeding risk recedes. LMWH is mainly excreted
renally, unlike UFH, which is excreted via the liver as well;
therefore, there is risk of LMWH accumulation in patients
with renal failure. According to the manufacturer’s in-
structions, dose adjustments and/or anti-factor Xa moni-
toring should be performed if patients with renal failure
require LMWH for longer than one week and have a
bleeding tendency.
There has been some interest in the administration of
a monitored dose of LMWH to trauma patients with a
high risk of VTE. Connelly et al. administered more
LMWH based on TEG® monitoring; however, the study
showed no difference in VTE rates among the 89 pa-
tients who were not and the 96 who were monitored
[854]. Ko et al. dosed LMWH based on anti-factor Xa
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levels in 87 patients versus 118 in the control group
[855]. Most of the monitored group had enoxaparin
doses increased from 30mg to 40 mg twice daily. The
incidence of VTE fell from 7.6% in the control group to
1.1% in the monitored group (p = 0.46) and no signifi-
cant difference was noted in the transfusion of RBC or
Hct at discharge. Singer et al. noted a fall in VTE rates
in 131 patients in whom anti-factor Xa activity was
monitored, but the study was flawed due to comparison
with a historical control group [856]. Some authors have
expressed interest in using DOAC instead of LMWH for
thromboprophylaxis; however, no adequately powered
RCT has addressed this issue [857].
Contraindications to pharmacological thromboprophy-
laxis include patients who are already receiving full-dose
anticoagulation, those with significant thrombocytopenia
(platelet count < 50 × 109/L), an untreated inherited or
acquired bleeding disorder, evidence of active bleeding,
uncontrolled hypertension (blood pressure > 230/120), a
lumbar puncture/spinal analgesia expected within the
next 12 h or performed within the last 4 h (24 h if trau-
matic), procedures with a high bleeding risk or a new
haemorrhagic stroke. However, a recent systematic re-
view found that pharmacological thromboprophylaxis
appears to be safe among patients with TBI and stabi-
lised haemorrhagic patterns [858].
The optimal timing for the initiation of pharmaco-
logical thromboprophylaxis may be difficult to estimate.
Data from 175,000 critical care admissions showed that
the risk of mortality was higher in those who did not re-
ceive thromboprophylaxis during the first 24 h [859].
This reflects the observation that those who bleed have
a higher rate of VTE than those who do not [860]. For
trauma patients with TBI, we suggest that pharmaco-
logical VTE prophylaxis be initiated with either LMWH,
or low-dose UFH in patients with renal failure, only after
a head CT confirms that ICH is stable and the absence
of persistent bleeding.
The use of prophylactic inferior vena cava filters is
common in some units; however, no evidence of added
benefit when used in combination with pharmacological
thromboprophylaxis exists. PE still occur despite the
presence of a filter, and filters have short- and long-term
complication rates, are associated with high cost and
often provide a false sense of security, delaying the use
of effective pharmacological thromboprophylaxis. Fur-
thermore, inferior vena cava filters require a second in-
vasive procedure to remove.
IX. Guideline implementation and quality control
Guideline implementation
Recommendation 38 We recommend the local imple-
mentation of evidence-based guidelines for management
of the bleeding trauma patient. (Grade 1B)
Assessment of bleeding control and outcome
Recommendation 39 We recommend that local clinical
quality and safety management systems include parame-
ters to assess key measures of bleeding control and out-
come. (Grade 1B)
Rationale
Implementation of treatment guidelines in complex
areas of clinical care, such as the management of trauma
patients, is challenging [861–865]. However, repetitive
educational activities addressing all healthcare providers
involved have been shown to be successful in increasing
guideline adherence [862, 865]. Therefore, the evaluation
of healthcare provider perspectives on the guideline
quality plays an important role in a successful imple-
mentation process [862]. High guideline credibility, as
well as a strong and well-communicated leadership com-
mitment to the guidelines, can increase adherence [862].
Furthermore, monitoring of guideline adherence, via
chart review [865] or video recording in the trauma bay
or the emergency department [861], with feedback to all
healthcare providers involved has been found to improve
guideline adherence.
Higher guideline adherence in turn results in im-
proved survival in adult [863] and paediatric [862]
patients suffering from TBI. Additionally, in general
trauma, adherence to these European guidelines on the
management of bleeding trauma patients resulted in
higher patient survival [41]. In a multivariate analysis
after adjustment for the ISS, the per-patient guideline
adherence rate was a highly significant factor for a
decreased mortality at 30 days (OR 0.47 (0.31–0.72,
p= 0.0004) [41]. In a similar study, the outcome of major
trauma patients was compared before and after the imple-
mentation of strict trauma treatment guidelines, mostly
identical to these guidelines, in particular regarding
goal-directed coagulation and transfusion protocols, pri-
mary WBCT, the use of TXA, restrictive fluid therapy (pref-
erably crystalloids), permissive hypovolemia/hypotension
and damage-control surgery [43]. The primary outcome
was the observed vs the TASH [866] score-predicted inci-
dence of massive transfusion from emergency department/
operating room arrival until ICU admission. The observed
incidence of massive transfusion (12.4%) was similar to the
TASH prediction (12.1%) prior to the introduction of
trauma treatment guidelines. However, with the introduc-
tion of treatment guidelines, the observed massive trans-
fusion incidence of 3.7% was significantly lower than the
TASH prediction of 7.5% (p < 0.01). Interestingly, the per-
centage of transfused patients and the amount of trans-
fused blood products were also significantly decreased, as
was hospital mortality [43]. Thus, implementation of
evidence-based guidelines for management of the bleeding
trauma patient is likely to improve the outcome.
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The implementation of our recommendations might
be facilitated by a checklist approach analogous to the
Safe Surgery Initiative [867], which led to fewer postop-
erative complications [868]. In addition or alternatively,
it may be possible to implement our recommendations
using “bundles”, as has been successfully achieved
during implementation of the Surviving Sepsis Campaign
guidelines [869, 870]. Suggested items that should be
included in such a checklist are summarised in Table 4.
Suggested patient management bundles are listed in
Table 5.
Training in trauma care should emphasise the key role
of coagulation in determining outcome. Increasing
clinician knowledge and understanding in this area
should be an integral part of the implementation of the
algorithm. All trauma care centres should evaluate their
own performance using a routine institutional quality
management programme. An audit of adherence to best
practice, including feedback and practice change where
needed, should be included as part of the local
implementation of these guidelines. In order to evaluate
the quality of care provided to the patient who is bleed-
ing after major trauma, we suggest that adherence to the
following quality standards be assessed:
 Time from injury to the initiation of intervention
to stop bleeding (surgery or embolisation) in
hypotensive patients who do not respond to initial
resuscitation
 Time from hospital arrival to availability of a full set
of blood results [full blood count, PT, fibrinogen,
calcium, viscoelastic testing (if available)]
 Proportion of patients receiving TXA within 3 h
after injury
 Time from hospital arrival to CT scan in bleeding
patients without an obvious source of haemorrhage
 Damage-control surgical techniques used in
accordance with R18
 Thromboprophylaxis commenced in accordance
with R37
Table 4 Treatment pathway checklist. Hb, haemoglobin; TBI, traumatic brain injury
Treatment phase Yes No N/A Reason for variance
Initial assessment and management
Extent of traumatic haemorrhage assessed ☐ ☐ ☐
Patient in shock with identified source of bleeding treated immediately ☐ ☐ ☐
Patient in shock with unidentified source of bleeding sent for
further investigation
☐ ☐ ☐
Coagulation, haematocrit, serum lactate, base deficit assessed ☐ ☐
Antifibrinolytic therapy initiated ☐ ☐
Patient history of anticoagulant therapy assessed (vitamin K antagonists,
antiplatelet agents, oral anticoagulants)
☐ ☐ ☐
Resuscitation
Systolic blood pressure of 80–90 mmHg achieved in absence of TBI ☐ ☐ ☐
Measures to achieve normothermia implemented ☐ ☐
Target Hb level 70–90 g/L achieved ☐ ☐ ☐
Surgical intervention
Abdominal bleeding control achieved ☐ ☐ ☐
Pelvic ring closed and stabilised ☐ ☐
Peritoneal packing, angiographic embolisation or surgical bleeding control
completed in haemodynamically unstable patient
☐ ☐ ☐
Damage-control surgery performed in haemodynamically unstable patient ☐ ☐ ☐
Local haemostatic measures applied ☐ ☐ ☐
Thromboprophylactic therapy recommended ☐ ☐ ☐
Coagulation management
Coagulation, haematocrit, serum lactate, base deficit, calcium reassessed ☐ ☐ ☐
Target fibrinogen level 1.5–2 g/L achieved ☐ ☐ ☐
Target platelet level achieved ☐ ☐ ☐
Prothrombin complex concentrate administered if indicated due to
vitamin K antagonist, oral anticoagulant or evidence from viscoelastic methods
☐ ☐ ☐
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Discussion
These guidelines (summarised in Additional file 3) reflect
the management of significant bleeding and coagulopathy
following major trauma based on the current published
scientific evidence. Expert opinion and current clinical
practice were also considered, particularly in areas in which
randomised clinical trials have not or cannot be performed
for practical or ethical reasons. Recommendations pub-
lished in previous editions of the guideline [36–39] were
reconsidered and revised as appropriate.
The recommendations included in the guideline are
intended to guide the management of patients during
the early phase of hospital care following traumatic in-
jury. However, some of the recommendations and prin-
ciples discussed may also apply to the pre-hospital
setting. Specific examples include the use of tourniquets
(R2) and the first administration of TXA (R22) at the
site of injury.
In this fifth version, the overall organisation of the
guideline has been revised to better reflect the decision-
making process along the patient pathway and group rec-
ommendations behind the rationale for key decision
points. The guideline now has nine separate chapters,
organised in approximate temporal sequence (Fig. 2).
These chapters are now patient- or problem-oriented ra-
ther than related to treatment modalities. In particular,
the former chapter on further resuscitation measures has
now been reorganised into three separate chapters (chap-
ters VI, VII, VIII).
Chapter VI (“Further goal-directed coagulation man-
agement”) now discusses goal-directed therapy (R25),
which comprises either an FFP-based strategy (R26) or
CFC-based management (R27), including a new state-
ment about the use of FXIII replacement therapy. This
chapter comprises recommendations regarding fibrinogen
supplementation (R28), platelet administration (R29), cal-
cium (R30) and rFVIIa (R31). Chapter VII (“Reversal of
antithrombotic agents”) discusses monitoring and treat-
ment of trauma patients who are anticoagulated (R33, R34,
R35) or being treated with platelet inhibitors (R36). The
number of patients in this group is rapidly increasing, and
their treatment represents a significant challenge if such
patients suffer major trauma. Finally, chapter VIII
(“Thromboprophylaxis”) provides a recommendation for
the prophylactic prevention of thromboembolic complica-
tions (R37) in major trauma patients, which is increasingly
recognised as important, particularly in patients treated
prior to traumatic injury with oral anticoagulants and/or
platelet inhibitors.
The present guideline represents an educational aid to
improve and standardise the care of the bleeding trauma
patient across Europe and beyond. The recommenda-
tions that comprise the final chapter IX (“Implementa-
tion & quality control”) continue to encourage the local
implementation (R38) of evidence-based guidelines for
the management of the bleeding patient following trau-
matic injury and that local quality and safety manage-
ment systems (R39) specifically assess key measures of
bleeding control and outcome.
We continue to concur that both children and elderly
adults who have not been pre-treated with anticoagulant
or antiplatelet agents should generally be managed in
the same manner as the normal adult patient. However,
most clinical studies investigate standard size; otherwise,
healthy adults and do not stratify by characteristics that
might justify more nuanced recommendations. Therefore,
except where addressed for specific recommendations in
the guideline, we are unable to make informed
Table 5 Suggested management bundles. BE, base excess; CT, computed tomography; FAST, focused assessment with sonography
in trauma; Hb, haemoglobin; PT, prothrombin time
Pre-hospital bundle Intra-hospital bundle Coagulation bundle
• Pre-hospital time minimised
• Tourniquet employed in case of
life-threatening bleeding from
extremities
• Damage-control resuscitation concept
applied
• Trauma patient transferred directly to an
adequate trauma specialty centre
• Full blood count, PT, fibrinogen, calcium,
viscoelastic testing, lactate, BE and pH
assessed within the first 15 min
• Immediate intervention applied in patients
with haemorrhagic shock and an identified
source of bleeding unless initial
resuscitation measures are successful
• Immediate further investigation
undertaken using FAST, CT or immediate
surgery if massive intra-abdominal
bleeding is present in patients presenting
with haemorrhagic shock and an
unidentified source of bleeding
• Damage-control surgery concept applied if
shock or coagulopathy are present
• Damage-control resuscitation concept
continued until the bleeding source is
identified and controlled
• Restrictive erythrocyte transfusion strategy
(Hb 70–90 g/L) applied
• Tranexamic acid administered as early as
possible
• Acidosis, hypothermia and hypocalcaemia
treated
• Fibrinogen maintained at 1.5–2 g/L
• Platelets maintained at > 100 × 109/L
• Prothrombin complex concentrate
administered in patients pre-treated with
warfarin or direct-acting oral coagulants
(until antidotes are available)
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Fig. 2 a Summary of treatment modalities for the bleeding trauma patients included in this guideline. CT, computed tomography; FAST, focused
assessment with sonography in trauma; Hb, haemoglobin; PT, prothrombin time. b Summary of treatment modalities for the bleeding trauma
patients included in this guideline. FFP, fresh frozen plasma; Hb, haemoglobin; RBC, red blood cells; TBI, traumatic brain injury; TXA, tranexamic
acid. c Summary of treatment modalities for the bleeding trauma patients included in this guideline. APA, antiplatelet agent; APTT, activated
partial thromboplastin time; FFP, fresh frozen plasma; FXIII, factor XIII; PCC, prothrombin complex concentrate; PT, prothrombin time; rFVIIa,
recombinant activated coagulation factor VII; TBI, traumatic brain injury; TXA, tranexamic acid
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assessment with sonography in trauma; Hb, haemoglobin; PT, prothrombin time. b Summary of treatment modalities for the bleeding trauma
patients included in this guideline. FFP, fresh frozen plasma; Hb, haemoglobin; RBC, red blood cells; TBI, traumatic brain injury; TXA, tranexamic
acid. c Summary of treatment modalities for the bleeding trauma patients included in this guideline. APA, antiplatelet agent; APTT, activated
partial thromboplastin time; FFP, fresh frozen plasma; FXIII, factor XIII; PCC, prothrombin complex concentrate; PT, prothrombin time; rFVIIa,
recombinant activated coagulation factor VII; TBI, traumatic brain injury; TXA, tranexamic acid
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recommendations for the treatment of many subpopula-
tions that may include children, women, specific ethnic
groups, individuals with high or low body mass indices or
many other co-morbidities or conditions.
The frequent scientific citations and downloads of the
previous editions of the guideline [36–39] demonstrate
the interest in the subject matter and popularity of these
guidelines. Only reports showing improved outcomes can
serve as final proof of the usefulness of these guidelines,
however, and publications from Italian, French and Swiss
trauma centres [41, 43, 523] are promising.
Conclusions
The appropriate management of trauma patients with
massive bleeding and coagulopathy remains a major
challenge in routine clinical practice. A multidisciplinary
approach and adherence to evidence-based guidance are
key to improving patient outcomes, which could now be
shown in the first outcome studies.
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RBC: Red blood cells; RCT: Randomised controlled trial; RD: Risk difference;
REBOA: Resuscitative endovascular balloon occlusion of the aorta;
RETIC: Reversal of Trauma Induced Coagulopathy Using Coagulation Factor
Concentrates or Fresh Frozen Plasma; rFVIIa: Recombinant activated
coagulation factor VII; ROTEM: Rotational thromboelastometry;
RPH: Retroperitoneal haemorrhage; RR: Risk ratio; r-TEG: Rapid
thromboelastography; SI: Shock index; SMR: Standardised mortality ratio;
SOP: Standard operating procedure; TACO: Transfusion-associated circulatory
overload; TASH: Trauma-associated severe haemorrhage; TBI: Traumatic brain
injury; TEG: Thrombelastography; TEG-PM: Thrombelastography platelet
mapping; TEM: Thromboelastometry; TRALI: Transfusion-related acute lung
injury; TRAP: Thrombin receptor activating peptide; TRICC: Transfusion
Requirements in Critical Care; TXA: Tranexamic acid; UFH: Unfractionated
heparin; VASP: Vasodilator-stimulated phosphoprotein; VEM: Viscoelastic
methods; VKA: Vitamin K antagonist; VN®-ASA: VerifyNow® platelet reactivity
test for aspirin; VTE: Venous thromboembolism; WBCT: Whole-body
computed tomography; WHO: World Health Organization
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